Improved streaming proxy assays before single cell CITER-SEQ
By using specific oligonucleotide identifier sequences and binding reagents for detectable conjugates to measure cell component target expression in single-cell CITE-Seq experiments, the problems of high detection costs and waste of reagents are solved, and the problem of high detection costs and waste of reagents is achieved. Accurate measurement of single-cell protein expression and reagent optimization.
Patent Information
- Application Number
- CN202380026168.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-22
- Filing Date
- 2023-03-08
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art detects a large number of AbSeq markers in single-cell CITE-Seq experiments with high cost and difficult to estimate marker expression levels, resulting in waste of reagents, and the number of available dye-oligonucleotide conjugates is limited, which has an increase in the presence of multivariate flow agent determination requirements.
By contacting more than one cell component binding agent with more than one cell component target and measuring using a specific oligonucleotide identifier sequence, the emission of detectable conjugates is achieved by incorporating the amount of emission to achieve a measurement. Accurate measurement and optimization of target expression of cell components.
It reduces the cost of single-cell CITE-Seq experiments, improves the accuracy and efficiency of reagent use, ensures the accuracy of protein expression information before sequencing, and reduces reagent waste.
Smart Images

Figure BDA0005032077940000851 
Figure BDA0005032077940000861 
Figure HDA0005032077960000011
Abstract
Description
[0001] Related Applications
[0002] This application claims priority to U.S. Provisional Application No. 63 / 318,046, filed on March 9, 2022; and U.S. Provisional Application No. 63 / 384,735, filed on November 22, 2022. The entire contents of these applications are hereby expressly incorporated by reference in their entirety.
[0003] Reference to a sequence listing
[0004] This application is submitted together with a sequence listing in electronic format. The sequence listing is provided as a file entitled 68EB-317351-WO, which was created on March 8, 2023 and is 16.0 kilobytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.
[0005] background
[0006] field
[0007] The present disclosure relates generally to the field of molecular biology, such as the use of molecular barcoding to determine protein expression profiles in cells.
[0008] Description of the Prior Art
[0009] Current technology allows for the measurement of gene expression of single cells in a massively parallel manner (e.g., >10,000 cells) by attaching cell-specific oligonucleotide barcodes to multiple (A) mRNA molecules from individual cells when each cell is co-localized with barcoded reagent beads in a compartment. Gene expression can affect protein expression. Protein-protein interactions can affect gene expression and protein expression. There is a need for systems and methods that can quantitatively analyze protein expression in cells and simultaneously measure protein expression and gene expression in cells. Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq) is a single-cell phenotyping method that can detect proteins by sequencing using quantitative readouts using antibody oligonucleotide conjugates (e.g., AbSeq reagents). Despite the increasing awareness and adoption of this advanced technology by researchers, the cost of performing single-cell CITE-Seq can be high when researchers want to detect a large number of AbSeq markers. When designing an AbSeq panel for a single cell CITE-Seq experiment for a biological system, it may be difficult to estimate marker expression levels (and therefore the amount of appropriate AbSeq reagents) before conducting a single cell CITE-Seq workflow. Some markers in an AbSeq panel may show low expression or generally high expression, and money may be wasted on reagents that do not provide much information. Therefore, a cost-effective assay is needed to examine surface protein expression using accurate AbSeq reagents in relevant biological samples to guide AbSeq panel design and ensure protein expression prior to sequencing. In some embodiments, the number of different dye-oligonucleotide conjugates currently available may be limited, and there is a need for methods and compositions for increased multiplex flow proxy assays.
[0010] Overview
[0011] The disclosure herein includes methods for measuring the expression of a cellular component target in a cell. In some embodiments, the method includes: contacting more than one first cellular component binding reagent with a first more than one cell comprising more than one cellular component target, wherein each of the more than one first cellular component binding reagents comprises a cellular component binding reagent-specific oligonucleotide, the cellular component binding reagent-specific oligonucleotide comprising a unique identifier sequence for the first cellular component binding reagent, and wherein the first cellular component binding reagent is capable of specifically binding to at least one of the more than one cellular component targets. The method may include: contacting the first more than one cell associated with the first cellular component binding reagent with more than one first detectable conjugate, wherein each of the more than one first detectable conjugates comprises a detectable portion or a precursor thereof and a unique identifier-specific oligonucleotide, the unique identifier-specific oligonucleotide comprising a sequence configured to bind to a unique identifier sequence, wherein the first detectable conjugate capable of binding to the same unique identifier sequence comprises the same detectable portion or a precursor thereof, and wherein the first detectable conjugate capable of binding to different unique identifier sequences comprises different detectable portions or precursors thereof. The method may include: measuring the emission of the detectable portion of each first detectable conjugate with an instrument as an indication of the amount of each first cell component binding agent bound to the cell component target and the first detectable conjugate. The method may include: after contacting the first more than one cell associated with the first cell component binding agent with more than one first detectable conjugate, removing one or more first detectable conjugates that are not in contact with the first more than one cell (which is associated with the first cell component binding agent). In some embodiments, removing one or more first detectable conjugates that are not in contact with the first more than one cell (which is associated with the first cell component binding agent) includes removing one or more first detectable conjugates that are not in contact with the corresponding unique identifier sequence of the cell component binding agent-specific oligonucleotide.
[0012] The disclosure herein includes methods for measuring the expression of a cell component target in a cell. In some embodiments, the method includes: contacting more than one first cell component binding reagent with more than one first detectable conjugate. In some embodiments, each of more than one first cell component binding reagents includes a cell component binding reagent specific oligonucleotide, the cell component binding reagent specific oligonucleotide includes a unique identifier sequence for the first cell component binding reagent, and wherein the first cell component binding reagent is capable of specifically binding to at least one of a plurality of cell component targets. In some embodiments, each of more than one first detectable conjugates includes a detectable portion or a precursor thereof and a unique identifier specific oligonucleotide, the unique identifier specific oligonucleotide includes a sequence configured to bind to a unique identifier sequence, wherein the first detectable conjugate capable of binding to the same unique identifier sequence includes the same detectable portion or a precursor thereof, and wherein the first detectable conjugate capable of binding to different unique identifier sequences includes different detectable portions or precursors thereof. The method may include: contacting more than one first cell component binding reagent associated with more than one first detectable conjugate with a first more than one cell comprising more than one cell component target. The method may include: measuring the emission of the detectable portion of each first detectable conjugate with an instrument as an indication of the amount of each first cellular component binding reagent bound to the cellular component target and the first detectable conjugate. The method may include: after contacting more than one first cellular component binding reagent with more than one first detectable conjugate, removing one or more first detectable conjugates that are not in contact with more than one first cellular component binding reagent from the more than one first detectable conjugates. In some embodiments, removing one or more first detectable conjugates that are not in contact with more than one first cellular component binding reagent includes removing one or more first detectable conjugates that are not in contact with the corresponding unique identifier sequence of the cellular component binding reagent-specific oligonucleotide.
[0013] The disclosure herein includes a method for measuring the expression of a cell component target in a cell. In some embodiments, the method includes: contacting more than one first cell component binding reagent with more than one second detectable conjugate in more than one partition. In some embodiments, each of more than one first cell component binding reagent comprises a cell component binding reagent specific oligonucleotide, and the cell component binding reagent specific oligonucleotide comprises a unique identifier sequence for the first cell component binding reagent, wherein each cell component binding reagent specific oligonucleotide comprises a shared sequence, wherein the shared sequence is the same for all cell component binding reagent specific oligonucleotides across more than one first cell component binding reagent, wherein the first cell component binding reagent is capable of specifically binding at least one of more than one cell component target. In some embodiments, each of more than one second detectable conjugate comprises a detectable portion or its precursor and a shared oligonucleotide, and the shared oligonucleotide comprises a sequence configured to bind to the shared sequence. In some embodiments, each of the more than one partitions comprises: a first cell component binding reagent in more than one first cell component binding reagent, wherein the cell component binding reagents in the same partition comprise the same unique identifier sequence and are capable of specifically binding to the same cell component target, and wherein the cell component binding reagents in different partitions comprising different unique identifiers are capable of specifically binding to different cell component targets; and a second detectable conjugate in more than one second detectable conjugate, wherein the second detectable conjugates in the same partition comprise the same detectable moiety or a precursor thereof, and wherein the second detectable conjugates in different partitions comprise different detectable moieties or precursors thereof. The method may include: contacting more than one first cell component binding reagent associated with more than one second detectable conjugate with a first more than one cell comprising more than one cell component target. The method may include: measuring the emission of the detectable moiety of each second detectable conjugate with an instrument as an indication of the amount of each first cell component binding reagent bound to the cell component target and the second detectable conjugate. The method may include: after contacting more than one first cell component binding reagent with more than one second detectable conjugate, removing one or more second detectable conjugates that are not in contact with more than one first cell component binding reagent in more than one second detectable conjugate. In some embodiments, removing one or more second detectable conjugates that are not in contact with more than one first cell component binding reagent includes removing one or more second detectable conjugates that are not in contact with the corresponding shared sequence of the cell component binding reagent specific oligonucleotide. The method may include: after contacting more than one first cell component binding reagent with more than one second detectable conjugate in more than one partition, pooling the contents of the more than one partition.
[0014] The disclosure herein includes a test kit. The test kit may include: more than one first cell component binding reagent, wherein each of more than one first cell component binding reagent includes a cell component binding reagent specific oligonucleotide, the cell component binding reagent specific oligonucleotide includes a unique identifier sequence for the first cell component binding reagent, and wherein the first cell component binding reagent can be specifically bound to at least one of more than one cell component targets. In some embodiments, each cell component binding reagent specific oligonucleotide includes a shared sequence. In some embodiments, the shared sequence is the same as all cell component binding reagent specific oligonucleotides across more than one first cell component binding reagent. The test kit may include: more than one second cell component binding reagent, wherein the second cell component binding reagent can be specifically bound to at least one of more than one cell component targets, wherein the second cell component binding reagent does not include a cell component binding reagent specific oligonucleotide, wherein one or more of the first cell component binding reagent and one or more of the second cell component binding reagent can be combined with the same cell component target. The kit may comprise: more than one first detectable conjugate, wherein each of the more than one first detectable conjugates comprises a detectable moiety or a precursor thereof and a unique identifier-specific oligonucleotide comprising a sequence configured to bind to a unique identifier sequence, wherein first detectable conjugates capable of binding to the same unique identifier sequence comprise the same detectable moiety or a precursor thereof, and wherein first detectable conjugates capable of binding to different unique identifier sequences comprise different detectable moieties or precursors thereof. The kit may comprise: more than one second detectable conjugate, wherein each of the more than one second detectable conjugates comprises a detectable moiety or a precursor thereof and a shared oligonucleotide comprising a sequence configured to bind to the shared sequence, wherein at least two of the more than one second detectable conjugates comprise different detectable moieties or precursors thereof. The kit may comprise: a primer capable of hybridizing to a first universal sequence or its complement. The kit may comprise: a primer capable of hybridizing to a second universal sequence or its complement. The kit may comprise: more than one oligonucleotide barcode, wherein each of the more than one oligonucleotide barcode comprises a first universal sequence, a first molecular marker, and a target binding region, and wherein at least 10 of the more than one oligonucleotide barcodes comprise different first molecular marker sequences. In some embodiments, the cell component binding reagent-specific oligonucleotide comprises a second molecular marker. The kit may comprise: a buffer, a box, or both. The kit may comprise: one or more reagents for reverse transcription reactions and / or amplification reactions.
[0015] As disclosed herein, the method may include: if the emission indicates that the abundance of the first cell component binding reagent is higher or lower than a predetermined abundance range: contacting the second more than one cell with the first cell component binding reagent in a manner configured to achieve the abundance of the first cell component binding reagent within the predetermined abundance range. In some embodiments, the predetermined abundance range includes a dynamic range in which acceptable linearity and efficiency of the detection of the cell component binding reagent are observed. In some embodiments, contacting the second more than one cell with the first cell component binding reagent in a manner configured to achieve the abundance of the first cell component binding reagent within the predetermined abundance range includes contacting the second more than one cell with the first cell component binding reagent with a change amount relative to the first contact step. The method may include: contacting the first more than one cell and / or the second more than one cell with more than one second cell component binding reagent, wherein the second cell component binding reagent is capable of specifically binding to at least one of more than one cell component targets, wherein the second cell component binding reagent does not contain a cell component binding reagent-specific oligonucleotide, wherein one or more of the first cell component binding reagent and one or more of the second cell component binding reagent are capable of binding to the same cell component target. In some embodiments, contacting a second more than one cell with a first cell component binding reagent in a manner configured to achieve the abundance of the first cell component binding reagent within the predetermined abundance range includes contacting a second more than one cell with a mixture of the first cell component binding reagent and a second cell component binding reagent capable of binding the same cell component target as the first cell component binding reagent with a titration ratio configured to achieve the abundance of the first cell component binding reagent within the predetermined abundance range. The titration ratio can be configured so that the sequencing reads containing the unique identifier sequence for the first cell component binding reagent account for less than about 5% of the total sequencing reads. The method may include: after contacting more than one first cell component binding reagent with the first more than one cell and / or the second more than one cell, removing one or more first cell component binding reagents that are not in contact with the first more than one cell and / or the second more than one cell. Removing one or more first cell component binding reagents that are not in contact with the first more than one cell and / or the second more than one cell may include removing one or more first cell component binding reagents that are not in contact with at least one corresponding to more than one first cell component target.
[0016] In some embodiments, the method does not include a protein-based reagent capable of binding to the first cellular component binding reagent. In some embodiments, the unique identifier-specific oligonucleotide and / or the shared oligonucleotide do not bind to the first cellular component binding reagent via a mechanism other than nucleic acid hybridization. In some embodiments, the first cellular component binding reagent does not include a detectable portion or a precursor thereof.
[0017] In some embodiments, the first more than one cell and the second more than one cell are derived from the same sample. In some embodiments, the first more than one cell and / or the second more than one cell include T cells, B cells, tumor cells, myeloid cells, blood cells, normal cells, fetal cells, maternal cells or mixtures thereof. In some embodiments, the cell component target includes a protein target. In some embodiments, the first cell component binding reagent and / or the second cell component binding reagent include an antibody or a fragment thereof. The cell component target may include carbohydrates, lipids, proteins, extracellular proteins, cell surface proteins, cell markers, B cell receptors, T cell receptors, major histocompatibility complexes, tumor antigens, receptors, intracellular proteins or any combination thereof.
[0018] The method can be multiplexed. In some embodiments, more than one cell component target includes at least about 2, 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or more different cell component targets. In some embodiments, more than one first cell component binding reagent and / or more than one second cell component binding reagent include at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10000 different cell component binding reagents. In some embodiments, more than one first detectable conjugate includes at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10000 different first detectable conjugates. In some embodiments, the different first detectable conjugates comprise two or more overlapping dyes that can be distinguished by spectral cytometry. In some embodiments, more than one second detectable conjugate comprises at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10000 different second detectable conjugates. In some embodiments, the different second detectable conjugates comprise two or more overlapping dyes that can be distinguished by spectral cytometry.
[0019] In some embodiments, the length of the unique identifier specific oligonucleotide and / or shared oligonucleotide is 5-500 nucleotides. In some embodiments, the sequence configured to bind the unique identifier sequence includes a sequence complementary to at least a portion of the unique identifier sequence. In some embodiments, the shared sequence is a sequence complementary to the capture sequence configured to capture the cell component binding reagent specific oligonucleotide, and the sequence configured to bind the shared sequence is a capture sequence. In some embodiments, the capture sequence includes a poly (dT) region. In some embodiments, the shared sequence is a second universal sequence, and the sequence configured to bind the shared sequence is a sequence complementary to at least a portion of the second universal sequence. In some embodiments, the second universal sequence includes a binding site and / or a sequencing adapter, its complementary sequence and / or a portion thereof of a sequencing primer. In some embodiments, the sequencing adapter includes a P5 sequence, a P7 sequence, its complementary sequence and / or a portion thereof. In some embodiments, the sequencing primer includes a read 1 sequencing primer, a read 2 sequencing primer, its complementary sequence and / or a portion thereof. In some embodiments, the contacting step includes hybridization of a cell component binding reagent specific oligonucleotide and a unique identifier specific oligonucleotide. In some embodiments, the contacting step comprises hybridization of a cellular component binding reagent specific oligonucleotide and a shared oligonucleotide. In some embodiments, the detectable moiety comprises an optical moiety, a luminescent moiety, an electrochemically active moiety, a nanoparticle, or a combination thereof. In some embodiments, the nanoparticle comprises a quantum dot. In some embodiments, the luminescent moiety comprises a chemiluminescent moiety, an electroluminescent moiety, a photoluminescent moiety, or a combination thereof. In some embodiments, the photoluminescent moiety comprises a fluorescent moiety, a phosphorescent moiety, or a combination thereof. In some embodiments, the fluorescent moiety comprises a fluorescent dye. The method may include: performing a reaction to convert a precursor of the detectable moiety into the detectable moiety. In some embodiments, the detectable moiety comprises BD Horizon Real Blue TM 780 (RB780), BD HorizonReal Yellow TM 586 (RY586) and / or Brilliant Violet TM421 (BV421). In some embodiments, the detectable portion comprises one or more of DAPI, BUV661, RY586, AF647, Cy5, RB780, ROX, BV421, FAM and Cy3. In some embodiments, the unique identifier specific oligonucleotide and / or shared oligonucleotide is or comprises locked nucleic acid (LNA), peptide nucleic acid (PNA), DNA, LNA / PNA chimera, LNA / DNA chimera, PNA / DNA chimera or any combination thereof. In some embodiments, the unique identifier specific oligonucleotide and / or shared oligonucleotide comprises a joint, and wherein the unique identifier specific oligonucleotide and / or shared oligonucleotide is associated with the detectable portion or its precursor through a joint. In some embodiments, the joint comprises a carbon chain, optionally the carbon chain comprises 2-30 carbons, and optionally the carbon chain also comprises 12 carbons. In some embodiments, the joint comprises 5' amino modifier C12 (5AmMC12) or a derivative thereof. In some embodiments, the unique identifier specific oligonucleotide and / or shared oligonucleotide comprises an affinity portion. In some embodiments, the detectable portion or its precursor comprises a binding partner of the affinity portion. In some embodiments, the affinity portion comprises biotin, streptavidin, heparin, an aptamer, a click chemistry portion, digoxin, one or more primary amines, one or more carboxyl groups, one or more hydroxyl groups, one or more aldehydes, one or more ketones, derivatives thereof, or any combination thereof. In some embodiments, the detectable portion or its precursor is conjugated to a unique identifier-specific oligonucleotide and / or a shared oligonucleotide by a 1,3-dipolar cycloaddition reaction, a hetero-Diels-Alder reaction, a nucleophilic substitution reaction, a non-hydronal carbonyl reaction, a carbon-carbon multiple bond addition reaction, an oxidation reaction, a click reaction, or any combination thereof. In some embodiments, the instrument comprises a flow cytometer. In some embodiments, the flow cytometer comprises a conventional flow cytometer, a spectral flow cytometer, a hyperspectral flow cytometer, an imaging flow cytometer, or any combination thereof. In some embodiments, the cellular component binding reagent specific oligonucleotide comprises a sequence complementary to a capture sequence of an oligonucleotide barcode, the capture sequence being configured to capture the sequence of the cellular component binding reagent specific oligonucleotide. In some embodiments, the sequence of the cellular component binding reagent specific oligonucleotide complementary to the capture sequence comprises a poly (dA) region.
[0020] The method may include: contacting more than one oligonucleotide barcode with a cell component binding reagent specific oligonucleotide for hybridization, wherein each of the oligonucleotide barcodes comprises a first molecular marker and a first universal sequence; and extending more than one oligonucleotide barcode hybridized with the cell component binding reagent specific oligonucleotide to produce more than one barcoded cell component binding reagent specific oligonucleotide, each of the more than one barcoded cell component binding reagent specific oligonucleotide comprises a sequence complementary to at least a portion of the unique identifier sequence and a first molecular marker. The method may include: obtaining sequence information of more than one barcoded cell component binding reagent specific oligonucleotide or its product to determine the copy number of at least one cell component target in more than one cell component target in one or more of the first more than one cell and / or the second more than one cell. In some embodiments, obtaining sequence information includes attaching a sequencing adapter to more than one barcoded cell component binding reagent specific oligonucleotide or its product. In some embodiments, the number of unique first molecular marker sequences associated with a unique identifier sequence for a first cellular component binding reagent capable of specifically binding to at least one cellular component target in the sequencing data indicates the number of copies of at least one cellular component target in one or more of the first more than one cell and / or the second more than one cell.
[0021] More than one cell component target may include more than one protein target, and wherein the first cell component binding reagent is capable of specifically binding to at least one of the more than one protein targets. In some embodiments, more than one cell component target includes a cell surface protein, an intracellular protein, a cell marker, a B cell receptor, a T cell receptor, an antibody, a major histocompatibility complex, a tumor antigen, a receptor, or a combination thereof. In some embodiments, the first cell component binding reagent and / or the second cell component binding reagent includes an antibody or a fragment thereof. In some embodiments, the antibody or fragment thereof comprises a monoclonal antibody, a Fab, a Fab', a F(ab')2, a Fv, a scFv, a dsFv, a diabody, a triabody, a tetrabody, a multispecific antibody formed by an antibody fragment, a single domain antibody (sdAb), a single chain comprising complementary scFv (tandem scFv) or a bispecific tandem scFv, an Fv construct, a disulfide-linked Fv, a dual variable domain immunoglobulin (DVD-Ig) binding protein or a nanobody, an aptamer, an affimer, an affilin, an affitin, an affimer, an alphabody, anticalin, avimer, DARPin, Fynomer, a Kunitz domain peptide, a monospecific antibody, or any combination thereof.
[0022] In some embodiments, the cell component binding reagent specific oligonucleotide comprises one or more of the following: (a) a second molecular marker sequence, optionally the second molecular marker sequence is 2-20 nucleotides in length; (b) an alignment sequence adjacent to a poly (dA) region, optionally the alignment sequence is one or more nucleotides in length, or two or more nucleotides; and (c) a joint, wherein the cell component binding reagent specific oligonucleotide is associated with the first cell component binding reagent through a joint. In some embodiments, the second molecular marker sequences of at least two cell component binding reagent specific oligonucleotides are different, and the unique identifier sequences of at least two cell component binding reagent specific oligonucleotides are the same. In some embodiments, the second molecular marker sequences of at least two cell component binding reagent specific oligonucleotides are different, and the unique identifier sequences of at least two cell component binding reagent specific oligonucleotides are different. In some embodiments, the number of unique second molecular marker sequences associated with the unique identifier sequence of the first cell component binding reagent capable of specifically binding to at least one cell component target in the sequencing data indicates the number of copies of at least one cell component target in one or more of the first more than one cell and / or the second more than one cell. In some embodiments, (a) the alignment sequence comprises guanine, cytosine, thymine, uracil, or a combination thereof; (b) the alignment sequence comprises a poly(dT) sequence, a poly(dG) sequence, a poly(dC) sequence, a poly(dU) sequence, or a combination thereof; and / or (c) the alignment sequence is located 5' of the poly(dA) region. In some embodiments, the linker comprises a carbon chain, optionally the carbon chain comprises 2-30 carbons, and optionally the carbon chain comprises 12 carbons. In some embodiments, the linker comprises a 5' amino modifier C12 (5AmMC12) or a derivative thereof.
[0023] Cell component binding reagent specific oligonucleotide can be associated with the first cell component binding reagent. In some embodiments, the cell component binding reagent specific oligonucleotide is covalently attached to the first cell component binding reagent and / or non-covalently attached to the first cell component binding reagent. In some embodiments, the cell component binding reagent specific oligonucleotide is conjugated with the first cell component binding reagent. In some embodiments, the cell component binding reagent specific oligonucleotide is conjugated with the first cell component binding reagent by a chemical group selected from the following: UV light cleavable group, streptavidin, biotin, amine and combination thereof. In some embodiments, the cell component binding reagent specific oligonucleotide is configured to be detached from the first cell component binding reagent. The method may include: dissociating the cell component binding reagent specific oligonucleotide from the first cell component binding reagent. Dissociating the cell component binding reagent specific oligonucleotide may include dissociating the cell component binding reagent specific oligonucleotide from the first cell component binding reagent by UV light cleavage, chemical treatment, heating, enzyme treatment or any combination thereof. In some embodiments, dissociation occurs after barcoding the cellular component binding reagent specific oligonucleotide and / or wherein dissociation occurs before barcoding the cellular component binding reagent specific oligonucleotide.The cellular component binding reagent specific oligonucleotide may be configured to be non-detachable from the first cellular component binding reagent.
[0024] In some embodiments, one or more single cells in the first more than one cell and / or the second more than one cell contain a copy of a nucleic acid target. The method may include: contacting more than one oligonucleotide barcode with a copy of the nucleic acid target for hybridization, wherein each of the more than one oligonucleotide barcode contains a first universal sequence, a target binding region capable of hybridizing with a copy of the nucleic acid target, and a first molecular marker; extending the more than one oligonucleotide barcode hybridized with the copy of the nucleic acid target to produce more than one barcoded nucleic acid molecules, each of the more than one barcoded nucleic acid molecules containing a sequence complementary to at least a portion of the nucleic acid target; and obtaining sequence information of more than one barcoded nucleic acid molecules or their products to determine the number of copies of the nucleic acid target in each of the one or more single cells. In some embodiments, determining the number of copies of the nucleic acid target in each of the one or more single cells includes determining the number of copies of the nucleic acid target in each of the one or more single cells based on the number of first molecular markers with different sequences associated with more than one barcoded nucleic acid molecules or their products, their complements, or a combination thereof. In some embodiments, obtaining sequencing data comprises attaching sequencing adapters to more than one barcoded nucleic acid molecule or its product. In some embodiments, more than one barcoded nucleic acid molecule comprises a barcoded deoxyribonucleic acid (DNA) molecule and / or a barcoded ribonucleic acid (RNA) molecule. In some embodiments, the nucleic acid target comprises a nucleic acid molecule (e.g., ribonucleic acid (RNA), messenger RNA (mRNA), microRNA, small interfering RNA (siRNA), RNA degradation products, RNA comprising a poly (A) tail, or any combination thereof, optionally, mRNA encoding an immune receptor).
[0025] In some embodiments, at least 10 of more than one oligonucleotide barcodes comprise different first molecular marker sequences. In some embodiments, each first molecular marker of more than one oligonucleotide barcode comprises at least 6 nucleotides. In some embodiments, more than one oligonucleotide barcode is associated with a solid support, and optionally, more than one oligonucleotide barcode associated with the same solid support each comprises the same sample marker. In some embodiments, each sample marker of more than one oligonucleotide barcode comprises at least 6 nucleotides. In some embodiments, more than one oligonucleotide barcode each comprises a cell marker, and optionally, each cell marker of the more than one oligonucleotide barcode comprises at least 6 nucleotides. In some embodiments, the oligonucleotide barcodes associated with the same solid support comprise the same cell marker. In some embodiments, the oligonucleotide barcodes associated with different solid supports comprise different cell markers.
[0026] The method may include associating a synthetic particle comprising more than one oligonucleotide barcode with a single cell in the first more than one single cell and / or the second more than one single cell. The method may include lysing the single cell after associating the synthetic particle with the single cell, and optionally lysing the single cell includes heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof. In some embodiments, the synthetic particle and the single cell are in the same well. In some embodiments, the synthetic particle and the single cell are in the same droplet. In some embodiments, at least one of the more than one oligonucleotide barcode is fixed or partially fixed on the synthetic particle, or at least one of the more than one oligonucleotide barcode is encapsulated or partially encapsulated in the synthetic particle. In some embodiments, the synthetic particle is destructible. The synthetic particles can be or can include beads, such as agarose beads, streptavidin beads, agarose beads, magnetic beads, conjugated beads, protein A conjugated beads, protein G conjugated beads, protein A / G conjugated beads, protein L conjugated beads, oligo(dT) conjugated beads, silica beads, silica-like beads, anti-biotin microbeads, anti-fluorescent dye microbeads, or any combination thereof; a material selected from the following: polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic substances, ceramics, plastics, glass, methylstyrene, acrylic polymers, titanium, latex, agarose gel, cellulose, nylon, silicone, and any combination thereof; or a destructible hydrogel particle. In some embodiments, each of more than one oligonucleotide barcode comprises a linker functional group. In some embodiments, the synthetic particles comprise a third solid support functional group. The support functional group and the linker functional group can be associated with each other. In some embodiments, the linker functional group and the support functional group are individually selected from the following: C6, biotin, streptavidin, one or more primary amines, one or more aldehydes, one or more ketones, and any combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Non-limiting exemplary random bar codes are illustrated.
[0029] Figure 2 A non-limiting exemplary workflow for random barcoding and digital counting is shown.
[0030] Figure 3 is a schematic diagram illustrating a non-limiting exemplary method for generating an indexed library of randomly barcoded targets from more than one target.
[0031] Figure 4 Shown is a schematic diagram of an exemplary protein binding reagent (illustrated here as an antibody) associated with an oligonucleotide comprising a unique identifier for the protein binding reagent.
[0032] Figure 5 Shown is a schematic diagram of an exemplary binding reagent (pictured here as an antibody) associated with an oligonucleotide containing a unique identifier for sample indexing to determine whether cells are from the same sample or different samples.
[0033] Figure 6 A schematic diagram is shown of an exemplary workflow for simultaneously determining cellular component expression (eg, protein expression) and gene expression in a high-throughput manner using oligonucleotide-linked antibodies.
[0034] Figure 7 A schematic diagram showing an exemplary workflow for sample indexing using oligonucleotide-linked antibodies.
[0035] Figure 8 A schematic diagram showing a non-limiting exemplary workflow for barcoding of a binding reagent oligonucleotide (illustrated here, an antibody oligonucleotide) associated with a binding reagent (illustrated here, an antibody).
[0036] Figure 9A-9D Non-limiting exemplary designs of oligonucleotides for simultaneous determination of protein expression and gene expression and for sample indexing are shown.
[0037] Fig.10 A schematic diagram of non-limiting exemplary oligonucleotide sequences for simultaneous determination of protein expression and gene expression and for sample indexing is shown.
[0038] Figure 11A-11B Non-limiting exemplary designs of oligonucleotides for simultaneous determination of protein expression and gene expression and for sample indexing are shown.
[0039] Figures 12A-12D Non-limiting exemplary workflows provided herein are depicted. Fig. 12A A non-limiting exemplary schematic diagram of currently available flow cytometry assays is depicted. Fig. 12B A non-limiting exemplary schematic diagram of a first multiplex protein marker detection workflow disclosed herein is depicted. Fig. 12C A non-limiting exemplary schematic diagram of a second multiplex protein marker detection workflow disclosed herein is depicted. Fig.12D A non-limiting exemplary schematic diagram of a third multiplex protein marker detection workflow disclosed herein is depicted. The hybridization between the antibody-oligonucleotide conjugate and the dye-oligonucleotide conjugate is Figures 12A-12D Each workflow is depicted on the right side.
[0040] Figure 13A-13C Non-limiting exemplary flow cytometry data are depicted. Fig.13A Depicted are data relating to the simultaneous detection of several protein markers using the methods provided herein. Fig. 13BDepicted are exemplary data demonstrating that group resolution is comparable between the three assay workflows. Fig. 13C Depicted are exemplary data comparing the multiplex protein marker detection workflow provided herein to a singleplex flow cytometric proxy assay.
[0041] Fig.14 A non-limiting exemplary workflow for preparing the disclosed detectable conjugates (eg, dye-oligonucleotide conjugates) is depicted.
[0042] Figure 15A-Figure 15C Depicted are non-limiting exemplary embodiments of detectable conjugates provided herein comprising: a detectable moiety from the Real Blue or Real Yellow dye family (e.g., RY586 and / or RB780) ( Fig.15A ); optional detectable moiety-oligonucleotide conjugate ( Fig. 15B ); and peptide nucleic acid (PNA) ( Fig. 15C ).
[0043] Fig.16 Depicted are data demonstrating the feasibility of a 10-color flow cytometry panel using the novel dye-oligonucleotide conjugates provided herein.
[0044] Figure 17A-17C Depicted are data associated with three different types of novel dye-oligonucleotide conjugates provided herein: CD3 AbSeq+ dye-oligonucleotide conjugate ( Fig.17A ); CD8 AbSeq+Biotin-dT 25 +Streptavidin-dye ( Fig. 17B ); and CD8 AbSeq+PNA or DNA dT 25 -Cy3( Fig. 17C ).
[0045] Details
[0046] Reference is made to the accompanying drawings forming a part of this document in the following detailed description. In the accompanying drawings, similar symbols generally identify similar components unless the context otherwise indicates. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized and other changes may be made without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure as generally described herein and illustrated in the accompanying drawings can be arranged, replaced, combined, separated, and designed in a variety of different configurations, all of which are expressly contemplated herein and form a part of the present disclosure.
[0047] All patents, published patent applications, other publications, and sequences from GenBank and other databases mentioned herein are incorporated by reference in their entirety with respect to the relevant art.
[0048] The disclosure herein includes methods, compositions and kits for measuring the expression of a cell component target in a cell without sequencing. In some embodiments, the method includes: contacting more than one first cell component binding reagent with a first more than one cell containing more than one cell component target, wherein each of the more than one first cell component binding reagents includes a cell component binding reagent specific oligonucleotide, the cell component binding reagent specific oligonucleotide includes a unique identifier sequence for the first cell component binding reagent, and wherein the first cell component binding reagent is capable of specifically binding to at least one of the more than one cell component targets. The method may include: generating an amplicon of one or more unique identifier sequences in the first cell component binding reagent. The method may include: determining the amount of one or more amplicons as an indication of the amount of the cell component target bound by one or more of the first cell component binding reagents.
[0049] Quantifying small amounts of nucleic acids, such as messenger ribonucleotide (mRNA) molecules, is important (e.g., clinically important) for determining genes expressed in cells, for example, at different stages of development or under different environmental conditions. However, determining the absolute number of nucleic acid molecules (e.g., mRNA molecules) can also be very challenging, especially when the number of molecules is very small. One method for determining the absolute number of molecules in a sample is the digital polymerase chain reaction (PCR). Ideally, PCR produces identical copies of molecules in each cycle. However, PCR can have the disadvantage that each molecule is replicated with a random probability, and this probability varies depending on the PCR cycle and the gene sequence, which leads to amplification bias and inaccurate gene expression measurements. Random barcodes with unique molecular labels (molecular labels, also called molecular indexes (MI)) can be used to count the number of molecules and correct for amplification bias. Methods such as Precise TM Random barcoding using the ELISA® assay (Cellular Research, Inc. San Jose, CA) can correct for bias introduced by PCR and library preparation steps by labeling mRNA during reverse transcription (RT) using molecular markers (ML).
[0050] Precise TMThe assay can utilize a non-depleting pool of random barcodes with a large number (e.g., 6561 to 65536) of unique molecular markers on poly (T) oligonucleotides to hybridize with all poly (A)-mRNAs in the sample during the RT step. The random barcode can include a universal PCR priming site. During RT, the target gene molecule reacts randomly with the random barcode. Each target molecule can hybridize with the random barcode, resulting in the generation of randomly barcoded complementary ribonucleotides (cDNA) molecules. After labeling, the randomly barcoded cDNA molecules from the microwells of the microplate can be pooled into a single tube for PCR amplification and sequencing. The original sequencing data can be analyzed to generate the number of reads, the number of random barcodes with unique molecular markers, and the number of mRNA molecules.
[0051] Methods for determining the mRNA expression profile of single cells can be performed in a massively parallel manner. For example, Precise TM The assay can be used to simultaneously determine the mRNA expression profiles of more than 10,000 cells. The number of single cells (e.g., hundreds or thousands of single cells) used for analysis per sample may be lower than the capacity of current single cell technology. Pooling cells from different samples can improve the capacity utilization of current single cell technology, thereby reducing the reagent waste and cost of single cell analysis. The present disclosure provides a sample indexing method for distinguishing cells from different samples for cDNA library preparation, which is prepared for cell analysis, such as single cell analysis. Pooling cells from different samples can minimize the differences in the cDNA library preparation of cells from different samples, thereby achieving more accurate comparison of different samples.
[0052] The disclosure herein includes methods for measuring the expression of a cellular component target in a cell. In some embodiments, the method includes: contacting more than one first cellular component binding reagent with a first more than one cell comprising more than one cellular component target, wherein each of the more than one first cellular component binding reagents comprises a cellular component binding reagent-specific oligonucleotide, the cellular component binding reagent-specific oligonucleotide comprising a unique identifier sequence for the first cellular component binding reagent, and wherein the first cellular component binding reagent is capable of specifically binding to at least one of the more than one cellular component targets. The method may include: contacting the first more than one cell associated with the first cellular component binding reagent with more than one first detectable conjugate, wherein each of the more than one first detectable conjugates comprises a detectable portion or a precursor thereof and a unique identifier-specific oligonucleotide, the unique identifier-specific oligonucleotide comprising a sequence configured to bind to a unique identifier sequence, wherein the first detectable conjugate capable of binding to the same unique identifier sequence comprises the same detectable portion or a precursor thereof, and wherein the first detectable conjugate capable of binding to different unique identifier sequences comprises different detectable portions or precursors thereof. The method can include measuring, with an instrument, the emission of the detectable moiety of each first detectable conjugate as an indication of the amount of each first cellular component binding agent bound to the cellular component target and the first detectable conjugate.
[0053] The disclosure herein includes methods for measuring the expression of a cell component target in a cell. In some embodiments, the method includes: contacting more than one first cell component binding reagent with more than one first detectable conjugate. In some embodiments, each of more than one first cell component binding reagents includes a cell component binding reagent specific oligonucleotide, which includes a unique identifier sequence for the first cell component binding reagent, and wherein the first cell component binding reagent is capable of specifically binding to at least one of more than one cell component targets. In some embodiments, each of more than one first detectable conjugates includes a detectable portion or a precursor thereof and a unique identifier specific oligonucleotide, the unique identifier specific oligonucleotide including a sequence configured to bind to a unique identifier sequence, wherein the first detectable conjugate capable of binding to the same unique identifier sequence includes the same detectable portion or a precursor thereof, and wherein the first detectable conjugate capable of binding to different unique identifier sequences includes different detectable portions or precursors thereof. The method may include: contacting more than one first cell component binding reagent associated with more than one first detectable conjugate with a first more than one cell comprising more than one cell component target. The method can include measuring, with an instrument, the emission of the detectable moiety of each first detectable conjugate as an indication of the amount of each first cellular component binding agent bound to the cellular component target and the first detectable conjugate.
[0054] The disclosure herein includes methods for measuring the expression of a cell component target in a cell. In some embodiments, the method includes: contacting more than one first cell component binding reagent with more than one second detectable conjugate in more than one partition. In some embodiments, each of more than one first cell component binding reagent comprises a cell component binding reagent specific oligonucleotide, the cell component binding reagent specific oligonucleotide comprises a unique identifier sequence for the first cell component binding reagent, wherein each cell component binding reagent specific oligonucleotide comprises a shared sequence, wherein the shared sequence is the same across all cell component binding reagent specific oligonucleotides of more than one first cell component binding reagent, wherein the first cell component binding reagent is capable of specifically binding at least one of more than one cell component target. In some embodiments, each of more than one second detectable conjugate comprises a detectable portion or its precursor and a shared oligonucleotide, and the shared oligonucleotide comprises a sequence configured to bind to a shared sequence. In some embodiments, each of the more than one partitions comprises: a first cellular component binding reagent in more than one first cellular component binding reagent, wherein the cellular component binding reagents located in the same partition comprise the same unique identifier sequence and are capable of specifically binding to the same cellular component target, and wherein the cellular component binding reagents located in different partitions comprise different unique identifiers and are capable of specifically binding to different cellular component targets; and a second detectable conjugate in more than one second detectable conjugate, wherein the second detectable conjugates located in the same partition comprise the same detectable moiety or a precursor thereof, and wherein the second detectable conjugates located in different partitions comprise different detectable moieties or precursors thereof.
[0055] The kit may comprise: a primer capable of hybridizing to a first universal sequence or its complement. The kit may comprise: a primer capable of hybridizing to a second universal sequence or its complement. The kit may comprise: more than one oligonucleotide barcode, wherein each of the more than one oligonucleotide barcode comprises a first universal sequence, a first molecular marker, and a target binding region, and wherein at least 10 of the more than one oligonucleotide barcodes comprise different first molecular marker sequences. In some embodiments, the cell component binding reagent-specific oligonucleotide comprises a second molecular marker. The kit may comprise: a buffer, a box, or both. The kit may comprise: one or more reagents for reverse transcription reactions and / or amplification reactions.
[0056] definition
[0057] Unless otherwise defined, the technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. See, for example, Singleton et al., Dictionary of Microbiology and Molecular Biology, 2nd ed., J. Wiley & Sons (New York, NY 1994); Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press (Cold Spring Harbor, NY 1989). For the purposes of the present disclosure, the following terms are defined below.
[0058] As used herein, the term "adapter" may mean a sequence that promotes the amplification or sequencing of an associated nucleic acid. The associated nucleic acid may include a target nucleic acid. The associated nucleic acid may include one or more of a spatial marker, a target marker, a sample marker, an index marker, or a barcode sequence (e.g., a molecular marker). The adaptor may be linear. The adaptor may be a pre-adenylated adaptor. The adaptor may be double-stranded or single-stranded. One or more adaptors may be located at the 5' end or 3' end of the nucleic acid. When the adaptor comprises a known sequence at the 5' end and the 3' end, the known sequence may be the same or different sequence. The adaptor located at the 5' end and / or the 3' end of the polynucleotide may be able to hybridize with one or more oligonucleotides fixed on the surface. In some embodiments, the adaptor may include a universal sequence. The universal sequence may be a region of a nucleotide sequence common to two or more nucleic acid molecules. Two or more nucleic acid molecules may also have regions of different sequences. Therefore, for example, the 5' adaptor may include the same and / or universal nucleic acid sequence, and the 3' adaptor may include the same and / or universal sequence. Universal sequences that may be present in different members of more than one nucleic acid molecule may allow the use of a single universal primer complementary to the universal sequence to replicate or amplify more than one different sequence. Similarly, at least one, two (e.g., a pair) or more universal sequences that may be present in different members of a set of nucleic acid molecules may allow the use of at least one, two (e.g., a pair) or more single universal primers complementary to the universal sequence to replicate or amplify more than one different sequence. Therefore, universal primers include sequences that can hybridize with such universal sequences. Molecules with target nucleic acid sequences may be modified to attach universal adapters (e.g., non-target nucleic acid sequences) to one or both ends of different target nucleic acid sequences. One or more universal primers attached to target nucleic acid may provide a site for universal primer hybridization. One or more universal primers attached to target nucleic acid may be identical or different from each other.
[0059] As used herein, an antibody can be a full-length (e.g., naturally occurring or formed by normal immunoglobulin gene fragment recombination processes) immunoglobulin molecule (e.g., an IgG antibody) or an immunologically active (i.e., specifically binding) portion of an immunoglobulin molecule (e.g., an antibody fragment).
[0060] In some embodiments, the antibody is a functional antibody fragment. For example, an antibody fragment can be a part of an antibody, such as F(ab')2, Fab', Fab, Fv, sFv, etc. Antibody fragments can bind to the same antigen recognized by a full-length antibody. Antibody fragments can include a fragment separated by the variable region of an antibody, such as a "Fv" fragment composed of the variable region of a heavy chain and a light chain, and a recombinant single-chain polypeptide molecule ("scFv protein") in which the light chain and the heavy chain variable region are connected by a peptide linker. Exemplary antibodies can include, but are not limited to, cancer cell antibodies, viral antibodies, antibodies that bind to cell surface receptors (e.g., CD8, CD34, and CD45), and therapeutic antibodies.
[0061] As used herein, the term "association" or "associated with..." can mean that two or more substances can be identified as being co-located at a certain point in time. Association can mean that two or more substances are or have been in similar containers. Association can be an informatics association. For example, digital information about two or more substances can be stored and can be used to determine that one or more substances are co-located at a certain point in time. Association can also be a physical association. In some embodiments, two or more associated substances are "tethered", "attached" or "fixed" to each other or to a common solid or semi-solid surface. Association can refer to a covalent or non-covalent means for attaching a label to a solid or semi-solid support (such as a bead). Association can be a covalent bond between a target and a label. Association can include hybridization between two molecules (such as a target molecule and a label).
[0062] As used herein, the term "complementary" can refer to the ability of accurate pairing between two nucleotides. For example, if the nucleotide of a nucleic acid at a given position can form a hydrogen bond with the nucleotide of another nucleic acid, the two nucleic acids are considered to be complementary to each other at the position. The complementarity between two single-stranded nucleic acid molecules can be "partial", in which only some nucleotides are combined, or it can be complete when there are all complementarities between single-stranded molecules. If the first nucleotide sequence is complementary to the second nucleotide sequence, the first nucleotide sequence can be referred to as the "complement" of the second sequence. If the first nucleotide sequence is complementary to a sequence opposite to the second sequence (that is, the nucleotide order is opposite), the first nucleotide sequence can be referred to as the "reverse complement" of the second sequence. As used herein, the terms "complement", "complementary" and "reverse complement" can be used interchangeably. It is understood from the present disclosure that if a molecule can hybridize with another molecule, it can be the complement of the molecule it hybridizes.
[0063] As used herein, the term "digital counting" may refer to a method for estimating the number of target molecules in a sample. Digital counting may include a step of determining the number of unique markers that have been associated with a target in a sample. This method, which may be stochastic in nature, converts the problem of counting molecules from one of localization and identification of identical molecules to a series of yes / no digital questions about detecting a set of predefined markers.
[0064] As used herein, the term "a label" or "more than one label" can refer to a nucleic acid code associated with a target in a sample. A label can be, for example, a nucleic acid label. A label can be a fully or partially amplifiable label. A label can be a fully or partially sequenceable label. A label can be a portion of a natural nucleic acid that can be identified as being distinguishable. A label can be a known sequence. A label can include a junction of a nucleic acid sequence, such as a junction of a natural and a non-natural sequence. As used herein, the term "label" can be used interchangeably with the term "index," "tag," or "label-tag." A label can convey information. For example, in various embodiments, a label can be used to determine the identity of a sample, the source of a sample, the identity of a cell, and / or a target.
[0065] As used herein, the term "non-depleting reservoir" may refer to a pool of barcodes (e.g., random barcodes) composed of many different markers. A non-depleting reservoir may include a large number of different barcodes such that when the non-depleting reservoir is associated with a target pool, each target may be associated with a unique barcode. The uniqueness of each labeled target molecule can be determined by the statistics of random selection and depends on the number of copies of the same target molecule in the set compared to the diversity of the marker. The size of the resulting set of labeled target molecules can be determined by the stochastic nature of the barcoding process, and then analysis of the number of detected barcodes allows calculation of the number of target molecules present in the original set or sample. When the ratio of the number of copies of the target molecules present to the number of unique barcodes is low, the labeled target molecules are highly unique (i.e., the probability that more than one target molecule is labeled by a given marker is very low).
[0066] As used herein, the term "nucleic acid" refers to a polynucleotide sequence or a fragment thereof. Nucleic acid may include nucleotides. Nucleic acid may be exogenous or endogenous to a cell. Nucleic acid may be present in a cell-free environment. Nucleic acid may be a gene or a fragment thereof. Nucleic acid may be DNA. Nucleic acid may be RNA. Nucleic acid may include one or more analogs (e.g., altered backbones, sugars or nucleobases). Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acids, xenonucleic acid, morpholinos, locked nucleic acids, diol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to a sugar), thiol-containing nucleotides, biotin-linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, queuosine and wyosine. "Nucleic acid," "polynucleotide," "target polynucleotide," and "target nucleic acid" are used interchangeably.
[0067] Nucleic acids may include one or more modifications (e.g., base modifications, backbone modifications) to provide new or enhanced features (e.g., improved stability) to nucleic acids. Nucleic acids may include nucleic acid affinity tags. Nucleosides may be base-sugar combinations. The base portion of a nucleoside may be a heterocyclic base. The two most common categories of such heterocyclic bases are purine and pyrimidine. Nucleotides may be nucleosides that also include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides including furanose, the phosphate group may be linked to the 2', 3' or 5' hydroxyl portion of the sugar. When forming nucleic acids, the phosphate group may covalently link adjacent nucleosides to each other to form a linear polymeric compound. Subsequently, each end of this linear polymeric compound may be further linked to form a cyclic compound; however, linear compounds are generally suitable. Linear compounds may have internal nucleotide base complementarity, and may therefore be folded in a manner that produces a fully or partially double-stranded compound. In nucleic acids, phosphate groups may generally be referred to as the internucleoside backbone that forms nucleic acids. Linkages or backbones may be 3' to 5' phosphodiester linkages.
[0068] Nucleic acids can include modified backbones and / or modified internucleoside linkages. Modified backbones can include those that retain phosphorus atoms in the backbone and those that do not have phosphorus atoms in the backbone. Suitable modified nucleic acid backbones containing phosphorus atoms therein may include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates such as 3'-alkylenephosphonates, 5'-alkylenephosphonates, chiral phosphonates, phosphinates, phosphoramidates (including 3'-aminophosphoramidates and aminoalkylphosphoramidates, phosphorodiamidates, thionophosphoramidates), thioalkylphosphates, thioalkylphosphotriesters, selenophosphates and boranophosphates, analogs with normal 3'-5' linkages, 2'-5' linkages, and analogs with reversed polarity (wherein one or more of the internucleotide linkages are 3' to 3', 5' to 5', or 2' to 2' linkages).
[0069] Nucleic acids may include polynucleotide backbones formed by short chain alkyl or cycloalkyl nucleoside linkages, mixed heteroatoms, and alkyl or cycloalkyl nucleoside linkages, or one or more short chain heteroatomic or heterocyclic nucleoside linkages. These may include those with morpholino linkages (formed in part by the sugar portion of the nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methyleneformacetyl and thioformacetyl backbones; riboacetyl backbones; olefin-containing backbones; sulfamic acid ester backbones; methyleneimino and methylenehydrazine backbones; sulfonate and sulfonamide backbones; amide backbones; and those with mixed N, O, S and CH 2 Others that are part of the components.
[0070] Nucleic acid can include nucleic acid mimics.The term "simulations" can be intended to include polynucleotides in which only the furanose ring or the furanose ring and the internucleotide bond are replaced by non-furanose groups, and the replacement of the furanose ring can also be referred to as a sugar substitute (surrogate). The heterocyclic base moiety or the modified heterocyclic base moiety can be maintained to hybridize with an appropriate target nucleic acid. A kind of such nucleic acid can be a peptide nucleic acid (PNA). In PNA, the sugar backbone of the polynucleotide can be replaced by an amide-containing backbone, particularly by an aminoethylglycine backbone. Nucleotide can be retained and directly or indirectly combined with the aza nitrogen atom of the amide moiety of the backbone. The backbone in the PNA compound can include two or more aminoethylglycine units connected, which makes PNA have an amide-containing backbone. The heterocyclic base moiety can be directly or indirectly combined with the aza nitrogen atom of the amide moiety of the backbone.
[0071] Nucleic acid can include morpholino backbone structure.For example, nucleic acid can include 6-membered morpholino rings replacing ribose rings.In some of these embodiments, phosphorodiamidate or other non-phosphodiester internucleoside linkages can replace phosphodiester linkages.
[0072] Nucleic acid can include morpholino units (e.g., morpholino nucleic acids) having a connection to a heterocyclic base attached to a morpholino ring. A linking group can connect the morpholino monomer units in morpholino nucleic acids. Oligomeric compounds based on nonionic morpholinos can have less undesirable interactions with cellular proteins. Polynucleotides based on morpholinos can be nonionic mimics of nucleic acids. Various compounds within the morpholino category can be connected using different linking groups. Polynucleotide mimics of other categories can be referred to as cyclohexenyl nucleic acids (CeNA). The furanose rings commonly present in nucleic acid molecules can be replaced by cyclohexenyl rings. Phosphoramidite monomers protected by CeNA DMT can be prepared using phosphoramidite chemistry and used for oligomeric compound synthesis. CeNA monomers are incorporated into nucleic acid chains to increase the stability of DNA / RNA hybrids. CeNA oligoadenylates can form complexes with nucleic acid complements, with stability similar to natural complexes. Additional modifications may include locked nucleic acids (LNA) in which the 2'-hydroxyl group is linked to the 4' carbon atom of the sugar ring, thereby forming a 2'-C,4'-C-oxymethylene linkage, thereby forming a bicyclic sugar moiety. The linkage may be a methylene (-CH 2 -) n A group wherein n is 1 or 2. LNA and LNA analogs can show very high duplex thermal stability (Tm = +3°C to +10°C) with complementary nucleic acids, stability to 3'-exonuclease degradation and good solubility.
[0073] Nucleic acids can also include modifications or substitutions of nucleobases (also referred to as "bases"). As used herein, "unmodified" or "natural" nucleobases can include purine bases (e.g., adenine (A) and guanine (G)), and pyrimidine bases (e.g., thymine (T), cytosine (C), and uracil (U)). Modified nucleobases may include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl derivatives and other alkyl derivatives of adenine and guanine, 2-propyl derivatives and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C≡C-CH3) uracil and cytosine, and other pyrimidine bases. Alkynyl derivatives, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halogen, 8-amino, 8-thio, 8-thioalkyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halogen, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-aminoadenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Modified nucleobases may include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido (5,4-b) (1,4) benzoxazin-2 (3H) -one), phenothiazine cytidine (1H-pyrimido (5,4-b) (1,4) benzothiazin-2 (3H) -one), G-clamps such as substituted phenoxazine cytidine (e.g., 9-(2-aminoethoxy)-H-pyrimido (5,4-(b) (1,4) benzoxazin-2 (3H) -one), phenoxazine cytidine (1H-pyrimido (5,4-b) (1,4) benzothiazin-2 (3H) -one), Thiazide cytidine (1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one), G-clamps such as substituted phenoxazine cytidines (e.g., 9-(2-aminoethoxy)-H-pyrimido(5,4-(b)(1,4)benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido(4,5-b)indol-2-one), pyridoindole cytidine (H-pyrido(3',2':4,5)pyrrolo[2,3-d]pyrimidin-2-one).
[0074] As used herein, the term "sample" may refer to a composition comprising a target. Suitable samples for analysis by the disclosed methods, devices and systems include cells, tissues, organs or organisms. As used herein, the term "sampling device" or "device" may refer to a device that can take a slice of a sample and / or place the slice on a substrate. The sampling device may refer to, for example, a fluorescence activated cell sorter (FACS) machine, a cell sorter, a biopsy needle, a biopsy device, a tissue sectioning device, a microfluidic device, a blade grid and / or an ultramicrotome.
[0075] As used herein, the term "solid support" may refer to a discrete solid or semi-solid surface to which more than one barcode (e.g., a random barcode) may be attached. A solid support may include any type of solid, porous or hollow sphere, ball, bearing, cylinder, or other similar configuration consisting of plastic, ceramic, metal, or polymeric material (e.g., hydrogel) on which nucleic acids may be fixed (e.g., covalently or non-covalently). A solid support may include discrete particles that may be spherical (e.g., microspheres) or have a non-spherical or irregular shape, such as a cube, a cuboid, a cone, a cylinder, a cone, an ellipse, or a disc, etc. The shape of a bead may be non-spherical. More than one solid support spaced apart in an array may not include a substrate. A solid support may be used interchangeably with the term "bead".
[0076] As used herein, the term "random barcode" may refer to a polynucleotide sequence comprising a tag of the present disclosure. A random barcode may be a polynucleotide sequence that can be used for random barcoding. A random barcode may be used to quantify a target in a sample. A random barcode may be used to control errors that may occur after a tag is associated with a target. For example, a random barcode may be used to assess amplification or sequencing errors. A random barcode associated with a target may be referred to as a random barcode-target or a random barcode-tag-target.
[0077] As used herein, the term "gene-specific random barcode" may refer to a polynucleotide sequence comprising a tag and a gene-specific target binding region. A random barcode may be a polynucleotide sequence that can be used for random barcoding. A random barcode may be used to quantify a target in a sample. A random barcode may be used to control errors that may occur after a tag is associated with a target. For example, a random barcode may be used to assess amplification or sequencing errors. A random barcode associated with a target may be referred to as a random barcode-target or a random barcode-tag-target.
[0078] As used herein, the term "random barcoding" can refer to random labeling (e.g., barcoding) of nucleic acids. Random barcoding can utilize a recursive Poisson strategy to associate and quantify labels associated with a target. As used herein, the term "random barcoding" can be used interchangeably with "random labeling."
[0079] As used herein, the term "target" may refer to a composition that can be associated with a barcode (e.g., a random barcode). Exemplary suitable targets for analysis by the disclosed methods, devices, and systems include oligonucleotides, DNA, RNA, mRNA, microRNA, tRNA, etc. The target may be single-stranded or double-stranded. In some embodiments, the target may be a protein, peptide, or polypeptide. In some embodiments, the target is a lipid. As used herein, "target" may be used interchangeably with "species".
[0080] As used herein, the term "reverse transcriptase" may refer to a group of enzymes having reverse transcriptase activity (i.e., catalyzing the synthesis of DNA from an RNA template). Typically, such enzymes include, but are not limited to, reverse transcriptases derived from retroviral reverse transcriptases, retrotransposon reverse transcriptases, retroplasmid reverse transcriptases, retrotranscriptases, bacterial reverse transcriptases, and II group introns, and their mutants, variants, or derivatives. Non-retroviral reverse transcriptases include non-LTR retrotransposon reverse transcriptases, retroplasmid reverse transcriptases, retrotranscriptases, and II group intron reverse transcriptases. Examples of II group intron reverse transcriptases include Lactococcus lactis LI.LtrB intron reverse transcriptases, Thermosynechococcus elongatus TeI4c intron reverse transcriptases, or Geobacillus stearothermophilus GsI-IIC intron reverse transcriptases. Other classes of reverse transcriptases can include many types of non-retroviral reverse transcriptases (ie, retrovirals, group II introns, and diversity-generating retroelements, among others).
[0081] The terms "universal adapter primer," "universal primer adapter," or "universal adapter sequence" are used interchangeably to refer to a nucleotide sequence that can be used to hybridize with a barcode (e.g., a random barcode) to generate a gene-specific barcode. The universal adapter sequence can be, for example, a known sequence that is common to all barcodes used in the methods of the present disclosure. For example, when more than one target is labeled using the methods disclosed herein, each target-specific sequence can be connected to the same universal adapter sequence. In some embodiments, more than one universal adapter sequence can be used in the methods disclosed herein. For example, when more than one target is labeled using the methods disclosed herein, at least two target-specific sequences are connected to different universal adapter sequences. The universal adapter primer and its complement can be included in two oligonucleotides, one of which contains a target-specific sequence and the other oligonucleotide contains a barcode. For example, the universal adapter sequence can be a portion of an oligonucleotide containing a target-specific sequence to generate a nucleotide sequence complementary to a target nucleic acid. A second oligonucleotide containing a barcode and a complementary sequence to the universal adapter sequence can hybridize with the nucleotide sequence and generate a target-specific barcode (e.g., a target-specific random barcode). The universal adapter primer may have a different sequence than the universal PCR primer used in the methods of the present disclosure.
[0082] Barcode
[0083] Barcoding, such as random barcoding, has been described in, for example, Fu et al., Proc Natl Acad Sci U.S.A., 2011 May 31, 108(22):9026-31; US 2011 / 0160078; Fan et al., Science, 2015, 347(6222):1258367; US 2015 / 0299784; and WO 2015 / 031691; the contents of each of these, including any supporting or supplementary information or materials, are incorporated herein by reference in their entirety. In some embodiments, the barcodes disclosed herein may be random barcodes, which may be polynucleotide sequences that can be used to randomly label (e.g., barcode, tag) a target. A barcode can be referred to as a stochastic barcode if the ratio of the number of different barcode sequences of a stochastic barcode to the number of occurrences of any target to be labeled can be or can be about 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or a number or range between any two of these values. The target can be an mRNA species including mRNA molecules having the same or nearly the same sequence. A barcode can be referred to as a stochastic barcode if the ratio of the number of different barcode sequences of a stochastic barcode to the number of occurrences of any target to be labeled is at least or at most 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100: 1. The barcode sequences of a stochastic barcode can be referred to as molecular markers.
[0084] The barcode (e.g., random barcode) may include one or more labels. Exemplary labels may include universal labels, cell labels, barcode sequences (e.g., molecular labels), sample labels, plate labels, spatial labels, and / or pre-spatial labels. Figure 1An exemplary barcode 104 with spatial tags is shown. The barcode 104 can include a 5' amine that can link the barcode to a solid support 108. The barcode can include universal tags, dimensional tags, spatial tags, cellular tags, and / or molecular tags. The order of the different tags (including but not limited to universal tags, dimensional tags, spatial tags, cellular tags, and molecular tags) in the barcode can vary. For example, Figure 1 As shown in , the universal label can be the label on the most 5' side (5'-most label), and the molecular label can be the label on the most 3' side (3'-most label). Spatial labels, dimensional labels and cell labels can be in any order. In some embodiments, universal labels, spatial labels, dimensional labels, cell labels and molecular labels are in any order. The barcode can include a target binding region. The target binding region can interact with the target (e.g., target nucleic acid, RNA, mRNA, DNA) in the sample. For example, the target binding region can include an oligo (dT) sequence that can interact with the poly (A) tail of mRNA. In some embodiments, the label of the barcode (e.g., universal label, dimensional label, spatial label, cell label and barcode sequence) is separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more nucleotides.
[0085] Mark (for example, cell marker) can comprise a group of unique defined length nucleic acid subsequences, for example, each seven nucleotides (equivalent to the number of bits used in some Hamming error correction codes), which can be designed to provide error correction capabilities. The error correction subsequence group comprising seven nucleotide sequences can be designed so that any paired combination of the sequences in the group exhibits a defined "genetic distance" (or number of mismatched bases), for example, a group of error correction subsequences can be designed to exhibit a genetic distance of three nucleotides. In this case, the review of the error correction sequence in the sequence data group of the target nucleic acid molecule of the mark (described in more detail below) can allow people to detect or correct amplification errors or sequencing errors. In some embodiments, the length of the nucleic acid subsequence for generating the error correction code can vary, for example, their length can be the following or can be about the following: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 31, 40, 50 nucleotides or the nucleotides of the number or range between any two values in these values. In some embodiments, nucleic acid subsequences of other lengths can be used to generate error correction codes.
[0086] The barcode may include a target binding region. The target binding region may interact with a target in a sample. The target may be or include: ribonucleic acid (RNA), messenger RNA (mRNA), microRNA, small interfering RNA (siRNA), RNA degradation products, RNA each containing a poly (A) tail, or any combination thereof. In some embodiments, more than one target may include deoxyribonucleic acid (DNA).
[0087] In some embodiments, the target binding region may include an oligo (dT) sequence that can interact with the poly (A) tail of the mRNA. One or more markers of the barcode (e.g., universal markers, dimensional markers, spatial markers, cell markers, and barcode sequences (e.g., molecular markers)) may be separated from another or two remaining markers of the barcode by a spacer. The spacer may be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more nucleotides. In some embodiments, all markers of the barcode are not separated by a spacer.
[0088] General Tags
[0089] The barcode may include one or more universal markers. In some embodiments, one or more universal markers may be the same for all barcodes in the barcode group attached to a given solid support. In some embodiments, one or more universal markers may be the same for all barcodes attached to more than one bead. In some embodiments, the universal marker may include a nucleic acid sequence that can be hybridized with a sequencing primer. A sequencing primer may be used to sequence the barcode including the universal marker. A sequencing primer (e.g., a universal sequencing primer) may include a sequencing primer associated with a high-throughput sequencing platform. In some embodiments, the universal marker may include a nucleic acid sequence that can be hybridized with a PCR primer. In some embodiments, the universal marker may include a nucleic acid sequence that can be hybridized with a sequencing primer and a PCR primer. The nucleic acid sequence of the universal marker that can be hybridized with a sequencing primer or a PCR primer may be referred to as a primer binding site. The universal marker may include a sequence that can be used to initiate transcription of a barcode. The universal marker may include a sequence that can be used to extend a barcode or a region within a barcode. The length of the universal tag can be, is about, is at least, or is at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 200, 300 nucleotides, or a number or range between any two of these values. In some embodiments, a cleavable linker or modified nucleotide can be part of the universal tag sequence to enable the barcode to be cleaved from the support.
[0090] Dimension tagging
[0091] The barcode may include one or more dimensional markers. In some embodiments, the dimensional marker may include a nucleic acid sequence that provides information about the dimension in which the marker (e.g., random marker) occurs. For example, the dimensional marker may provide information about the time at which the target is barcoded. The dimensional marker may be associated with the time of barcoding (e.g., random barcoding) in the sample. The dimensional marker may be activated at the time of the marker. Different dimensional markers may be activated at different times. The dimensional marker provides information about the order in which the target, the target group, and / or the sample are barcoded. For example, a population of cells may be barcoded in the G0 phase of the cell cycle. In the G1 phase of the cell cycle, cells may be pulsed again with a barcode (e.g., a random barcode). In the S phase of the cell cycle, cells may be pulsed again with a barcode, and so on. The barcode at each pulse (e.g., each period of the cell cycle) may include different dimensional markers. In this way, the dimensional marker provides information about which targets are labeled in which period of the cell cycle. Dimensional markers may interrogate many different biological times. Exemplary biological events may include, but are not limited to, cell cycle, transcription (e.g., transcription initiation), and transcript degradation. In another example, a sample (e.g., a cell, a population of cells) may be labeled before and / or after treatment with a drug and / or therapy. Changes in the copy number of different targets may indicate the response of a sample to a drug and / or therapy.
[0092] Dimensional markers can be activatable. Activatable dimensional markers can be activated at a specific time point. Activatable markers can be, for example, constitutively activated (e.g., not closed). Activatable dimensional markers can be, for example, reversibly activated (e.g., activatable dimensional markers can be turned on and off). Dimensional markers can be, for example, reversibly activated at least 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times or more times. In some embodiments, dimensional markers can be activated by fluorescence, light, chemical events (e.g., cleavage, connecting another molecule, adding modifications (e.g., pegylation, sumoylate, acetylation, methylation, deacetylation, demethylation), photochemical events (e.g., photocaging) and the introduction of non-natural nucleotides.
[0093] In some embodiments, the dimensional marking can be the same for all barcodes (e.g., random barcodes) attached to a given solid support (e.g., beads), but different for different solid supports (e.g., beads). In some embodiments, at least 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, or 100% of the barcodes on the same solid support can contain the same dimensional marking.
[0094] Up to 106 or more unique dimensional marker sequences may be present in more than one solid support (e.g., bead). The length of the dimensional marker may be, about, at least, or at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 200, or a number or range between any two of these values.
[0095] Space Marking
[0096] The barcode may include one or more spatial markers. In some embodiments, the spatial marker may include a nucleic acid sequence that provides information about the spatial orientation of a target molecule associated with the barcode. The spatial marker may be associated with a coordinate in a sample. The coordinate may be a fixed coordinate. For example, the coordinate may be fixed with reference to a substrate. The spatial marker may be referenced to a two-dimensional or three-dimensional grid. The coordinate may be fixed with reference to a landmark. Landmarks may be identifiable in space. Landmarks may be structures that may be imaged. Landmarks may be biological structures, such as anatomical landmarks. Landmarks may be cell landmarks, such as organelles. Landmarks may be non-natural landmarks, such as structures with identifiable identifiers (such as color coding, barcodes, magnetic properties, fluorescence, radioactivity, or unique size or shape). Spatial markers may be associated with physical partitions (e.g., holes, containers, or droplets). In some embodiments, more than one spatial marker is used together to encode one or more positions in space.
[0097] The spatial label can be the same for all barcodes attached to a given solid support (e.g., bead), but different for different solid supports (e.g., beads). In some embodiments, the percentage of barcodes on the same solid support that comprise the same spatial label can be less than, about less than, at least less than, or at most less than 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, 100%, or a number or range between any two of these values.
[0098] Up to 106 or more unique spatial marker sequences can be present in more than one solid support (e.g., beads). The length of the spatial marker can be, about, at least, or at most nucleotides: 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 125, 150, 175, 200, 250, or 300 or a number or range between any two of these values.
[0099] Cell labeling
[0100] Barcode (for example, random barcode) can comprise one or more cell markers.In some embodiments, cell marker can comprise the nucleic acid sequence that provides the information for determining which target nucleic acid is derived from which cell.In some embodiments, cell marker is identical for all barcodes attached to a given solid support (for example, bead), but is different for different solid supports (for example, bead).In some embodiments, the percentage of the barcode comprising the same cell marker on the same solid support can be below, about below, at most below or at least below: 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, 100% or in any two of these values between the number or range.
[0101] Up to 106 or more unique cell marker sequences may be present in more than one solid support (e.g., beads). The length of a cell marker may be, about, at least, or at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 125, 150, 175, 200, or a number or range between any two of these values.
[0102] Barcode sequence
[0103] The barcode can comprise one or more barcode sequences. In some embodiments, the barcode sequence can comprise a nucleic acid sequence that provides identification information for a particular type of target nucleic acid species that hybridizes to the barcode. The barcode sequence can comprise a nucleic acid sequence that provides a counter (e.g., provides a rough estimate) for a particular occurrence of a target nucleic acid species that hybridizes to a barcode (e.g., a target binding region).
[0104] In some embodiments, a set of diverse barcode sequences are attached to a given solid support (e.g., a bead). In some embodiments, there may be or may be about the following unique molecular marker sequences: 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9For example, more than one barcode may include about 6561 barcode sequences with different sequences. As another example, more than one barcode may include about 65536 barcode sequences with different sequences. In some embodiments, there may be at least the following or at most the following: 10 2 10 3 10 4 10 5 10 6 10 7 10 8 Species or 10 9 A unique barcode sequence. A unique molecular marker sequence can be attached to a given solid support (e.g., a bead).
[0105] In different embodiments, the length of the barcode can be different. For example, the length of the barcode can be less than, about less than, at least less than, or at most less than 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 nucleotides, or a number or range between any two of these values.
[0106] Molecular markers
[0107] The barcode (e.g., a random barcode) can include one or more molecular markers. The molecular marker can include a barcode sequence. In some embodiments, the molecular marker can include a nucleic acid sequence that provides identification information for a specific type of target nucleic acid species that hybridizes to the barcode. The molecular marker can include a nucleic acid sequence that provides a counter for a specific occurrence of a target nucleic acid species that hybridizes to a barcode (e.g., a target binding region).
[0108] In some embodiments, a set of distinct molecular markers are attached to a given solid support (e.g., a bead). In some embodiments, there may be the following, or there may be about the following unique molecular marker sequences: 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 or a number or range between any two of these values. For example, more than one barcode may include about 6561 molecular markers with different sequences. As another example, more than one barcode may include about 65536 molecular markers with different sequences. In some embodiments, there may be at least the following, or at most the following unique molecular marker sequences: 102 10 3 10 4 10 5 10 6 10 7 10 8 Species or 10 9 A barcode having a unique molecular marker sequence can be attached to a given solid support (e.g., a bead).
[0109] For stochastic barcoding using more than one stochastic barcode, the ratio of the number of different molecular marker sequences to the number of occurrences of any target can be, is about, is at least, or is at most 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or a number or range between any two of these values. The target can be an mRNA species including mRNA molecules having the same or nearly the same sequence.
[0110] The length of a molecular marker can be, about, at least, or at most 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 nucleotides, or a number or range between any two of these values.
[0111] Target binding region
[0112] The barcode may include one or more target binding regions, such as capture probes. In some embodiments, the target binding region may hybridize with a target of interest. In some embodiments, the target binding region may include a nucleic acid sequence that specifically hybridizes with a target (e.g., a target nucleic acid, a target molecule, a cell nucleic acid to be analyzed) (e.g., specifically hybridizes with a specific gene sequence). In some embodiments, the target binding region may include a nucleic acid sequence that can be attached (e.g., hybridized) to a specific position of a specific target nucleic acid. In some embodiments, the target binding region may include a nucleic acid sequence that can specifically hybridize with a restriction enzyme site overhang (e.g., an EcoRI sticky end overhang). The barcode may then be attached to any nucleic acid molecule that includes a sequence complementary to a restriction site overhang.
[0113] In some embodiments, the target binding region may include a non-specific target nucleic acid sequence. Non-specific target nucleic acid sequences may refer to sequences that can bind to more than one target nucleic acid independently of the specific sequence of the target nucleic acid. For example, the target binding region may include a random polymer sequence or an oligo (dT) sequence hybridized with a poly (A) tail on an mRNA molecule. The random polymer sequence may be, for example, a random dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, nonamer, decamer or a higher polymer sequence of any length. In some embodiments, for all barcodes attached to a given bead, the target binding region is the same. In some embodiments, for more than one barcode attached to a given bead, the target binding region may include two or more different target binding sequences. The length of the target binding region can be less than, about less than, at least about less than, or at most about less than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 nucleotides, or a number or range between any two of these values.
[0114] In some embodiments, the target binding region can include oligo(dT), which can hybridize with mRNA comprising polyadenylated ends. The target binding region can be gene-specific. For example, the target binding region can be configured to hybridize with a specific region of the target. The length of the target binding region can be below, about below, at least below, or at most below: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or a number or range of nucleotides between any two of these values. When the barcode includes a gene-specific target binding region, the barcode can be referred to as a gene-specific barcode in this article.
[0115] Universal adapter primer
[0116] The barcode may comprise one or more universal adapter primers. For example, a gene-specific barcode (such as a gene-specific random barcode) may comprise a universal adapter primer. A universal adapter primer may refer to a universal nucleotide sequence that is common to all barcodes. A universal adapter primer may be used to construct a gene-specific barcode. The length of a universal adapter primer may be below, about below, at least below, or at most below: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or any two of these nucleotides or ranges. The length of a universal adapter primer may be 5-30 nucleotides.
[0117] Connectors
[0118] When the barcode comprises more than one type of marker (e.g., more than one cellular marker or more than one barcode sequence, such as a molecular marker), the markers can be interspersed with adapter tag sequences. The length of the adapter tag sequence can be less than, about less than, at least about less than, or at most about less than 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more nucleotides. The adapter tag sequence can be used to facilitate the synthesis of the barcode. The adapter tag can include an error correction (e.g., Hamming) code.
[0119] Solid support
[0120] In some embodiments, the barcodes disclosed herein (such as random barcodes) can be associated with solid supports. The solid support can be, for example, synthetic particles. In some embodiments, some or all barcode sequences (such as molecular markers of random barcodes (e.g., first barcode sequences)) of more than one barcode on a solid support have a difference of at least one nucleotide. The cell markers of the barcodes on the same solid support can be the same. The cell markers of the barcodes on different solid supports can have a difference of at least one nucleotide. For example, the first cell marker of the first more than one barcode on the first solid support can have the same sequence, and the second cell marker of the second more than one barcode on the second solid support can have the same sequence. The first cell marker of the first more than one barcode on the first solid support and the second cell marker of the second more than one barcode on the second solid support can have a difference of at least one nucleotide. The cell marker can be, for example, about 5-20 nucleotides long. The barcode sequence can be, for example, about 5-20 nucleotides long. The synthetic particles can be, for example, beads.
[0121] Pearl can be for example silica gel beads, controlled pore glass beads, magnetic beads, Dynabead, Sephadex / agarose gel beads, cellulose beads, polystyrene beads or any combination thereof. Pearl can include materials such as polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic substances, ceramics, plastics, glass, methylstyrene, acrylic polymers, titanium, latex, agarose gel, cellulose, nylon, silicone or any combination thereof. In some embodiments, pearl can be polymer beads (for example deformable beads or gel beads) (such as gel beads from 10XGenomics (San Francisco, CA)) functionalized with barcodes or random barcodes. In some embodiments, gel beads can include gel based on polymers. Gel beads can be produced, for example, by encapsulating one or more polymer precursors into droplets. After polymer precursors are exposed to accelerators (for example, tetramethylethylenediamine (TEMED)), gel beads can be produced.
[0122] The particles can be degradable. For example, the polymer beads can dissolve, melt or degrade, for example, under desired conditions. The desired conditions can include environmental conditions. The desired conditions can cause the polymer beads to dissolve, melt or degrade in a controlled manner. The gel beads can dissolve, melt or degrade due to chemical stimulation, physical stimulation, biological stimulation, thermal stimulation, magnetic stimulation, electrical stimulation, light stimulation or any combination thereof.
[0123] For example, analyte and / or reagent (such as oligonucleotide barcode) can be coupled / fixed to the inner surface of gel beads (for example, via the diffusion of oligonucleotide barcode and / or the material for producing oligonucleotide barcode) and / or the outer surface of gel beads or any other microcapsule described herein. Coupling / fixation can be via any form of chemical bonding (for example, covalent bond, ionic bond) or physical phenomenon (for example, van der Waals force, dipole-dipole interaction, etc.). In some embodiments, the coupling / fixation of reagent described herein with gel beads or any other microcapsule can be reversible, such as, for example, via unstable part (for example, via chemical crosslinking, including chemical crosslinking described herein). After applying stimulation, the unstable part can be cleaved and release the fixed reagent. In some embodiments, the unstable part is a disulfide bond. For example, in the case where the oligonucleotide barcode is fixed to the gel beads via a disulfide bond, exposing the disulfide bond to a reducing agent can cleave the disulfide bond and release the oligonucleotide barcode from the beads. The labile moiety can be included as part of a gel bead or microcapsule, as part of a chemical linker that connects a reagent or analyte to a gel bead or microcapsule, and / or as part of a reagent or analyte. In some embodiments, at least one barcode of more than one barcode can be immobilized on a particle, partially immobilized on a particle, encapsulated in a particle, partially encapsulated in a particle, or any combination thereof.
[0124] Gel beads may include a wide range of different polymers including, but not limited to, polymers, thermosensitive polymers, photosensitive polymers, magnetic polymers, pH sensitive polymers, salt sensitive polymers, chemical sensitive polymers, polyelectrolytes, polysaccharides, peptides, proteins and / or plastics. The polymer may include, but is not limited to, materials such as poly(N-isopropylacrylamide) (PNIPAAm), poly(styrene sulfonate) (PSS), poly(allylamine) (PAAm), poly(acrylic acid) (PAA), poly(ethyleneimine) (PEI), poly(bisallyldimethyl-ammonium chloride) (PDADMAC), poly(pyrrole) (poly(pyrolle), PPy), poly(vinylpyrrolidone) (PVPON), poly(vinylpyridine) (PVP), poly(methacrylic acid) (PMAA), poly(methyl methacrylate) (PMMA), polystyrene (PS), poly(tetrahydrofuran) (PTHF), poly(o-phthalaldehyde) (PPA), poly(hexylviologen) (PHV), poly(L-lysine) (PLL), poly(L-arginine) (PARG), and poly(lactic-co-glycolic acid) (PLGA).
[0125] Many chemical stimuli can be used to trigger the destruction, dissolution or degradation of beads. Examples of these chemical changes can include, but are not limited to, pH-mediated changes in the bead wall, disintegration of the bead wall via chemical cleavage of cross-links, triggered depolymerization of the bead wall, and bead wall switching reactions. Bulk changes can also be used to trigger the destruction of beads.
[0126] Bulk or physical alteration of microcapsules by various stimuli also provides many advantages in designing capsules to release agents. Bulk or physical alteration occurs on a macroscopic scale, where bead rupture is the result of mechanical-physical forces caused by the stimulus. These processes can include, but are not limited to, pressure-induced rupture, bead wall melting, or changes in the porosity of the bead wall.
[0127] Biostimulation can also be used to trigger the destruction, dissolution or degradation of beads. Generally, biological triggers are similar to chemical triggers, but many examples use biomolecules or molecules common in living systems, such as enzymes, peptides, sugars, fatty acids, nucleic acids, etc. For example, beads can include polymers with peptide crosslinks that are sensitive to cleavage by specific proteases. More specifically, one example can include microcapsules containing GFLGK peptide crosslinks. Upon addition of a biological trigger (such as the protease cathepsin B), the peptide crosslinks of the shell wall are cleaved and the contents of the beads are released. In other cases, the protease can be heat-activated. In another example, the beads include a shell wall that includes cellulose. The addition of chitosan hydrolase serves as a biotrigger for cleavage of cellulose bonds, depolymerization of the shell wall and release of its internal contents.
[0128] The beads can be induced to release their contents upon application of a thermal stimulus. Changes in temperature can cause various changes in the beads. Changes in heat can cause the beads to melt, causing the bead wall to disintegrate. In some cases, heating can increase the internal pressure of the internal components of the beads, causing the beads to rupture or explode. In some cases, heat can cause the beads to transform into a shrunken, dehydrated state. Heat can also act on thermosensitive polymers within the bead wall, causing the beads to break down.
[0129] Including magnetic nanoparticles in the bead wall of the microcapsule can allow for triggered rupture of the beads and directing the beads into an array. The device of the present disclosure may include magnetic beads for any purpose. For example, Fe 3 O 4 Nanoparticles incorporated into polyelectrolyte-containing beads trigger rupture in the presence of an oscillating magnetic field stimulus.
[0130] The beads can also be destroyed, dissolved or degraded as a result of electrical stimulation. Similar to the magnetic particles described in the previous section, the electrosensitive beads can allow for triggered rupture of the beads as well as other functions, such as alignment in an electric field, conductivity or redox reactions. In one example, beads containing electrosensitive materials are aligned in an electric field so that the release of internal reagents can be controlled. In other examples, the electric field can induce redox reactions within the bead wall itself, which can increase porosity.
[0131] Light stimulation can also be used to destroy the beads. Many light triggers are possible and can include systems using various molecules such as nanoparticles and chromophores that can absorb photons of a specific wavelength range. For example, metal oxide coatings can be used as capsule triggers. UV irradiation of polyelectrolyte capsules coated with SiO2 can cause the disintegration of the bead wall. In yet another example, photoconvertible materials such as azobenzene groups can be incorporated into the bead wall. Upon application of UV or visible light, chemicals such as these undergo reversible cis-to-trans isomerization upon absorption of photons. In this regard, the incorporation of photon switches can cause the bead wall to disintegrate or become more porous upon application of a light trigger.
[0132] For example, in Figure 2 In the non-limiting example of barcoding (e.g., random barcoding) illustrated in FIG, after introducing cells (such as single cells) into more than one microwell of a microwell array at block 208, beads may be introduced into more than one microwell of a microwell array at block 212. Each microwell may contain one bead. The beads may contain more than one barcode. The barcode may contain a 5' amine region attached to the bead. The barcode may contain a universal tag, a barcode sequence (e.g., a molecular tag), a target binding region, or any combination thereof.
[0133] The barcodes disclosed herein can be associated (e.g., attached) with a solid support (e.g., a bead). The barcodes associated with a solid support can each include a barcode sequence selected from at least 100 or 1000 barcode sequences with unique sequences. In some embodiments, different barcodes associated with a solid support can include barcodes with different sequences. In some embodiments, a certain percentage of the barcodes associated with a solid support include the same cell marker. For example, the percentage can be the following or can be about the following: 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99%, 100%, or a number or range between any two of these values. As another example, the percentage can be at least the following or can be at most the following: 60%, 70%, 80%, 85%, 90%, 95%, 97%, 99% or 100%. In some embodiments, the barcodes associated with a solid support can have the same cell marker. The barcodes associated with different solid supports can have different cell markers selected from at least 100 or 1000 cell markers having unique sequences.
[0134] The barcodes disclosed herein can be associated (e.g., attached) with a solid support (e.g., a bead). In some embodiments, more than one target in a sample can be barcoded with a solid support including more than one synthetic particle associated with more than one barcode. In some embodiments, a solid support can include more than one synthetic particle associated with more than one barcode. The spatial marking of more than one barcode on different solid supports can have a difference of at least one nucleotide. The solid support can include more than one barcode, for example, in two or three dimensions. The synthetic particle can be a bead. The bead can be a silica bead, a controlled pore glass bead, a magnetic bead, a Dynabead, a Sephadex / agarose gel bead, a cellulose bead, a polystyrene bead, or any combination thereof. The solid support can include a polymer, a matrix, a hydrogel, a needle array device, an antibody, or any combination thereof. In some embodiments, the solid support can float freely. In some embodiments, the solid support can be embedded in a semi-solid or solid array. The barcode may not be associated with the solid support. The barcode can be a single nucleotide. The barcode can be associated with a substrate.
[0135] As used herein, the terms "tethered," "attached," and "fixed" can be used interchangeably and can refer to covalent or non-covalent means for attaching a barcode to a solid support. Any of a variety of different solid supports can be used as a solid support for attaching pre-synthesized barcodes or for in situ solid phase synthesis of barcodes.
[0136] The solid support can be a bead. The bead can include one or more types of solid, porous or hollow spheres, balls, sockets, cylinders, or other similar configurations that can fix nucleic acids (e.g., covalently or non-covalently). The bead can be made of, for example, plastic, ceramic, metal, polymer material, or any combination thereof. The bead can be or include spherical (e.g., microspheres) or discrete particles with non-spherical or irregular shapes, such as cubes, cuboids, cones, cylinders, cones, ellipses, or discs. In some embodiments, the shape of the bead can be non-spherical.
[0137] The beads may include a variety of materials, including but not limited to paramagnetic materials (e.g., magnesium, molybdenum, lithium, and tantalum), superparamagnetic materials (e.g., ferrite (Fe 3 O 4 In some embodiments, the beads (e.g., beads to which the marker is attached) are hydrogel beads. In some embodiments, the beads include hydrogels.
[0138] Some embodiments disclosed herein include one or more particles (e.g., beads). Each particle can contain more than one oligonucleotide (e.g., barcode). Each of more than one oligonucleotide can contain a barcode sequence (e.g., a molecular marker sequence), a cell marker, and a target binding region (e.g., an oligo (dT) sequence, a gene-specific sequence, a random polymer, or a combination thereof). The cell marker sequence of each of more than one oligonucleotide can be the same. The cell marker sequences of the oligonucleotides on different particles can be different, so that the oligonucleotides on different particles can be identified. In different embodiments, the number of different cell marker sequences can be different. In some embodiments, the number of cell marker sequences may be less than, may be about less than, may be at least less than, or may be at most less than 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000 6 10 7 10 8 10 9In some embodiments, no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more particles in more than one particle include oligonucleotides with the same cell sequence. In some embodiments, more than one particle including oligonucleotides with the same cell sequence can be at most 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or more. In some embodiments, more than one particle does not have the same cell marker sequence.
[0139] More than one oligonucleotide on each particle can comprise different barcode sequences (e.g., molecular markers). In some embodiments, the number of barcode sequences can be less than, about less than, at least less than, or at most less than 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000 6 10 7 10 8 10 9In some embodiments, more than one oligonucleotide may contain a different barcode sequence. In some embodiments, more than one oligonucleotide may contain a different barcode sequence. In some embodiments, more than one oligonucleotide may contain a different barcode sequence. In some embodiments, more than one oligonucleotide may contain a different barcode sequence. In some embodiments, more than one oligonucleotide may contain a different barcode sequence. In some embodiments, more than one oligonucleotide may contain a different barcode sequence. In some embodiments, the ratio of the occurrence (or copies or number) of the target to be labeled and the different barcode sequences can be at least 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or more. In some embodiments, each of the more than one oligonucleotide further comprises a sample label, a universal label, or both. The particle can be, for example, a nanoparticle or a microparticle.
[0140] The size of the beads can be different. For example, the diameter of the beads can range from 0.1 micron to 50 microns. In some embodiments, the diameter of the beads can be or can be about 0.1 micron, 0.5 micron, 1 micron, 2 microns, 3 microns, 4 microns, 5 microns, 6 microns, 7 microns, 8 microns, 9 microns, 10 microns, 20 microns, 30 microns, 40 microns, or 50 microns or a number or range between any two of these values.
[0141] The diameter of the bead can be related to the diameter of the hole of the substrate. In some embodiments, the diameter of the bead can be longer or shorter than the diameter of the hole or about less than: 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or a number or range between any two values in these values. The diameter of the bead can be related to the diameter of the cell (e.g., a single cell trapped by the hole of the substrate). In some embodiments, the diameter of the bead can be longer or shorter than the diameter of the hole by at least or at most 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The diameter of the bead can be related to the diameter of the cell (e.g., a single cell trapped by the hole of the substrate). In some embodiments, the diameter of the bead can be less than, about less than, at least less than, or at most less than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300% longer or shorter than the diameter of the cell, or a number or range between any two of these values.
[0142] The beads can be attached to a substrate and / or embedded in a substrate. The beads can be attached to a gel, a hydrogel, a polymer and / or a matrix and / or embedded in a gel, a hydrogel, a polymer and / or a matrix. The spatial position of the beads in a substrate (e.g., a gel, a matrix, a support or a polymer) can be identified using a spatial marker present on a barcode on the beads, which can be used as a positional address.
[0143] Examples of beads may include, but are not limited to, streptavidin beads, agarose beads, magnetic beads, microbeads, antibody-conjugated beads (e.g., anti-immunoglobulin microbeads), protein A-conjugated beads, protein G-conjugated beads, protein A / G-conjugated beads, protein L-conjugated beads, oligo(dT)-conjugated beads, silica beads, silica-like beads, anti-biotin microbeads, anti-fluorescent dye microbeads, and BcMag™ carboxyl-terminated magnetic beads.
[0144] The beads can be associated with (e.g., impregnated with) quantum dots or fluorescent dyes to make them fluoresce in one fluorescent optical channel or more than one optical channel. The beads can be associated with iron oxide or chromium oxide to make them paramagnetic or ferromagnetic. The beads can be identifiable. For example, a camera can be used to image the beads. The beads can have a detectable code associated with the beads. For example, the beads can contain a barcode. The beads can change size, for example due to swelling in an organic or inorganic solution. The beads can be hydrophobic. The beads can be hydrophilic. The beads can be biocompatible.
[0145] The solid support (e.g., bead) can be visualized. The solid support can include a visualization label (e.g., a fluorescent dye). The solid support (e.g., bead) can be etched with an identifier (e.g., a number). The identifier can be visualized by imaging the bead.
[0146] The solid support may include soluble, semi-soluble or insoluble materials. When the solid support includes a linker, a scaffold, a building block or other reactive moiety attached thereto, the solid support may be referred to as "functionalized", while when the solid support lacks such reactive moieties attached thereto, the solid support may be referred to as "non-functionalized". The solid support may be free in solution, such as in a microtiter well; in a flow-through form, such as in a column; or used as a dipstick.
[0147] Solid supports can include membranes, paper, plastics, coating surfaces, flat surfaces, glass, slides, chips, or any combination thereof. Solid supports can take the form of resins, gels, microspheres, or other geometric configurations. Solid supports can include silicon dioxide chips, micron particles, nanoparticles, plates, arrays, capillaries, flat supports such as glass fiber filters, glass surfaces, metal surfaces (steel, gold, silver, aluminum, silicon, and copper), glass supports, plastic supports, silicon supports, chips, filters, membranes, microplates, slides, plastic materials including porous plates or membranes (e.g., formed by polyethylene, polypropylene, polyamide, polyvinylidene fluoride), and / or wafers, combs, needles or pinheads (e.g., suitable for combined synthesis or analysis of needle arrays) or beads, flat surfaces such as recesses or nanoliter well arrays of wafers (e.g., silicon wafers), wafers with recesses (with or without filter bottoms).
[0148] The solid support may include a polymer matrix (e.g., a gel, a hydrogel). The polymer matrix may be capable of permeating intracellular spaces (e.g., around organelles). The polymer matrix may be capable of being pumped throughout the circulatory system.
[0149] As used herein, substrate can refer to a solid support type. Substrate can refer to a solid support that can contain a barcode or a random barcode of the present disclosure. Substrate can, for example, include more than one micropore. Substrate can, for example, be a hole array including two or more micropores. In some embodiments, micropores can include a small reaction chamber of defined volume. In some embodiments, micropores can retain one or more cells. In some embodiments, micropores can only retain one cell. In some embodiments, micropores can retain one or more solid supports. In some embodiments, micropores can only retain one solid support. In some embodiments, micropores retain single cells and single solid supports (e.g., beads). Micropores can contain barcode reagents of the present disclosure.
[0150] Barcoding method
[0151] The present disclosure provides a method for estimating the number of different targets at different locations in a body sample (e.g., a tissue, an organ, a tumor, a cell). The method may include placing a barcode (e.g., a random barcode) in close proximity to the sample, lysing the sample, associating different targets with the barcode, amplifying the target and / or digitally counting the target. The method may also include analyzing and / or visualizing the information obtained from the spatial markers on the barcode. In some embodiments, the method includes visualizing more than one target in the sample. Mapping more than one target to a map of the sample may include generating a two-dimensional map or a three-dimensional map of the sample. Two-dimensional maps and three-dimensional maps may be generated before or after barcoding more than one target in the sample (e.g., random barcoding). Visualizing more than one target in the sample may include mapping more than one target to a map of the sample. Mapping more than one target to a map of the sample may include generating a two-dimensional map or a three-dimensional map of the sample. Two-dimensional maps and three-dimensional maps may be generated before or after barcoding more than one target in the sample. In some embodiments, the two-dimensional map and the three-dimensional map can be generated before or after the sample is lysed. Lysing the sample before or after generating the two-dimensional map or the three-dimensional map can include heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof.
[0152] Barcoding more than one target can include hybridizing more than one barcode to more than one target to generate barcoded targets (e.g., randomly barcoded targets). Barcoding more than one target can include generating an indexed library of barcoded targets. Generating an indexed library of barcoded targets can be performed with a solid support comprising more than one barcode (e.g., random barcodes).
[0153] Bring the sample and barcode into contact
[0154] The present disclosure provides methods for contacting a sample (e.g., a cell) with a substrate of the present disclosure. Samples including, for example, cells, organs, or tissue slices can be contacted with a barcode (e.g., a random barcode). Cells can be contacted, for example, by gravity flow, wherein the cells can be precipitated and a monolayer can be produced. The sample can be a tissue slice. The slice can be placed on a substrate. The sample can be one-dimensional (e.g., forming a flat surface). The sample (e.g., a cell) can be dispersed throughout a substrate, for example, by growing / culturing cells on a substrate.
[0155] When the barcode is in close proximity to the target, the target can hybridize to the barcode. The barcodes can be contacted in a non-exhaustive ratio so that each different target can be associated with a different barcode of the present disclosure. To ensure effective association between the target and the barcode, the target and the barcode can be cross-linked.
[0156] Cell lysis
[0157] After the distribution of cells and barcodes, the cells can be lysed to release the target molecules. Cell lysis can be accomplished by any of a variety of means, such as by chemical or biochemical means, by osmotic shock, or by means of thermal lysis, mechanical lysis or optical lysis. Cells can be lysed by adding a cell lysis buffer containing a detergent (e.g., SDS, lithium dodecyl sulfate, Triton X-100, Tween-20 or NP-40), an organic solvent (e.g., methanol or acetone) or a digestive enzyme (e.g., proteinase K, pepsin or trypsin) or any combination thereof. In order to increase the association of the target with the barcode, the diffusion rate of the target molecule can be changed by, for example, reducing the temperature of the lysate and / or increasing the viscosity of the lysate.
[0158] In some embodiments, filter paper can be used to crack the sample. The filter paper can be soaked with lysis buffer on the top of the filter paper. The filter paper can be applied to the sample with pressure, which can promote the cracking of the sample and the hybridization of the target of the sample with the substrate.
[0159] In some embodiments, lysis can be performed by mechanical lysis, thermal lysis, optical lysis and / or chemical lysis. Chemical lysis can include the use of digestive enzymes such as proteinase K, pepsin and trypsin. Cleavage can be performed by adding lysis buffer to the substrate. Lysis buffer can include Tris HCl. Lysis buffer can include at least about or at most about: 0.01M, 0.05M, 0.1M, 0.5M or 1M or more Tris HCl. Lysis buffer can include about 0.1M Tris HCl. The pH of the lysis buffer can be, about, at least about or at most about 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, or a number or range between any two of these values. Lysis buffer can include salt (e.g., LiCl). The salt concentration in the lysis buffer can be at least about 0.1M, 0.5M or 1M or higher. The salt concentration in the lysis buffer can be up to about 0.1M, 0.5M or 1M or higher. In some embodiments, the concentration of the salt in the lysis buffer is about 0.5M. The lysis buffer can contain a detergent (e.g., SDS, lithium dodecyl sulfate, triton X, tween, NP-40). The detergent concentration in the lysis buffer can be at least about or up to about 0.0001%, 0.0005%, 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6% or 7% or higher. In some embodiments, the detergent concentration in the lysis buffer is about 1% lithium dodecyl sulfate. The time used in the lysis method can depend on the amount of detergent used. In some embodiments, the more detergent is used, the less time is required for lysis. The lysis buffer can contain a chelating agent (e.g., EDTA, EGTA). The chelating agent concentration in the lysis buffer can be at least about 1mM, 5mM, 10mM, 15mM, 20mM, 25mM or 30mM or higher. The chelating agent concentration in the lysis buffer can be at most about 1mM, 5mM, 10mM, 15mM, 20mM, 25mM or 30mM or higher. In some embodiments, the chelating agent concentration in the lysis buffer is about 10mM. The lysis buffer can include a reducing agent (e.g., β-mercaptoethanol, DTT). The concentration of the reducing agent in the lysis buffer can be at least about or at most about 1mM, 5mM, 10mM, 15mM or 20mM or higher. In some embodiments, the lysis buffer can include about 0.1M Tris HCl, about pH 7.5, about 0.5M LiCl, about 1% lithium dodecyl sulfate, about 10mM EDTA and about 5mM DTT.
[0160] Lysis can be performed at a temperature of about 4° C., 10° C., 15° C., 20° C., 25° C., or 30° C. Lysis can be performed for about 1 minute, 5 minutes, 10 minutes, 15 minutes, or 20 minutes or more. The lysed cells can contain at least about or at most about 100,000, 200,000, 300,000, 400,000, 500,000, 600,000, or 700,000 or more target nucleic acid molecules.
[0161] Attaching barcodes to target nucleic acid molecules
[0162] After cell lysis and nucleic acid molecules are released from the cells, the nucleic acid molecules can be randomly associated with the barcodes of the co-located solid support. The association can include hybridizing the target recognition region of the barcode with the complementary portion of the target nucleic acid molecule (e.g., the oligo(dT) of the barcode can interact with the poly(A) tail of the target). The assay conditions for hybridization (e.g., buffer pH, ionic strength, temperature) can be selected to promote the formation of specific stable hybrids. In some embodiments, the nucleic acid molecules released from the lysed cells can be associated with more than one probe on the substrate (e.g., hybridized with the probe on the substrate). When the probe contains oligo(dT), the mRNA molecule can be hybridized with the probe and reverse transcribed. The oligo(dT) portion of the oligonucleotide can act as a primer for the first strand synthesis of the cDNA molecule. For example, in Figure 2 In the non-limiting example of barcoding illustrated in FIG, at block 216, the mRNA molecule can be hybridized to the barcode on the bead. For example, a single-stranded nucleotide fragment can be hybridized to the target binding region of the barcode.
[0163] Attachment can also include connecting the target recognition region of the barcode to a portion of the target nucleic acid molecule. For example, the target binding region can include a nucleic acid sequence that can be specifically hybridized with a restriction site overhang (e.g., EcoRI sticky end overhang). The assay procedure can also include treating the target nucleic acid with a restriction enzyme (e.g., EcoRI) to produce a restriction site overhang. The barcode can then be attached to any nucleic acid molecule comprising a sequence complementary to the restriction site overhang. Ligase (e.g., T4 DNA ligase) can be used to connect two fragments.
[0164] For example, in Figure 2 In the non-limiting example of barcoding illustrated in FIG, labeled targets (e.g., target-barcode molecules) from more than one cell (or more than one sample) can then be pooled, for example, into a tube at block 220. The labeled targets can be pooled by, for example, retrieving barcodes and / or beads to which target-barcode molecules are attached.
[0165] Recovery of a solid support-based collection of attached target-barcode molecules can be achieved by using magnetic beads and an externally applied magnetic field. After pooling the target-barcode molecules, all further processing can be performed in a single reaction vessel. Further processing can include, for example, reverse transcription reactions, amplification reactions, cleavage reactions, dissociation reactions and / or nucleic acid extension reactions. Further processing reactions can be performed within the microwells, i.e., without first pooling the labeled target nucleic acid molecules from more than one cell.
[0166] Reverse transcription
[0167] The present disclosure provides methods for using reverse transcription (e.g., Figure 2 The method of producing a target-barcode conjugate by adding a barcode and a complementary sequence of all or part of the target nucleic acid (i.e., a barcoded cDNA molecule, such as a randomly barcoded cDNA molecule). Reverse transcription of the associated RNA molecule can occur by adding a reverse transcription primer together with a reverse transcriptase. The reverse transcription primer can be an oligo (dT) primer, a random hexanucleotide primer, or a target-specific oligonucleotide primer. The length of the oligo (dT) primer can be 12-18 nucleotides or can be about 12-18 nucleotides, and binds to the endogenous poly (A) tail at the 3' end of the mammalian mRNA. The random hexanucleotide primer can bind to the mRNA at each complementary site. The target-specific oligonucleotide primer typically selectively triggers the mRNA of interest.
[0168] In some embodiments, the reverse transcription of the RNA molecule of the mark can occur by adding a reverse transcription primer. In some embodiments, the reverse transcription primer is an oligo (dT) primer, a random hexanucleotide primer or a target-specific oligonucleotide primer. Usually, the length of the oligo (dT) primer is 12-18 nucleotides, and is combined with the endogenous poly (A) tail at the 3' end of the mammalian mRNA. Random hexanucleotide primers can be combined with mRNA at each complementary site. Target-specific oligonucleotide primers selectively trigger interested mRNA usually.
[0169] Reverse transcription can occur repeatedly to produce more than one labeled cDNA molecule. Methods disclosed herein can include performing at least about or at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 reverse transcription reactions.
[0170] Amplification
[0171] One or more nucleic acid amplification reactions can be performed (e.g., Figure 2The amplification reaction may be performed in a multiplexed manner, wherein more than one target nucleic acid sequence is amplified simultaneously. The amplification reaction may be used to add sequencing adapters to the nucleic acid molecule. The amplification reaction may include amplifying at least a portion of the sample label (if present). The amplification reaction may include amplifying at least a portion of the cell label and / or barcode sequence (e.g., molecular label). The amplification reaction may include amplifying at least a portion of the sample label, cell label, spatial label, barcode sequence (e.g., molecular label), target nucleic acid, or a combination thereof. The amplification reaction can include amplifying 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 100% or any range or number between two of these values of more than one nucleic acid. The method can also include performing one or more cDNA synthesis reactions to generate one or more cDNA copies of a target-barcode molecule comprising a sample marker, a cell marker, a spatial marker and / or a barcode sequence (e.g., a molecular marker).
[0172] In some embodiments, amplification can be performed using polymerase chain reaction (PCR). As used herein, PCR can refer to a reaction for simultaneously extending a primer of a complementary strand of DNA to amplify a specific DNA sequence in vitro. As used herein, PCR can encompass derivative forms of reactions, including but not limited to, RT-PCR, real-time PCR, nested PCR, quantitative PCR, multiplexed PCR, digital PCR, and assembly PCR.
[0173] The amplification of the nucleic acid of labeling can include non-PCR-based methods. Examples of non-PCR-based methods include, but are not limited to, multiple displacement amplification (MDA), transcription-mediated amplification (TMA), amplification based on nucleic acid sequences (NASBA), chain displacement amplification (SDA), real-time SDA, rolling circle amplification, or ring-to-ring amplification. Other non-PCR-based amplification methods include more than one cycle of DNA synthesis and transcription of DNA-dependent RNA polymerase-driven transcription amplification or RNA-guided DNA synthesis and transcription to amplify DNA or RNA targets, ligase chain reaction (LCR) and Qβ replicase (Qβ) methods, the use of palindromic probes, chain displacement amplification, oligonucleotide-driven amplification using restriction endonucleases, primers hybridized to nucleic acid sequences and the resulting duplexes cleaved before extension reactions and amplification methods, chain displacement amplification, rolling circle amplification, and branch extension amplification (RAM) using nucleic acid polymerases lacking 5' exonuclease activity. In some embodiments, amplification does not produce circularized transcripts.
[0174] In some embodiments, the method disclosed herein also includes carrying out polymerase chain reaction to the labeled nucleic acid (e.g., labeled RNA, labeled DNA, labeled cDNA) to produce labeled amplicon (e.g., randomly labeled amplicon). The labeled amplicon can be a double-stranded molecule. The double-stranded molecule can include a double-stranded RNA molecule, a double-stranded DNA molecule, or an RNA molecule hybridized with a DNA molecule. One or both chains of the double-stranded molecule can include a sample label, a spatial label, a cell label, and / or a barcode sequence (e.g., a molecular label). The labeled amplicon can be a single-stranded molecule. The single-stranded molecule can include DNA, RNA, or a combination thereof. The nucleic acid of the present disclosure can include a synthetic or altered nucleic acid.
[0175] Amplification can include the use of one or more non-natural nucleotides. Non-natural nucleotides can include light unstable or triggerable nucleotides. Examples of non-natural nucleotides can include but are not limited to peptide nucleic acids (PNA), morpholino nucleic acids and locked nucleic acids (LNA) and glycol nucleic acids (GNA) and threose nucleic acids (TNA). Non-natural nucleotides can be added to one or more cycles of amplified reactions. Adding non-natural nucleotides can be used to identify the product of a specific cycle or time point in an amplified reaction.
[0176] Carrying out one or more amplification reactions can include using one or more primers.One or more primers can include, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 or more nucleotides.One or more primers can include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 or more nucleotides.One or more primers can anneal to at least a portion of a target (e.g., a randomly labeled target) of more than one mark.One or more primers can anneal to 3' ends or 5' ends of a target of more than one mark.One or more primers can anneal to an internal region of a target of more than one mark. The internal region can be at least about 50, 100, 150, 200, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 In some embodiments, the present invention provides at least one or more primers of the present invention. 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 650, 700, 750, 800, 850, 900 or 1000 nucleotides. One or more primers can include a group of fixed primers. One or more primers can include at least one or more custom primers. One or more primers can include at least one or more control primers. One or more primers can include at least one or more gene specific primers.
[0177] One or more primers may include universal primers. Universal primers may anneal to universal primer binding sites. One or more custom primers may anneal to the first sample label, the second sample label, spatial label, cell label, barcode sequence (e.g., molecular label), target or any combination thereof. One or more primers may include universal primers and custom primers. Custom primers may be designed to amplify one or more targets. Targets may include a subset of total nucleic acids in one or more samples. Targets may include a subset of total marker targets in one or more samples. One or more primers may include at least 96 or more custom primers, at least 960 or more custom primers, or at least 9600 or more custom primers. One or more custom primers may anneal to two or more different labeled nucleic acids. Two or more different labeled nucleic acids may correspond to one or more genes.
[0178] Any amplification scheme can be used in the methods of the present disclosure. For example, in one approach, the first round of PCR can use gene-specific primers and primers for universal Illumina sequencing primer 1 sequences to amplify molecules attached to beads. The second round of PCR can use nested gene-specific primers flanked by Illumina sequencing primer 2 sequences and primers for universal Illumina sequencing primer 1 sequences to amplify the first PCR product. The third round of PCR adds P5 and P7 and a sample index to turn the PCR product into an Illumina sequencing library. Sequencing using 150bp×2 sequencing can reveal cell markers and barcode sequences (e.g., molecular markers) on read 1, genes on read 2, and sample indexes on index 1 reads.
[0179] In some embodiments, chemical cleavage can be used to remove nucleic acid from substrate. For example, chemical groups or modified bases present in nucleic acid can be used to promote the removal of nucleic acid from solid support. For example, enzymes can be used to remove nucleic acid from substrate. For example, nucleic acid can be removed from substrate by restriction endonuclease digestion. For example, nucleic acid containing dUTP or ddUTP can be treated with uracil-d-glycosidase (UDG) to remove nucleic acid from substrate. For example, nucleic acid can be removed from substrate using enzymes (such as, base excision repair enzymes, such as apurinic / apyrimidinic (ap) endonucleases) that perform nucleotide excision. In some embodiments, photocleavable groups and light can be used to remove nucleic acid from substrate. In some embodiments, cleavable joints can be used to remove nucleic acid from substrate. For example, cleavable joints can include at least one of the following: biotin / avidin, biotin / streptavidin, biotin / neutravidin, Ig protein A, light-labile joints, acid or base-labile joint groups or adapters.
[0180] When the probe is gene specific, the molecule can be hybridized with the probe and reverse transcribed and / or amplified. In some embodiments, after the nucleic acid has been synthesized (e.g., reverse transcribed), the nucleic acid can be amplified. Amplification can be performed in a multiplex manner, wherein multiple target nucleic acid sequences are amplified simultaneously. Amplification can add sequencing adapters to the nucleic acid.
[0181] In some embodiments, amplification can be performed on a substrate, for example, with bridging amplification.cDNA can be added with homopolymer tails to produce compatible ends for bridging amplification using oligo (dT) probes on substrates.In bridging amplification, the primer complementary to the 3' end of the template nucleic acid can be the first primer in each pair of primers covalently attached to solid particles.When the sample containing the template nucleic acid contacts the particle and performs a single thermal cycle, the template molecule can be annealed to the first primer, and the first primer is extended in the forward direction by adding nucleotides to form a duplex molecule, which is composed of the template molecule and the newly formed DNA chain complementary to the template.In the heating step of the next cycle, the duplex molecule can be denatured, release the template molecule from the particle and leave the complementary DNA chain attached to the particle by the first primer.In the annealing stage of the subsequent annealing and extension steps, the complementary chain can be hybridized with the second primer, and the second primer is complementary to the segment of the complementary chain at the position removed from the first primer. This hybridization can cause complementary strands to form a bridge between the first primer and the second primer, connecting the first primer by a covalent bond and connecting the second primer by hybridization. In the extension phase, by adding nucleotides in the same reaction mixture, the second primer can be extended in the reverse direction, thereby converting the bridge into a double-stranded bridge. Then start the next cycle, and the double-stranded bridge can be denatured to produce two single-stranded nucleic acid molecules, each of which has an end attached to the particle surface via the first primer and the second primer, respectively, wherein the other end of each single-stranded nucleic acid molecule is unattached. In the annealing and extension steps of this second cycle, each chain can be hybridized with other complementary primers previously unused on the same particle to form a new single-stranded bridge. Two previously unused primers that are now hybridized are extended so that two new bridges are converted into double-stranded bridges.
[0182] An amplification reaction can include amplifying at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 100% of more than one nucleic acid.
[0183] The amplification of the labeled nucleic acid may include a PCR-based method or a non-PCR-based method. The amplification of the labeled nucleic acid may include an exponential amplification of the labeled nucleic acid. The amplification of the labeled nucleic acid may include a linear amplification of the labeled nucleic acid. Amplification may be performed by polymerase chain reaction (PCR). PCR may refer to a reaction for simultaneously extending the primers of the complementary strands of DNA to amplify a specific DNA sequence in vitro. PCR may encompass derivative forms of reactions, including but not limited to RT-PCR, real-time PCR, nested PCR, quantitative PCR, multiplexed PCR, digital PCR, inhibition PCR, semi-inhibition PCR, and assembly PCR.
[0184] Amplification of the labeled nucleic acid may include non-PCR-based methods, including but not limited to multiple displacement amplification (MDA), transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), real-time SDA, rolling circle amplification, or circle-to-circle amplification. Other non-PCR-based amplification methods include DNA-dependent RNA polymerase-driven RNA transcription amplification or more than one cycle of RNA-guided DNA synthesis and transcription to amplify DNA or RNA targets, ligase chain reaction (LCR), Qβ replicase (Qβ) method, use of palindromic probes, strand displacement amplification, oligonucleotide-driven amplification using restriction endonucleases, amplification methods that hybridize primers to nucleic acid sequences and cleave the resulting duplexes prior to extension reactions and amplification, strand displacement amplification using a nucleic acid polymerase lacking 5' exonuclease activity, rolling circle amplification, and / or branch extension amplification (RAM).
[0185] The method disclosed herein can also include performing a nested polymerase chain reaction on the amplified amplicon (e.g., target). The amplicon can be a double-stranded molecule. The double-stranded molecule can include a double-stranded RNA molecule, a double-stranded DNA molecule, or an RNA molecule hybridized with a DNA molecule. One or both chains of the double-stranded molecule can include a sample label or a molecular identifier label. Alternatively, the amplicon can be a single-stranded molecule. The single-stranded molecule can include DNA, RNA, or a combination thereof. The nucleic acid of the present invention can include a synthetic or altered nucleic acid.
[0186] In some embodiments, the method includes repeatedly amplifying the labeled nucleic acid to produce more than one amplicon. The methods disclosed herein may include performing at least about, at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 amplification reactions.
[0187] Amplification can also include adding one or more control nucleic acids to one or more samples comprising more than one nucleic acid. Amplification can also include adding one or more control nucleic acids to more than one nucleic acid. The control nucleic acid can include a control label.
[0188] Amplification can include the use of one or more non-natural nucleotides. Non-natural nucleotides can include light unstable and / or triggerable nucleotides. Examples of non-natural nucleotides include but are not limited to peptide nucleic acids (PNA), morpholinos and locked nucleic acids (LNA) and glycol nucleic acids (GNA) and threose nucleic acids (TNA). Non-natural nucleotides can be added to one or more cycles of amplified reactions. Adding non-natural nucleotides can be used to identify the product of a specific cycle or time point in an amplified reaction.
[0189] Carrying out one or more amplification reactions can include using one or more primers. One or more primers can include one or more oligonucleotides. One or more oligonucleotides can contain at least about 7-9 nucleotides. One or more oligonucleotides can contain less than 12-15 nucleotides. One or more primers can anneal to at least a portion of more than one labeled nucleic acid. One or more primers can anneal to the 3' end and / or 5' end of more than one labeled nucleic acid. One or more primers can anneal to the internal region of more than one labeled nucleic acid. The internal region can be at least about 50, 100, 150, 200, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 , 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 650, 700, 750, 800, 850, 900 or 1000 nucleotides. One or more primers may include a set of fixed primers. One or more primers may include at least one or more custom primers. One or more primers may include at least one or more control primers. One or more primers may include at least one or more housekeeping gene primers. One or more primers may include universal primers. Universal primers may anneal to universal primer binding sites. One or more custom primers can anneal to the first sample label, the second sample label, the molecular identifier label, the nucleic acid or its product. One or more primers can include universal primers and custom primers. Custom primers can be designed to amplify one or more target nucleic acids. Target nucleic acids can include a subset of total nucleic acids in one or more samples. In some embodiments, primers are probes attached to the array of the present disclosure.
[0190] In some embodiments, barcoding more than one target in a sample (e.g., random barcoding) further comprises generating an index library of barcoded targets (e.g., randomly barcoded targets) or barcoded fragments of targets. The barcode sequences of different barcodes (e.g., molecular markers of different random barcodes) can be different from each other. Generating an index library of barcoded targets comprises generating more than one index polynucleotide from more than one target in a sample. For example, for an index library of barcoded targets comprising a first index target and a second index target, the marker region of the first index polynucleotide can differ from the marker region of the second index polynucleotide by less than, about less than, at least less than, or at most less than: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 nucleotides, or a number or range of nucleotides between any two of these values. In some embodiments, generating an index library of barcoded targets includes contacting more than one target (e.g., mRNA molecules) with more than one oligonucleotide comprising a poly (T) region and a tag region; and performing first-strand synthesis using a reverse transcriptase to generate single-stranded labeled cDNA molecules (each comprising a cDNA region and a tag region), wherein the more than one target includes at least two mRNA molecules of different sequences, and the more than one oligonucleotide includes at least two oligonucleotides of different sequences. Generating an index library of barcoded targets may also include amplifying single-stranded labeled cDNA molecules to generate double-stranded labeled cDNA molecules; and performing nested PCR on double-stranded labeled cDNA molecules to generate labeled amplicons. In some embodiments, the method may include generating adapter-tagged amplicons.
[0191] Barcoding (e.g., random barcoding) can include the use of nucleic acid barcodes or tags to label individual nucleic acid (e.g., DNA or RNA) molecules. In some embodiments, it includes adding DNA barcodes or tags to cDNA molecules when generating cDNA molecules from mRNA. Nested PCR can be performed to minimize PCR amplification bias. Adapters used for sequencing (e.g., next generation sequencing (NGS)) can be added. For example, in Figure 2 At block 232 of the method, the sequencing results can be used to determine the sequence of cellular markers, molecular markers, and nucleotide fragments of one or more copies of the target.
[0192] Figure 3is a schematic diagram showing a non-limiting exemplary process for generating an index library of barcoded targets (e.g., randomly barcoded targets), such as an index library of barcoded mRNAs or fragments thereof. As shown in step 1, the reverse transcription process can encode each mRNA molecule with a unique molecular marker, a cell marker, and a universal PCR site. Specifically, by hybridizing (e.g., randomly hybridizing) a set of barcodes (e.g., random barcodes) 310 with a poly (A) tail region 308 of an RNA molecule 302, an RNA molecule 302 can be reverse transcribed to produce a labeled cDNA molecule 304 (including a cDNA region 306). Each of the barcodes 310 can include a target binding region, such as a poly (dT) region 312, a marker region 314 (e.g., a barcode sequence or molecule), and a universal PCR region 316.
[0193] In some embodiments, the cell marker may comprise 3 to 20 nucleotides. In some embodiments, the molecular marker may comprise 3 to 20 nucleotides. In some embodiments, each of more than one random barcode further comprises one or more of a universal marker and a cell marker, wherein the universal marker is the same for more than one random barcode on the solid support, and the cell marker is the same for more than one random barcode on the solid support. In some embodiments, the universal marker may comprise 3 to 20 nucleotides. In some embodiments, the cell marker comprises 3 to 20 nucleotides.
[0194] In some embodiments, the label region 314 may include a barcode sequence or molecular marker 318 and a cell marker 320. In some embodiments, the label region 314 may include one or more of a universal marker, a dimensional marker, and a cell marker. The length of the barcode sequence or molecular marker 318 may be less than, may be about less than, may be at least less than, or may be at most less than: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or range of nucleotides between any two of these values. The length of the cell label 320 can be, can be about, can be at least, or can be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or range of nucleotides between any two of these values. The length of the universal label can be, can be about, can be at least, or can be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or range of nucleotides between any two of these values. The universal label can be the same for more than one random barcode on the solid support, and the cell label is the same for more than one random barcode on the solid support. The length of a dimensional marker can be less than, can be about less than, can be at least less than, or can be at most less than: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 nucleotides or a number or range between any two of these values.
[0195] In some embodiments, the marker area 314 may include the following, may include about the following, may include at least the following, or may include at most the following: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or a number or range between any two of these values of different markers, such as barcode sequences or molecular markers 318 and cell markers 320. The length of each marker can be, can be about, can be at least, or can be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 nucleotides, or a number or range of nucleotides between any two of these values. A set of barcodes or random barcodes 310 can contain, can be about, can be at least, or can be at most 10, 20, 40, 50, 70, 80, 90, 100 nucleotides, or a number or range of nucleotides between any two of these values. 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 12 10 13 10 14 10 15 10 20 The barcodes or random barcodes 310 may be a number or range of barcodes or random barcodes 310 of any type or between any two of these values. And the group of barcodes or random barcodes 310 may, for example, each contain a unique tag region 314. The labeled cDNA molecules 304 may be purified to remove excess barcodes or random barcodes 310. Purification may include Ampure bead purification.
[0196] As shown in step 2, the products from the reverse transcription process in step 1 can be pooled into 1 tube and PCR amplified using the 1st PCR primer pool and the 1st universal PCR primer. Pooling is possible because of the unique tag region 314. In particular, the labeled cDNA molecules 304 can be amplified to produce nested PCR labeled amplicons 322. Amplification can include multiplex PCR amplification. Amplification can include multiplex PCR amplification using 96 multiplex primers in a single reaction volume. In some embodiments, in a single reaction volume, the multiplex PCR amplification can utilize the following, utilize about the following, utilize at least the following, or utilize at most the following: 10, 20, 40, 50, 70, 80, 90, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 12 10 13 10 14 10 15 10 20 Amplification can include using a first PCR primer pool 324 including custom primers 326A-C targeting a specific gene and a universal primer 328. Custom primers 326 can hybridize to a region within the cDNA portion 306' of the labeled cDNA molecule 304. Universal primers 328 can hybridize to universal PCR region 316 of the labeled cDNA molecule 304.
[0197] like Figure 3As shown in step 3 of , the product from the PCR amplification in step 2 can be amplified with a nested PCR primer pool and a second universal PCR primer. Nested PCR can minimize PCR amplification bias. In particular, the amplicon 322 of the nested PCR marker can be further amplified by nested PCR. Nested PCR can include multiple PCR performed in a single reaction volume using a nested PCR primer pool 330 of nested PCR primers 332a-c and a second universal PCR primer 328'. The nested PCR primer pool 330 may include the following, may include about the following, may include at least the following, or may include at most the following: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or a number or range between any two of these values of different nested PCR primers 332. Nested PCR primer 332 may include adapter 334 and hybridize to a region within cDNA portion 306″ of labeled amplicon 322. Universal primer 328′ may include adapter 336 and hybridize to universal PCR region 316 of labeled amplicon 322. Thus, step 3 produces adapter-tagged amplicon 338. In some embodiments, nested PCR primer 332 and second universal PCR primer 328′ may not include adapter 334 and adapter 336. Instead, adapter 334 and adapter 336 may be attached to the product of nested PCR to produce adapter-tagged amplicon 338.
[0198] As shown in step 4, the PCR product from step 3 can be PCR amplified for sequencing using library amplification primers. In particular, one or more additional assays can be performed on the adapter-tagged amplicon 338 using adapter 334 and adapter 336. Adapter 334 and adapter 336 can hybridize with primer 340 and primer 342. One or more primers 340 and primer 342 can be PCR amplification primers. One or more primers 340 and primer 342 can be sequencing primers. One or more adapters 334 and adapter 336 can be used for further amplification of adapter-tagged amplicon 338. One or more adapters 334 and adapter 336 can be used for sequencing adapter-tagged amplicon 338. Primer 342 can include a plate index 344 so that the amplicons generated using the same set of barcodes or random barcodes 310 can be sequenced in one sequencing reaction using next generation sequencing (NGS).
[0199] Compositions comprising a cellular component binding agent associated with an oligonucleotide
[0200] Some embodiments disclosed herein provide more than one composition, each composition comprising a cell component binding agent (such as a protein binding agent) conjugated to an oligonucleotide, wherein the oligonucleotide comprises a unique identifier for the cell component binding agent conjugated thereto. U.S. Patent Application Publication No. US2018 / 0088112 and No. US2018 / 0346970 describe cell component binding agents (such as barcoded antibodies) and their uses (such as sample indexes of cells); the content of each patent application is incorporated herein by reference in its entirety. Cell component binding agents may include intracellular target binding agents, cell surface target binding agents and / or nuclear target binding agents. Binding agents (e.g., cell component binding agents) may be associated with binding agent oligonucleotides. Binding agent oligonucleotides may include intracellular target binding agent specific oligonucleotides, cell surface target binding agent specific oligonucleotides and / or nuclear target binding agent specific oligonucleotides.
[0201] Cell component binding reagents can be capable of specifically binding to cell component targets (e.g., intracellular targets, nuclear targets, cell surface targets). For example, the binding targets of cell component binding reagents can be the following or include the following: carbohydrates, lipids, proteins, extracellular proteins, cell surface proteins, cell markers, B cell receptors, T cell receptors, major histocompatibility complexes, tumor antigens, receptors, integrins, intracellular proteins, or any combination thereof. In some embodiments, cell component binding reagents (e.g., protein binding reagents) can specifically bind to antigen targets or protein targets. In some embodiments, each oligonucleotide can include a barcode, such as a random barcode. The barcode can include a barcode sequence (e.g., a molecular marker), a cell marker, a sample marker, or any combination thereof. In some embodiments, each oligonucleotide can include a joint. In some embodiments, each oligonucleotide can include a binding site for an oligonucleotide probe, such as a poly (A) tail. For example, a poly (A) tail can, for example, not be anchored to a solid support or be anchored to a solid support. The poly(A) tail may be about 10 to 50 nucleotides in length, for example, 18 nucleotides in length. The oligonucleotide may comprise deoxyribonucleotides, ribonucleotides, or both.
[0202] The unique identifier can be, for example, a nucleotide sequence with any suitable length, for example, about 4 nucleotides to about 200 nucleotides. In some embodiments, the unique identifier is a nucleotide sequence with a length of 25 nucleotides to about 45 nucleotides. In some embodiments, the unique identifier can have a length of, about, less than, or greater than: 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 200 nucleotides or any two of the above values.
[0203] In some embodiments, the unique identifier is selected from a group of different unique identifiers. A group of different unique identifiers may include the following or may include about the following: 20 kinds, 30 kinds, 40 kinds, 50 kinds, 60 kinds, 70 kinds, 80 kinds, 90 kinds, 100 kinds, 200 kinds, 300 kinds, 400 kinds, 500 kinds, 600 kinds, 700 kinds, 800 kinds, 900 kinds, 1000 kinds, 2000 kinds, 5000 kinds or the different unique identifiers of the numerals or scope between any two of these values. A group of different unique identifiers may include at least the following or include at most the following: 20 kinds, 30 kinds, 40 kinds, 50 kinds, 60 kinds, 70 kinds, 80 kinds, 90 kinds, 100 kinds, 200 kinds, 300 kinds, 400 kinds, 500 kinds, 600 kinds, 700 kinds, 800 kinds, 900 kinds, 1000 kinds, 2000 kinds or 5000 kinds of different unique identifiers. In some embodiments, a set of unique identifiers is designed to have minimal sequence homology with the DNA or RNA sequence of the sample to be analyzed. In some embodiments, the sequences of a set of unique identifiers differ from each other or from their complement by less than or about less than: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or a number or range of nucleotides between any two of these values. In some embodiments, the sequences of a set of unique identifiers differ from each other or from their complement by at least less than or at most less than: 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides. In some embodiments, the sequences of a set of unique identifiers differ from each other or from their complement by at least 3%, 5%, 8%, 10%, %, 20% or more.
[0204] In some embodiments, the unique identifier may include a binding site for a primer (such as a universal primer). In some embodiments, the unique identifier may include at least two binding sites for a primer (such as a universal primer). In some embodiments, the unique identifier may include at least three binding sites for a primer (such as a universal primer). Primers may be used to amplify the unique identifier, for example, by PCR amplification. In some embodiments, primers may be used for nested PCR reactions.
[0205] Any suitable cell component binding reagent is contemplated in the present disclosure, such as protein binding reagent, antibody or its fragment, aptamer, small molecule, ligand, peptide, oligonucleotide or any combination thereof. In some embodiments, the cell component binding reagent can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a single-chain antibody (sc-Ab) or its fragment, such as Fab, Fv. In some embodiments, more than one cell component binding reagent can include the following, including about the following, including at least the following or including at most the following different cell component reagents: 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 5000 or a number or range between any two of these values.
[0206] Oligonucleotides can be conjugated to cellular component binding agents through various mechanisms. In some embodiments, oligonucleotides can be covalently conjugated to cellular component binding agents. In some embodiments, oligonucleotides can be non-covalently conjugated to cellular component binding agents. In some embodiments, oligonucleotides are conjugated to cellular component binding agents through a linker. The linker can be, for example, capable of cleaving or detaching from the cellular component binding agent and / or the oligonucleotide. In some embodiments, the linker can include a chemical group that reversibly attaches the oligonucleotide to the cellular component binding agent. The chemical group can be conjugated to the linker, for example, through an amine group. In some embodiments, the linker can include a chemical group that forms a stable bond with another chemical group that is conjugated to the cellular component binding agent. For example, the chemical group can be a UV light cleavable group, a disulfide bond, streptavidin, biotin, or an amine, etc. In some embodiments, the chemical group can be conjugated to the cellular component binding agent through an amino acid such as a primary amine on lysine or the N-terminus. Commercially available conjugation kits such as Protein-Oligo conjugation kits (Solulink, Inc., San Diego, CA), Thunder- The oligo conjugation system (Innova Biosciences, Cambridge, UK) conjugates oligonucleotides to cellular component binding agents.
[0207] Oligonucleotide can be conjugated with any suitable site of cell component binding reagent (for example, protein binding reagent), provided that oligonucleotide does not interfere with the specific binding between cell component binding reagent and its cell component target.In some embodiments, cell component binding reagent is protein, such as antibody.In some embodiments, cell component binding reagent is not antibody.In some embodiments, oligonucleotide can be conjugated with antibody anywhere (for example Fc region, CH1 domain, CH2 domain, CH3 domain and CL domain) except antigen binding site.The method of conjugating oligonucleotide with cell component binding reagent (for example antibody) has previously been disclosed in for example U.S. Patent No. 6,531,283, its content is hereby explicitly incorporated by reference with its entirety.The stoichiometry of oligonucleotide and cell component binding reagent can change.In order to increase the sensitivity of detecting cell component binding reagent specific oligonucleotide in sequencing, it can be advantageous to increase the ratio of oligonucleotide and cell component binding reagent during conjugation.In some embodiments, each cell component binding reagent can be conjugated with a single oligonucleotide molecule. In some embodiments, each cellular component binding reagent can be conjugated to more than one oligonucleotide molecule, for example, to at least or at most 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000, or a number or range between any two of these values, wherein each of the oligonucleotide molecules comprises the same or different unique identifier.
[0208] In some embodiments, more than one cell component binding reagent can be specifically bound to more than one cell component target in a sample, such as a single cell, more than one cell, a tissue sample, a tumor sample, a blood sample, etc. In some embodiments, more than one cell component target includes cell surface proteins, cell markers, B cell receptors, T cell receptors, antibodies, major histocompatibility complexes, tumor antigens, receptors, or any combination thereof. In some embodiments, more than one cell component target may include intracellular cell components. In some embodiments, more than one cell component may be the following of all cell components (e.g., proteins) in a cell or organism, about the following, at least the following, or at most the following: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or a number or range between any two of these values. In some embodiments, more than one cellular component target may include, include about, include at least, or include at most: 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000, 10000, or a number or range between any two of these values of different cellular component targets.
[0209] Figure 4 The schematic diagram of an exemplary cellular component binding agent (e.g., antibody) associated with an oligonucleotide comprising a unique identifier sequence for an antibody (e.g., conjugated) is shown. The oligonucleotide conjugated with a cellular component binding agent, the oligonucleotide conjugated with a cellular component binding agent, or the oligonucleotide previously conjugated with a cellular component binding agent may be referred to as an antibody oligonucleotide (abbreviated as a binding agent oligonucleotide) herein. The oligonucleotide conjugated with an antibody, the oligonucleotide conjugated with an antibody, or the oligonucleotide previously conjugated with an antibody may be referred to as an antibody oligonucleotide (abbreviated as "AbOligo" or "AbO") herein. The oligonucleotide may also include other components, including but not limited to one or more joints, one or more unique identifiers for an antibody, optionally one or more barcode sequences (e.g., molecular markers) and many (A) tails. In some embodiments, the oligonucleotide may include joints, unique identifiers, barcode sequences (e.g., molecular markers) and many (A) tails from 5' to 3'. The antibody oligonucleotide may be an mRNA mimic.
[0210] Figure 5A schematic diagram of an exemplary cellular component binding reagent (e.g., antibody) associated with an oligonucleotide comprising a unique identifier sequence for an antibody (e.g., conjugated) is shown. The cellular component binding reagent may be capable of specifically binding to at least one cellular component target (such as an antigen target or a protein target). The binding reagent oligonucleotide (e.g., a sample index oligonucleotide or an antibody oligonucleotide) may include a sequence (e.g., a sample index sequence) for carrying out the method of the present disclosure. For example, the sample index oligonucleotide may include a sample index sequence for identifying the sample source of one or more cells in a sample. The index sequence (e.g., sample index sequence) of at least two compositions (e.g., sample index compositions) comprising two cellular component binding reagents in more than one composition comprising a cellular component binding reagent may include different sequences. In some embodiments, the binding reagent oligonucleotide is not homologous to the genomic sequence of the species. The binding reagent oligonucleotide may be configured to (or may be) be capable of detaching from or not being capable of detaching from the cellular component binding reagent.
[0211] The oligonucleotide conjugated to the cell component binding reagent may, for example, comprise a barcode sequence (e.g., a molecular marker sequence), a poly(A) tail, or a combination thereof. The oligonucleotide conjugated to the cell component binding reagent may be an mRNA mimic. In some embodiments, the sample index oligonucleotide comprises a sequence complementary to the capture sequence of at least one barcode in more than one barcode. The target binding region of the barcode may comprise a capture sequence. The target binding region may, for example, comprise a poly(dT) region. In some embodiments, the sequence of the sample index oligonucleotide complementary to the capture sequence of the barcode may comprise a poly(A) tail. The sample index oligonucleotide may comprise a molecular marker.
[0212] In some embodiments, a binding reagent oligonucleotide (e.g., a sample oligonucleotide, an intracellular target binding reagent specific oligonucleotide, a cell surface target binding reagent specific oligonucleotide, a nuclear target binding reagent specific oligonucleotide) comprises a nucleotide sequence having a length of about, at least, or at most 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 110, 1200, 1300, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 128, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420 , 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730 940, 950, 960, 970, 980, 990, 1000, or a number or range between any two of these values.
[0213] In some embodiments, the cell component binding reagent (e.g., intracellular target binding reagent, cell surface target binding reagent or nuclear target binding reagent) comprises an antibody, a tetramer, an aptamer, a protein scaffold or a combination thereof. The cell component binding reagent can be a protein binding reagent. The binding reagent oligonucleotide can be conjugated to the cell component binding reagent, for example, through a joint. The binding reagent oligonucleotide can include a joint. The joint can include a chemical group. The chemical group can be reversibly or irreversibly attached to the molecule of the cell component binding reagent. The chemical group can be a UV light cleavable group, a disulfide bond, streptavidin, biotin, an amine and any combination thereof.
[0214] The cellular component binding reagent can bind to ADAM10, CD156c, ANO6, ATP1B2, ATP1B3, BSG, CD147, CD109, CD230, CD29, CD298, ATP1B3, CD44, CD45, CD47, CD51, CD59, CD63, CD97, CD98, SLC3A2, CLDND1, HLA-ABC, ICAM1, ITFG3, MPZL1, NA K ATPase α1, ATP1A1, NPTN, PMCA ATPase, ATP2B1, SLC1A5, SLC29A1, SLC2A1, SLC44A2, or any combination thereof.
[0215] The protein target can be or can comprise an extracellular protein, an intracellular protein, or any combination thereof. In some embodiments, the antigen or protein target is or comprises a cell surface protein, a cell marker, a B cell receptor, a T cell receptor, a major histocompatibility complex, a tumor antigen, a receptor, an integrin, or any combination thereof. The antigen or protein target can be, or comprise, a lipid, a carbohydrate, or a combination thereof. The protein target can be selected from many protein targets. The number of antigenic targets or protein targets can be below, about below, at least below, or at most below: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, or a number or range between any two of these values.
[0216] Cellular component binding reagents (e.g., protein binding reagents) can be associated with two or more binding reagent oligonucleotides (e.g., sample index oligonucleotides, intracellular target binding reagent specific oligonucleotides, cell surface target binding reagent specific oligonucleotides, nuclear target binding reagent specific oligonucleotides) having the same sequence. Cellular component binding reagents can be associated with two or more binding reagent oligonucleotides having different sequences. In different embodiments, the number of binding reagent oligonucleotides associated with a cellular component binding reagent can be different. The number of binding agent oligonucleotides having the same sequence or different sequences can be or can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or a number or range between any two of these values.
[0217] More than one composition comprising a cellular component binding reagent (e.g., more than one sample indexing composition) may include one or more additional cellular component binding reagents that are not conjugated to a binding reagent oligonucleotide (such as a sample indexing oligonucleotide), which are also referred to herein as cellular component binding reagents that do not contain binding reagent oligonucleotides (such as cellular component binding reagents that do not contain sample indexing oligonucleotides). In different embodiments, the number of additional cellular component binding reagents in more than one composition may be different. In some embodiments, the number of additional cellular component binding reagents may be, is about, is at least or is at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or range between any two of these values. In some embodiments, any of the cellular component binding reagents and additional cellular component binding reagents may be the same.
[0218] In some embodiments, a mixture is provided comprising a cellular component binding agent conjugated to one or more binding agent oligonucleotides (e.g., a sample index oligonucleotide, an intracellular target binding agent specific oligonucleotide, a cell surface target binding agent specific oligonucleotide, a nuclear target binding agent specific oligonucleotide) and a cellular component binding agent not conjugated to the binding agent oligonucleotide. The mixture can be used in some embodiments of the methods disclosed herein, for example, to contact one or more samples and / or one or more cells. In different embodiments, the ratio of the following (1) to (2) in the mixture can be different: (1) the number of cellular component binding agents conjugated to the binding agent oligonucleotide, (2) the number of another cellular component binding agent (e.g., the same cellular component binding agent) not conjugated to the binding agent oligonucleotide (e.g., a sample index oligonucleotide) or one or more other binding agent oligonucleotides.In some embodiments, the ratio can be, is about, is at least, or is at most 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.5, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20. , 1:21, 1:22, 1:23, 1:24, 1:25, 1:26, 1:27, 1:28, 1:29, 1:30, 1:31, 1:32, 1:33, 1:34, 1:35, 1:36, 1:37, 1:38, 1:39, 1:40, 1:41, 1:42, 1:43, 1:44, 1:45, 1:46, 1:47, 1:48, 1:49, 1:50, 1:51, 1:52, 1:53, 1:54, 1:55, 1:56 , 1:57, 1:58, 1:59, 1:60, 1:61, 1:62, 1:63, 1:64, 1:65, 1:66, 1:67, 1:68, 1:69, 1:70, 1:71, 1:72, 1:73, 1:74, 1:75, 1:76, 1:77, 1:78, 1:79, 1:80, 1:81, 1:82, 1:83, 1:84, 1:85, 1:86, 1:87, 1:88, 1:89, 1:90, 1:91, 1:92 2, 1:93, 1:94, 1:95, 1:96, 1:97, 1:98, 1:99, 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, 1:1000, 1:2000, 1:3000, 1:4000, 1:5000, 1:6000, 1:7000, 1:8000, 1:9000, 1:10000, or a number or range between any two of the recited values.In some embodiments, the ratio can be, is about, is at least, or is at least, or is at most the following: 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, 2:1, 2.5:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1、21:1、22:1、23:1、24:1、25:1、26:1、27:1、28:1、29:1、30:1、31:1、32:1、33:1、34:1、35:1、36:1、37:1、38:1、39:1、40:1、41:1、42:1、43:1、44:1、45:1、46:1、47:1、48:1、49:1、50:1、51:1、52:1、53:1、54:1、55:1、5 6:1、57:1、58:1、59:1、60:1、61:1、62:1、63:1、64:1、65:1、66:1、67:1、68:1、69:1、70:1、71:1、72:1、73:1、74:1、75:1、76:1、77:1、78:1、79:1、80:1、81:1、82:1、83:1、84:1、85:1、86:1、87:1、88:1、89:1、90:1、91:1、92 :1, 93:1, 94:1, 95:1, 96:1, 97:1, 98:1, 99:1, 100:1, 200:1, 300:1, 400:1, 500:1, 600:1, 700:1, 800:1, 900:1, 1000:1, 2000:1, 3000:1, 4000:1, 5000:1, 6000:1, 7000:1, 8000:1, 9000:1, 10000:1, or a number or range between any two of these values.
[0219] The cellular component binding reagent may or may not be conjugated to a binding reagent oligonucleotide (e.g., a sample index oligonucleotide, an intracellular target binding reagent specific oligonucleotide, a cell surface target binding reagent specific oligonucleotide, a nuclear target binding reagent specific oligonucleotide). In some embodiments, in a mixture comprising a cellular component binding reagent conjugated to a binding reagent oligonucleotide and one or more cellular component binding reagents not conjugated to a binding reagent oligonucleotide, the percentage of the cellular component binding reagent conjugated to a binding reagent oligonucleotide (e.g., a sample index oligonucleotide) may be, is about, is at least, or is at most the following: 0.000000001%, 0.00000001%, 0.00000001%, 0.00000002%, 0.00000003%, 0.00000004%, 0.00000005%, 0.00000006%, 0.00000007%, 0.00000008%, 0.00000009%, 0.00000010%, 0.000000011%, 0.000000012%, 0.000000013%, 0.000000014%, 0.000000015%, 0.000000016%, 0.000000017%, 0.000000018%, 0.000000019%, 0.00000001 01%, 0.000001%, 0.00001%, 0.0001%, 0.001%, 0.01%, 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29 %, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, %, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values.
[0220] In some embodiments, in a mixture comprising a cellular component binding reagent conjugated to a binding reagent oligonucleotide (e.g., a sample index oligonucleotide, an intracellular target binding reagent specific oligonucleotide, a cell surface target binding reagent specific oligonucleotide, a cell nuclear target binding reagent specific oligonucleotide) and a cellular component binding reagent not conjugated to a sample index oligonucleotide, the cellular component binding reagent not conjugated to the binding reagent oligonucleotide (e.g., a sample index oligonucleotide, an intracellular target binding reagent specific oligonucleotide, a cell surface target binding reagent specific oligonucleotide, a cell nuclear target binding reagent specific oligonucleotide) is The percentage of cellular component binding agent conjugated to the nuclear target binding agent specific oligonucleotide) can be, is about, is at least or is at most 0.000000001%, 0.00000001%, 0.0000001%, 0.000001%, 0.00001%, 0.0001%, 0.001%, 0.01%, 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60% , 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values.
[0221] Cocktails
[0222] The mixture of cellular component binding reagent (for example antibody mixture) can be used to increase the labeling sensitivity in the method disclosed herein.Not limited by any particular theory, it is believed that this may be because cellular component expression or protein expression can change between cell type and cell state, making it challenging to find a universal cellular component binding reagent or antibody for marking all cell types.For example, the mixture of cellular component binding reagent can be used to allow more sample types to be more sensitive and effectively labeled.The mixture of cellular component binding reagent can include two or more different types of cellular component binding reagents, for example, cellular component binding reagent or antibody of a wider range.The cellular component binding reagent that different cellular component targets are marked can be brought together to produce a mixture that is enough to mark all cell types or one or more cell types of interest.
[0223] In some embodiments, each in more than one composition (such as sample index composition) comprises cellular component binding reagent.In some embodiments, the composition in more than one composition comprises two or more cellular component binding reagents, wherein each in two or more cellular component binding reagents is associated with binding reagent oligonucleotide (such as sample index oligonucleotide), wherein at least one in two or more cellular component binding reagents can be specifically bound with at least one in one or more cellular component targets.The sequence of the binding reagent oligonucleotide associated with two or more cellular component binding reagents can be the same.The sequence of the binding reagent oligonucleotide associated with two or more cellular component binding reagents can comprise different sequences.Each in more than one composition can comprise two or more cellular component binding reagents.
[0224] In different embodiments, the number of different types of cell component binding reagents (such as CD147 antibody and CD47 antibody) in the composition can be different. The composition with two or more different types of cell component binding reagents can be referred to as cell component binding reagent mixture (such as sample index composition mixture) in this article. The number of different types of cell component binding reagents in the mixture can be different. In some embodiments, the number of different types of cell component binding reagents in the mixture can be below, about below, at least below or at most below: 2 kinds, 3 kinds, 4 kinds, 5 kinds, 6 kinds, 7 kinds, 8 kinds, 9 kinds, 10 kinds, 20 kinds, 30 kinds, 40 kinds, 50 kinds, 60 kinds, 70 kinds, 80 kinds, 90 kinds, 100 kinds, 200 kinds, 300 kinds, 400 kinds, 500 kinds, 600 kinds, 700 kinds, 800 kinds, 900 kinds, 1000 kinds, 10000 kinds, 100000 kinds or any two between these values or the numeral or scope. Different types of cellular component binding reagents can be conjugated to binding reagent oligonucleotides having the same or different sequences (eg, sample index sequences).
[0225] Quantitative analysis of cellular component targets
[0226] The description herein includes methods for quantitatively analyzing more than one cell component target (e.g., protein target) in a sample using oligonucleotide probes, which can associate a barcode sequence (e.g., a molecular marker sequence) with an oligonucleotide of a cell component binding reagent (e.g., a protein binding reagent). Cell component binding reagents can include intracellular target binding reagents, cell surface target binding reagents, and / or nuclear target binding reagents. The oligonucleotides of the cell component binding reagents can be or include antibody oligonucleotides, sample index oligonucleotides, cell identification oligonucleotides, control particle oligonucleotides, control oligonucleotides, interaction determination oligonucleotides, intracellular target binding reagent specific oligonucleotides, cell surface target binding reagent specific oligonucleotides, and / or nuclear target binding reagent specific oligonucleotides. In some embodiments, the sample can be a single cell, more than one cell, a tissue sample, a tumor sample, a blood sample, etc. The sample can include a mixture of cell types (such as normal cells, tumor cells, blood cells, B cells, T cells, maternal cells, fetal cells) or a mixture of cells from different subjects. In some embodiments, the sample can include more than one single cell separated into individual compartments such as micropores in a micropore array.
[0227] The binding targets of more than one cellular component target (i.e., cellular component target) can be or can include the following: carbohydrates, lipids, proteins, extracellular proteins, cell surface proteins, cell markers, B cell receptors, T cell receptors, major histocompatibility complexes, tumor antigens, receptors, integrins, intracellular proteins, or any combination thereof. In some embodiments, the cellular component target is a protein target. In some embodiments, more than one cellular component target includes a cell surface protein, a cell marker, a B cell receptor, a T cell receptor, an antibody, a major histocompatibility complex, a tumor antigen, a receptor, or any combination thereof. In some embodiments, more than one cellular component target can include an intracellular cellular component. In some embodiments, the more than one cellular component can be less than, about less than, at least less than, or at most less than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or a number or range between any two of these values of all encoded cellular components in an organism. In some embodiments, the more than one cellular component target can include at least the following: 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000, 10000 or more different cellular component targets.
[0228] In some embodiments, more than one cellular component binding reagent is contacted with the sample for specific binding to more than one cellular component target. Unbound cellular component binding reagents can be removed by, for example, washing. In embodiments where the sample comprises cells, any cellular component binding reagents that do not specifically bind to cells can be removed.
[0229] In some cases, cells from a cell colony can be separated (e.g., isolated) into the holes of a substrate of the present disclosure. The cell colony can be diluted before separation. The cell colony can be diluted so that at least or at most 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the holes of the substrate accommodate single cells. The cell population can be diluted so that the number of cells in the diluted population is, is at least, or is at most 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the number of wells on the substrate. In some cases, the cell population is diluted so that the number of cells is about 10% of the number of wells in the substrate.
[0230] The distribution of single cells in the holes of the substrate can follow a Poisson distribution. For example, the probability that a hole of the substrate has more than one cell can be at least or at most 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% or more. The distribution of single cells in the holes of the substrate can be random. The distribution of single cells in the holes of the substrate can be non-random. The cells can be separated so that one hole of the substrate only accommodates one cell. In some embodiments, the cell component binding reagent can be conjugated with a fluorescent molecule to achieve flow sorting of cells into individual compartments.
[0231] In some embodiments, the methods disclosed herein provide contacting more than one composition with a sample to specifically bind to more than one cellular component target. It should be understood that the conditions used can allow specific binding of cellular component binding agents such as antibodies to cellular component targets. After the contact step, unbound compositions can be removed. For example, in an embodiment where the sample comprises cells and the composition specifically binds to a cellular component target such as a cell surface protein that is a cell surface cellular component, the unbound composition can be removed by washing the cells with a buffer solution so that only the composition specifically bound to the cellular component target is retained with the cells.
[0232] In some embodiments, the methods disclosed herein can include associating an oligonucleotide comprising a barcode sequence (e.g., a molecular marker), a cell marker, a sample marker, or any combination thereof (e.g., a barcode or a random barcode) with more than one oligonucleotide associated with a cellular component binding reagent. For example, more than one oligonucleotide probe comprising a barcode can be used to hybridize with more than one oligonucleotide of a composition.
[0233] More than one oligonucleotide probe can be fixed on a solid support.Solid support can be free floating, such as beads in solution.Solid support can be embedded in semi-solid or solid arrays.In some embodiments, more than one oligonucleotide probe may not be fixed on a solid support.When more than one oligonucleotide probe is very close to more than one oligonucleotide of a cell component binding reagent, more than one oligonucleotide of a cell component binding reagent can hybridize with the oligonucleotide probe.Oligonucleotide probes can contact with a non-exhaustive ratio so that every different oligonucleotide of a cell component binding reagent can be associated with an oligonucleotide probe with different barcode sequences (e.g., molecular markers) of the present disclosure.
[0234] Method disclosed herein can include making oligonucleotides depart from the cell component binding reagents that are specifically combined with the cell component target. Departure can be carried out in various ways to separate chemical groups from cell component binding reagents, such as UV light cracking, chemical treatment (e.g., dithiothreitol treatment), heating, enzyme treatment or its any combination. Making oligonucleotides depart from cell component binding reagents can be carried out before, after or during the step of making more than one oligonucleotide probe and more than one oligonucleotide hybridization of compositions.
[0235] Methods for simultaneous quantitative analysis of cellular components and nucleic acid targets
[0236] The method disclosed herein can also be used to use the compositions disclosed herein and oligonucleotide probes to simultaneously quantitatively analyze more than one cell component target (e.g., protein target, cell surface target, intracellular target, nuclear target) and more than one nucleic acid target molecule in a sample, and the oligonucleotide probe can associate a barcode sequence (e.g., a molecular marker sequence) with both the oligonucleotide and nucleic acid target molecules of a cell component binding reagent. Other methods for simultaneously quantitatively analyzing more than one cell component target and more than one nucleic acid target molecule are described in US2018 / 0088112 and US2018 / 0346970; the contents of each of these applications are incorporated herein by reference in their entirety. In some embodiments, the sample can be a single cell, more than one cell, a tissue sample, a tumor sample, a blood sample, etc. In some embodiments, the sample can include a mixture of cell types (such as normal cells, tumor cells, blood cells, B cells, T cells, maternal cells, fetal cells) or a mixture of cells from different subjects. In some embodiments, the sample can include more than one single cell separated into individual compartments such as micropores in a micropore array.
[0237] More than one cell component target can include cell surface targets, intracellular targets, nuclear targets, cell surface proteins, cell markers, B cell receptors, T cell receptors, antibodies, major histocompatibility complexes, tumor antigens, receptors or any combination thereof. In some embodiments, more than one cell component target can include intracellular cell components. In some embodiments, more than one cell component can be below, about below, at least below or at most below all cell components (such as expressed proteins) in an organism or one or more cells of an organism: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or a number or range between any two of these values. In some embodiments, more than one cellular component target may include, include about, include at least, or include at most: 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000, 10000, or a number or range between any two of these values of different cellular component targets.
[0238] In some embodiments, more than one cellular component binding reagent is contacted with the sample for specific binding to more than one cellular component target. Unbound cellular component binding reagents can be removed by, for example, washing. In embodiments where the sample comprises cells, any cellular component binding reagents that do not specifically bind to cells can be removed.
[0239] In some cases, cells from a cell colony can be separated (e.g., separated) into the holes of the substrate of the present disclosure. The cell colony can be diluted before separation. The cell colony can be diluted so that at least or at most 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the holes of the substrate accommodate single cells. The cell colony can be diluted so that the number of cells in the diluted colony is below or at most below: 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the number of holes on the substrate. In some cases, the cell population is diluted so that the number of cells is about 10% of the number of wells in the substrate.
[0240] The distribution of single cells in the pores of the substrate can follow a Poisson distribution. For example, the probability that a pore of the substrate has more than one cell can be at least 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% or more. The distribution of single cells in the pores of the substrate can be random. The distribution of single cells in the pores of the substrate can be non-random. The cells can be separated so that one pore of the substrate only accommodates one cell.
[0241] In some embodiments, methods disclosed herein provide contacting more than one composition with a sample to specifically bind to more than one cellular component target. It should be understood that the conditions used can allow specific binding of cellular component binding agents such as antibodies to cellular component targets. After the contact step, unbound compositions can be removed. For example, in embodiments where the sample comprises cells and the cellular component target specifically bound by the composition is on the cell surface (such as a cell surface protein), the unbound composition can be removed by washing the cells with a buffer solution so that only the composition specifically bound to the cellular component target is retained with the cell.
[0242] In some embodiments, methods disclosed herein can provide for releasing more than one nucleic acid target molecule from a sample (e.g., a cell). For example, cells can be lysed to release more than one nucleic acid target molecule. Cell lysis can be accomplished in any of a variety of ways, for example, by chemical treatment, osmotic shock, heat treatment, mechanical treatment, optical treatment, or any combination thereof. Cells can be lysed by adding a cell lysis buffer comprising a detergent (e.g., SDS, lithium dodecyl sulfate, Triton X-100, Tween-20, or NP-40), an organic solvent (e.g., methanol or acetone), or a digestive enzyme (e.g., proteinase K, pepsin, or trypsin), or any combination thereof.
[0243] More than one nucleic acid molecule can include multiple nucleic acid molecules. In some embodiments, more than one nucleic acid molecule can include DNA molecules, RNA molecules, genomic DNA molecules, mRNA molecules, rRNA molecules, siRNA molecules or combinations thereof, and can be double-stranded or single-stranded. In some embodiments, more than one nucleic acid molecule includes the following, includes about the following, includes at least the following or includes at most the following: 100 kinds, 1000 kinds, 10000 kinds, 20000 kinds, 30000 kinds, 40000 kinds, 50000 kinds, 100000 kinds, 1000000 kinds or the number or the material of the range between any two of these values. More than one nucleic acid molecule can be or come from a sample, such as a single cell or more than one cell. In some embodiments, more than one nucleic acid molecule can be gathered from more than one sample, such as gathered from more than one single cell.
[0244] The methods disclosed herein can include associating a barcode (e.g., a random barcode) with more than one nucleic acid target molecule and more than one oligonucleotide of a cellular component binding agent, wherein the barcode (e.g., a random barcode) can include a barcode sequence (such as a molecular marker), a cell marker, a sample marker, or any combination thereof. For example, more than one oligonucleotide probe comprising a random barcode can be used to hybridize with more than one nucleic acid target molecule and more than one oligonucleotide in the composition.
[0245] More than one oligonucleotide probe can be fixed on a solid support. The solid support can be free-floating, such as a bead in a solution. The solid support can be embedded in a semi-solid or solid array. In some embodiments, more than one oligonucleotide probe may not be fixed on a solid support. When more than one oligonucleotide probe is closely approached by more than one oligonucleotide of more than one nucleic acid target molecule and a cell component binding agent, more than one oligonucleotide of more than one nucleic acid target molecule and a cell component binding agent can be hybridized with the oligonucleotide probe. The oligonucleotide probe can be contacted with an inexhaustible ratio so that the oligonucleotide of each different nucleic acid target molecule and a cell component binding agent can be associated with an oligonucleotide probe with different barcode sequences (such as molecular markers) of the present disclosure.
[0246] In some embodiments, method disclosed herein provides and makes oligonucleotide be separated from the cell component binding reagent that is specifically combined with cell component target.Disengagement can be carried out in various ways so that chemical group is separated from cell component binding reagent, such as UV light cracking, chemical treatment (for example dithiothreitol treatment), heating, enzyme treatment or its any combination.Oligonucleotide is separated from cell component binding reagent and can be carried out before, after or during the step of hybridizing more than one oligonucleotide probe with more than one nucleic acid target molecule and composition more than one oligonucleotide.
[0247] Simultaneous quantification of protein and nucleic acid targets
[0248] The methods disclosed herein can also be used for simultaneous quantitative analysis of more than one type of target molecule, such as protein and nucleic acid targets. For example, the target molecule can be or include a cellular component. Figure 6 A schematic diagram of an exemplary method for quantitatively analyzing nucleic acid targets and other cell component targets (e.g., proteins) simultaneously in a single cell is shown. In some embodiments, more than one composition 605a, 605b, 605c, etc., each comprising a cell component binding reagent such as an antibody, is provided. Different cell component binding reagents such as antibodies that are bound to different cell component targets are conjugated with different unique identifiers. Next, the cell component binding reagent can be incubated with a sample comprising more than one cell 610. Different cell component binding reagents can be specifically bound to cell components such as cell markers, B cell receptors, T cell receptors, antibodies, major histocompatibility complexes, tumor antigens, receptors, or any combination thereof on the cell surface. Unbound cell component binding reagents can be removed, for example, by washing cells with buffer. Then, cells with cell component binding reagents can be separated into more than one compartment such as a microwell array, wherein the size of a single compartment 615 is suitable for single cells and a single bead 620. Each bead can include more than one oligonucleotide probe and barcode sequence (e.g., molecular marker sequence), and the oligonucleotide probe can include a cell marker common to all oligonucleotide probes on the bead. In some embodiments, each oligonucleotide probe can include a target binding region, such as a poly (dT) sequence. The oligonucleotide 625 conjugated with a cell component binding agent can be separated from the cell component binding agent using chemistry, optics, or other means. Cells can be lysed 635 to release intracellular nucleic acids, such as genomic DNA or cell mRNA 630. Cell mRNA 630, oligonucleotide 625, or both can be captured by the oligonucleotide probe on the bead 620, for example, by hybridizing with poly (dT) sequences to capture. Reverse transcriptase can be used to extend the oligonucleotide probe hybridized with cell mRNA 630 and oligonucleotide 625 as a template using cell mRNA 630 and oligonucleotide 625. The extended product produced by reverse transcriptase can be amplified and sequenced. Sequencing reads can be demultiplexed or identified by cell markers, barcodes (e.g., molecular markers), genes, or cell component binding reagent-specific oligonucleotides (e.g., antibody-specific oligonucleotides), which can generate a digital representation of the cell component and gene expression of each single cell in the sample.
[0249] Barcode association
[0250] Oligonucleotides associated with cell component binding reagents (e.g., antigen binding reagents or protein binding reagents) and / or nucleic acid molecules can be randomly associated with oligonucleotide probes (e.g., barcodes, such as random barcodes). Oligonucleotides associated with cell component binding reagents, referred to herein as binding reagent oligonucleotides, can be or include oligonucleotides of the present disclosure, such as antibody oligonucleotides, sample index oligonucleotides, cell identification oligonucleotides, control particle oligonucleotides, control oligonucleotides, and interaction determination oligonucleotides. Association can, for example, include hybridizing the target binding region of an oligonucleotide probe with the complementary portion of the oligonucleotide of a target nucleic acid molecule and / or a protein binding reagent. For example, the oligo (dT) region of a barcode (e.g., random barcode) can interact with the poly (A) tails of the oligonucleotide of a target nucleic acid molecule and / or a protein binding reagent. The assay conditions (e.g., buffer pH, ionic strength, temperature, etc.) for hybridization can be selected to promote the formation of specific stable hybrids.
[0251] The present disclosure provides methods for associating molecular markers with target nucleic acids and / or oligonucleotides associated with cell component binding agents using reverse transcription. Reverse transcriptase can use both RNA and DNA as templates. For example, the oligonucleotides initially conjugated on the cell component binding agent can be RNA bases or DNA bases or both. In addition to the sequence of the binding agent sequence or a portion thereof, the binding agent oligonucleotide can be copied and connected (e.g., covalently linked) to cell markers and barcode sequences (e.g., molecular markers). As another example, in addition to the sequence of mRNA molecules or a portion thereof, mRNA molecules can be copied and connected (e.g., covalently linked) to cell markers and barcode sequences (e.g., molecular markers).
[0252] In some embodiments, molecular markers can be added by connecting a portion of an oligonucleotide probe target binding region and a portion of a target nucleic acid molecule and / or an oligonucleotide associated with a cellular component binding reagent (e.g., currently or previously associated). For example, the target binding region can include a nucleic acid sequence that can specifically hybridize with a restriction site overhang (e.g., an EcoRI sticky end overhang). The method can also include treating the target nucleic acid and / or the oligonucleotide associated with a cellular component binding reagent with a restriction enzyme (e.g., EcoRI) to produce a restriction site overhang. A ligase (e.g., T4 DNA ligase) can be used to connect the two fragments.
[0253] Determine the number or presence of unique molecular marker sequences
[0254] Methods disclosed herein may include determining the number or presence of unique molecular marker sequences for each unique identifier, each nucleic acid target molecule and / or each binding agent oligonucleotide (e.g., antibody oligonucleotide). For example, sequencing reads may be used to determine the number of unique molecular marker sequences for each unique identifier, each nucleic acid target molecule and / or each binding agent oligonucleotide. As another example, sequencing reads may be used to determine the presence or absence of molecular marker sequences (e.g., molecular marker sequences associated with targets, binding agent oligonucleotides, intracellular target binding agent specific oligonucleotides, cell surface target binding agent specific oligonucleotides and / or nuclear target binding agent specific oligonucleotides, antibody oligonucleotides, sample index oligonucleotides, cell identification oligonucleotides, control particle oligonucleotides, control oligonucleotides, and interaction determination oligonucleotides).
[0255] In some embodiments, the number of unique molecular marker sequences for each unique identifier, each nucleic acid target molecule and / or each binding agent oligonucleotide indicates the amount of each cellular component target (e.g., antigen target, protein target, cell surface target, intracellular target, nuclear target) and / or each nucleic acid target molecule in the sample. In some embodiments, the amount of the cellular component target and its corresponding nucleic acid target molecule, such as the amount of mRNA molecule, can be compared with each other. In some embodiments, the amount of the cellular component target and its corresponding nucleic acid target molecule, such as the ratio of the amount of mRNA molecule, can be calculated. The cellular component target can be, for example, a cell surface protein marker. In some embodiments, the ratio between the protein level of the cell surface protein marker and the mRNA level of the cell surface protein marker is low.
[0256] The methods disclosed herein can be used for various applications. For example, the methods disclosed herein can be used for proteome and / or transcriptome analysis of a sample. In some embodiments, the methods disclosed herein can be used to identify cell component targets and / or nucleic acid targets, i.e., biomarkers, in a sample. In some embodiments, the cell component target and the nucleic acid target correspond to each other, i.e., the nucleic acid target encodes the cell component target. In some embodiments, the methods disclosed herein can be used to identify a cell component target having a desired ratio between the amount of a cell component target and its corresponding nucleic acid target molecule, such as an mRNA molecule, in a sample. In some embodiments, the ratio is below or about below: 0.001, 0.01, 0.1, 1, 10, 100, 1000, or a number or range between any two of these values. In some embodiments, the ratio is at least below or at most below: 0.001, 0.01, 0.1, 1, 10, 100, or 1000. In some embodiments, the methods disclosed herein can be used to identify a cellular component target in a sample, wherein the amount of nucleic acid target molecules corresponding to the cellular component target in the sample is or is about 1000, 100, 10, 5, 2, 1, 0, or a number or range between any two of these values. In some embodiments, the methods disclosed herein can be used to identify a cellular component target in a sample, wherein the amount of nucleic acid target molecules corresponding to the cellular component target in the sample is more than or less than 1000, 100, 10, 5, 2, 1, or 0.
[0257] Compositions and kits
[0258] Some embodiments disclosed herein provide kits and compositions for simultaneous quantitative analysis of more than one cellular component (e.g., protein, cell surface target, intracellular target, nuclear target) and / or more than one nucleic acid target molecule in a sample. In some embodiments, the kit and composition may include: more than one cellular component binding reagent (e.g., more than one protein binding reagent) each conjugated to an oligonucleotide, wherein the oligonucleotide comprises a unique identifier for the cellular component binding reagent; and more than one oligonucleotide probe, wherein each of the more than one oligonucleotide probe comprises a target binding region, a barcode sequence (e.g., a molecular marker sequence), wherein the barcode sequence is from a set of different unique barcode sequences. In some embodiments, each oligonucleotide may include a molecular marker, a cell marker, a sample marker, or any combination thereof. In some embodiments, each oligonucleotide may include a joint. In some embodiments, each oligonucleotide may include a binding site for an oligonucleotide probe, such as a poly (A) tail. For example, a poly (A) tail may be, for example, oligodA18 (not anchored to a solid support) or oligoA18V (anchored to a solid support). Oligonucleotides can contain DNA residues, RNA residues, or both.
[0259] The disclosure herein includes more than one sample indexing composition. Each of the more than one sample indexing composition may include two or more cellular component binding reagents. Each of the two or more cellular component binding reagents may be associated with a sample indexing oligonucleotide. At least one of the two or more cellular component binding reagents may be capable of specifically binding to at least one cellular component target. The sample indexing oligonucleotide may include a sample indexing sequence for identifying the sample origin of one or more cells in the sample. The sample indexing sequences of at least two of the more than one sample indexing compositions may include different sequences.
[0260] The disclosure herein includes methods and kits for sample indexing. In some embodiments, each of the two sample indexing compositions comprises a cellular component binding reagent (e.g., a protein binding reagent) associated with a sample indexing oligonucleotide, wherein the cellular component binding reagent is capable of specifically binding to at least one of one or more cellular component targets (e.g., one or more protein targets), wherein the sample indexing oligonucleotide comprises a sample indexing sequence, and wherein the sample indexing sequences of the two sample indexing compositions comprise different sequences. In some embodiments, the sample indexing oligonucleotide comprises a molecular marker sequence, a binding site for a universal primer, or a combination thereof.
[0261] The unique identifier (or oligonucleotide associated with a cellular component binding reagent, such as a binding reagent oligonucleotide, an intracellular target binding reagent specific oligonucleotide, a cell surface target binding reagent specific oligonucleotide, a nuclear target binding reagent specific oligonucleotide, an antibody oligonucleotide, a sample indexing oligonucleotide, a cell identification oligonucleotide, a control particle oligonucleotide, a control oligonucleotide, or an interaction determination oligonucleotide) can have any suitable length, for example, from about 25 nucleotides to about 45 nucleotides long. In some embodiments, the unique identifier can have a length of, about, less than, or greater than: 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 200 nucleotides, or a range between any two of the above values.
[0262] In some embodiments, the unique identifier is selected from a group of different unique identifiers. A group of different unique identifiers can include the following, include about the following, include at least the following or include at most the following: 20 kinds, 30 kinds, 40 kinds, 50 kinds, 60 kinds, 70 kinds, 80 kinds, 90 kinds, 100 kinds, 200 kinds, 300 kinds, 400 kinds, 500 kinds, 600 kinds, 700 kinds, 800 kinds, 900 kinds, 1000 kinds, 2000 kinds, 5000 kinds or the different unique identifiers of the number or range between any two of these values. In some embodiments, a group of unique identifiers is designed to have the minimum sequence homology with the DNA or RNA sequence of the sample to be analyzed. In some embodiments, the sequence of a group of unique identifiers differs from each other or from its complement by less than or about the following: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides or the number or range between any two of these values. In some embodiments, the sequences of a set of unique identifiers differ from each other or their complements by at least or at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.
[0263] In some embodiments, the unique identifier may include a binding site for a primer (such as a universal primer). In some embodiments, the unique identifier may include at least two binding sites for a primer (such as a universal primer). In some embodiments, the unique identifier may include at least three binding sites for a primer (such as a universal primer). Primers may be used to amplify the unique identifier, for example, by PCR amplification. In some embodiments, primers may be used for nested PCR reactions.
[0264] Any suitable cell component binding agent is contemplated in the present disclosure, such as any protein binding agent (e.g., antibody or fragment thereof, aptamer, small molecule, ligand, peptide, oligonucleotide, etc. or any combination thereof). In some embodiments, the cell component binding agent can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a single chain antibody (scAb) or a fragment thereof, such as Fab and Fv. In some embodiments, more than one protein binding agent can include the following, including about the following, including at least the following, or including at most the following: 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 5000 or a number or range between any two of these values of different protein binding agents.
[0265] In some embodiments, the oligonucleotide is conjugated with a cell component binding agent through a joint. In some embodiments, the oligonucleotide can be covalently conjugated with a protein binding agent. In some embodiments, the oligonucleotide can be non-covalently conjugated with a protein binding agent. In some embodiments, the joint can include a chemical group that reversibly or irreversibly attaches the oligonucleotide to the protein binding agent. The chemical group can be conjugated with a joint, for example, through an amine group. In some embodiments, the joint can include a chemical group that forms a stable bond with another chemical group conjugated to a protein binding agent. For example, the chemical group can be a UV light cleavable group, a disulfide bond, streptavidin, biotin, an amine, etc. In some embodiments, the chemical group can be conjugated with a protein binding agent through an amino acid such as a primary amine on lysine or the N-terminus. The oligonucleotide can be conjugated with any suitable site of the protein binding agent, as long as it does not interfere with the specific binding between the protein binding agent and its protein target. In the embodiment where the protein binding agent is an antibody, the oligonucleotide can be conjugated with the antibody anywhere (e.g., Fc region, CH1 binding domain, CH2 binding domain, CH3 binding domain, CL binding domain) except for the antigen binding site. In some embodiments, each protein binding reagent can be conjugated to a single oligonucleotide molecule. In some embodiments, each protein binding reagent can be conjugated to more than one oligonucleotide molecule, for example, at least or at most 2, 3, 4, 5, 10, 20, 30, 40, 50, 100 or 1000 oligonucleotide molecules, wherein each oligonucleotide molecule comprises the same unique identifier. In some embodiments, each protein binding reagent can be conjugated to more than one oligonucleotide molecule, for example, at least or at most 2, 3, 4, 5, 10, 20, 30, 40, 50, 100 or 1000 oligonucleotide molecules, wherein each oligonucleotide molecule comprises the same unique identifier.
[0266] In some embodiments, more than one cell component binding reagent (e.g., protein binding reagent) can specifically bind to more than one cell component target (e.g., protein target) in a sample. The sample can be, include, be obtained from, or be derived from: a single cell, more than one cell, a tissue sample, a tumor sample, a blood sample, etc. In some embodiments, more than one cell component target includes a cell surface protein, a cell marker, a B cell receptor, a T cell receptor, an antibody, a major histocompatibility complex, a tumor antigen, a receptor, or any combination thereof. In some embodiments, more than one cell component target may include an intracellular protein. In some embodiments, more than one cell component target may include an intracellular protein. In some embodiments, more than one cell component target can be below, about below, at least below, or at most below: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or a number or range between any two of these values of all cell component targets (e.g., proteins expressed or potentially expressed) in an organism. In some embodiments, more than one cell component target can include, about below, at least below, or at most below: 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000, 10000 or a number or range between any two of these values of different cell component targets.
[0267] Sample indexing using oligonucleotide-conjugated cellular component binding reagents
[0268] The disclosure herein includes methods for sample identification. In some embodiments, the method includes: contacting one or more cells from each of more than one sample with a sample index composition in more than one sample index composition, wherein each of the one or more cells comprises one or more cellular component targets, wherein each of the more than one sample index composition comprises a cellular component binding reagent associated with a sample index oligonucleotide, wherein the cellular component binding reagent is capable of specifically binding to at least one of the one or more cellular component targets, wherein the sample index oligonucleotide comprises a sample index sequence, and wherein the sample index sequences of at least two of the more than one sample index compositions comprise different sequences; removing unbound sample index compositions in the more than one sample index composition; barcoding (e.g., random barcoding) the sample index oligonucleotides using more than one barcode (e.g., random barcodes) to produce more than one barcoded sample index oligonucleotides; obtaining sequencing data for the more than one barcoded sample index oligonucleotides; and identifying the sample origin of at least one of the one or more cells based on the sample index sequence of at least one of the more than one barcoded sample index oligonucleotides.
[0269] In some embodiments, barcoding a sample index oligonucleotide using more than one barcode comprises: contacting the more than one barcode with the sample index oligonucleotide to produce a barcode that hybridizes to the sample index oligonucleotide; and extending the barcode that hybridizes to the sample index oligonucleotide to produce more than one barcoded sample index oligonucleotide. Extending the barcode can include extending the barcode using a DNA polymerase to produce more than one barcoded sample index oligonucleotide. Extending the barcode can include extending the barcode using a reverse transcriptase to produce more than one barcoded sample index oligonucleotide.
[0270] Oligonucleotides conjugated to antibodies, oligonucleotides for conjugating to antibodies, or oligonucleotides previously conjugated to antibodies are referred to herein as antibody oligonucleotides ("AbOligo"). In the context of sample indexing, antibody oligonucleotides are referred to herein as sample indexing oligonucleotides. Antibodies conjugated to antibody oligonucleotides are referred to herein as hot antibodies (hotantibody) or oligonucleotide antibodies. Antibodies not conjugated to antibody oligonucleotides are referred to herein as cold antibodies (coldantibody) or no oligonucleotide antibodies. Oligonucleotides conjugated to binding agents (e.g., protein binding agents), oligonucleotides for conjugating to binding agents, or oligonucleotides previously conjugated to binding agents are referred to herein as reagent oligonucleotides. In the context of sample indexing, reagent oligonucleotides are referred to herein as sample indexing oligonucleotides. Binding agents conjugated to antibody oligonucleotides are referred to herein as hot binding agents or oligonucleotide binding agents. Binding agents not conjugated to antibody oligonucleotides are referred to herein as cold binding agents or no oligonucleotide binding agents.
[0271] Figure 7 A schematic diagram of an exemplary workflow for sample indexing using a cellular component binding reagent associated with an oligonucleotide is shown. In some embodiments, more than one composition 705a, 705b, etc., each comprising a binding reagent, is provided. The binding reagent can be a protein binding reagent, such as an antibody. The cellular component binding reagent can include an antibody, a tetramer, an aptamer, a protein scaffold, or a combination thereof. The binding reagent of more than one composition 705a, 705b can be combined with the same cellular component target. For example, the binding reagent of more than one composition 705a, 705b can be the same (except for the sample index oligonucleotide associated with the binding reagent).
[0272] Different compositions can include binding agents conjugated to sample index oligonucleotides with different sample index sequences. In different embodiments, the number of different compositions can be different. In some embodiments, the number of different compositions can be below, about below, at least below, or at most below: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, or a number or range between any two of these values.
[0273] In some embodiments, the sample index oligonucleotides of the binding reagents in a composition can contain the same sample index sequence. The sample index oligonucleotides of the binding reagents in a composition can be different. In some embodiments, the percentage of sample index oligonucleotides of the binding reagents in a composition that have the same sample index sequence can be less than, about less than, at least less than, or at most less than: 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69% , 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or a number or range between any two of these values.
[0274] Composition 705a and 705b can be used for marking samples in different samples. For example, the sample index oligonucleotide of cell component binding reagent in composition 705a can have a kind of sample index sequence, and can be used for marking the cell 710a (shown in black circle) in sample 707a (such as patient's sample). The sample index oligonucleotide of cell component binding reagent in composition 705b can have another sample index sequence, and can be used for marking the cell 710b (shown in shaded circle) in sample 707b (such as another patient's sample or another sample of the same patient). Cell component binding reagent can specifically bind to cell component target or protein (such as cell marker, B cell receptor, T cell receptor, antibody, major histocompatibility complex, tumor antigen, receptor or any combination thereof) on cell surface. Unbound cell component binding reagent can be removed, for example, by washing cells with buffer.
[0275] Then, the cell with cell component binding reagent can be separated into more than one compartment such as microwell array, wherein the size of single compartment 715a, 715b is suitable for single cell 710a and single bead 720a or single cell 710b and single bead 720b.Each bead 720a, 720b can include more than one oligonucleotide probe and molecular marker sequence, and the more than one oligonucleotide probe can include the cell labeling common to all oligonucleotide probes on bead.In some embodiments, every kind of oligonucleotide probe can include target binding region, for example many (dT) sequences.The sample index oligonucleotide 725a put together with the cell component binding reagent of composition 705a can be configured to (or can) be able to break away from or cannot break away from the cell component binding reagent from the cell component binding reagent.The sample index oligonucleotide 725a put together with the cell component binding reagent of composition 705a can use chemistry, optics or other means to break away from the cell component binding reagent. The sample index oligonucleotide 725b conjugated to the cell component binding reagent of the composition 705b can be configured to be (or can be) capable of being detached from the cell component binding reagent or incapable of being detached from the cell component binding reagent. The sample index oligonucleotide 725b conjugated to the cell component binding reagent of the composition 705b can be detached from the cell component binding reagent using chemical, optical or other means.
[0276] Cell 710a can be cracked to release nucleic acid in cell 710a, such as genomic DNA or cell mRNA 730a.Cracked cell 735a is shown in the circle of dotted line.Cell mRNA 730a, sample index oligonucleotide 725a or both can be captured by the oligonucleotide probe on pearl 720a, for example, by hybridizing with many (dT) sequences to capture.Reverse transcriptase can be used for using cell mRNA 730a and oligonucleotide 725a to extend the oligonucleotide probe hybridized with cell mRNA 730a and oligonucleotide 725a as template.Extension product produced by reverse transcriptase can be amplified and sequence checked.
[0277] 730b.Similarly, cell 710b can be cracked to release nucleic acid in cell 710b, such as genomic DNA or cell mRNA 730b.Cracked cell 735b is shown in the circle of dotted line.Cell mRNA 730b, sample index oligonucleotide 725b or both can be captured by the oligonucleotide probe on pearl 720b, for example, by catching with poly (dT) sequence hybridization.Reverse transcriptase can be used for using cell mRNA 730b and oligonucleotide 725b to extend the oligonucleotide probe hybridized with cell mRNA 730b and oligonucleotide 725b as template.The extension product that reverse transcriptase produces can be increased and sequence checked.
[0278] The sequencing reads can be demultiplexed for cell markers, molecular markers, gene identities, and sample identities (e.g., based on the sample index sequences of sample index oligonucleotides 725a and 725b). Demultiplexing of cell markers, molecular markers, and gene identities can produce a digital representation of the gene expression of each single cell in the sample. Demultiplexing of cell markers, molecular markers, and sample identities using the sample index sequences of sample index oligonucleotides can be used to determine the source of the sample.
[0279] Cellular component binding reagents for cell component binding reagents on the cell surface can be conjugated with a library of unique sample index oligonucleotides to allow cells to retain sample identity. For example, antibodies for cell surface markers can be conjugated with a library of unique sample index oligonucleotides to allow cells to retain sample identity. This will enable more than one sample to be loaded into the same RhapsodyTM box (cartridge), because throughout the library preparation and sequencing process, information related to the sample source is retained. Sample indexing can allow multiple samples to be run together in a single experiment, thereby simplifying and shortening the experimental time, and eliminating batch effect (batch effect).
[0280] The disclosure herein includes methods for sample identification. In some embodiments, the method includes: contacting one or more cells from each of more than one sample with a sample indexing composition in more than one sample indexing composition, wherein each of the one or more cells comprises one or more cellular component targets, wherein each of the more than one sample indexing composition comprises a cellular component binding reagent associated with a sample indexing oligonucleotide, wherein the cellular component binding reagent is capable of specifically binding to at least one of the one or more cellular component targets, wherein the sample indexing oligonucleotide comprises a sample indexing sequence, and wherein the sample indexing sequences of at least two of the more than one sample indexing compositions comprise different sequences; removing unbound sample indexing compositions in the more than one sample indexing compositions. The method may include barcoding (e.g., random barcoding) a sample index oligonucleotide using more than one barcode (e.g., random barcodes) to produce more than one barcoded sample index oligonucleotide; obtaining sequencing data for the more than one barcoded sample index oligonucleotide; and identifying the sample origin of at least one cell among the one or more cells based on the sample index sequence of at least one barcoded sample index oligonucleotide of the more than one barcoded sample index oligonucleotides.
[0281] In some embodiments, a method for sample identification comprises: contacting one or more cells from each of more than one sample with a sample index composition in more than one sample indexing compositions, wherein each of the one or more cells comprises one or more cellular component targets, wherein each of the more than one sample indexing compositions comprises a cellular component binding reagent associated with a sample indexing oligonucleotide, wherein the cellular component binding reagent is capable of specifically binding to at least one of the one or more cellular component targets, wherein the sample indexing oligonucleotide comprises a sample index sequence, and wherein the sample index sequences of at least two of the more than one sample indexing compositions comprise different sequences; removing unbound sample index compositions in the more than one sample indexing compositions; and identifying the sample origin of at least one cell in the one or more cells based on the sample index sequence of at least one sample indexing oligonucleotide of the more than one sample indexing compositions.
[0282] In some embodiments, identifying the sample origin of at least one cell comprises: barcoding (e.g., randomly barcoding) sample index oligonucleotides of more than one sample index composition using more than one barcode (e.g., random barcodes) to produce more than one barcoded sample index oligonucleotide; obtaining sequencing data for more than one barcoded sample index oligonucleotide; and identifying the sample origin of the cell based on the sample index sequence of at least one barcoded sample index oligonucleotide of the more than one barcoded sample index oligonucleotide. In some embodiments, barcoding sample index oligonucleotides using more than one barcode to produce more than one barcoded sample index oligonucleotides comprises randomly barcoding sample index oligonucleotides using more than one random barcode to produce more than one random barcoded sample index oligonucleotides.
[0283] In some embodiments, identifying the sample origin of at least one cell can include identifying the presence or absence of a sample index sequence of at least one sample index oligonucleotide of more than one sample index composition. Identifying the presence or absence of a sample index sequence can include: replicating at least one sample index oligonucleotide to produce more than one replicated sample index oligonucleotide; obtaining sequencing data of the more than one replicated sample index oligonucleotide; and identifying the sample origin of the cell based on the sample index sequence of the replicated sample index oligonucleotide in the more than one sample index oligonucleotide corresponding to the at least one barcoded sample index oligonucleotide in the sequencing data.
[0284] In some embodiments, replicating at least one sample index oligonucleotide to produce more than one replicated sample index oligonucleotide comprises: ligating a replication adaptor to the at least one barcoded sample index oligonucleotide prior to replicating the at least one barcoded sample index oligonucleotide. Replicating the at least one barcoded sample index oligonucleotide may comprise replicating the at least one barcoded sample index oligonucleotide using a replication adaptor ligated to the at least one barcoded sample index oligonucleotide to produce more than one replicated sample index oligonucleotide.
[0285] In some embodiments, replicating at least one sample index oligonucleotide to produce more than one replicated sample index oligonucleotide comprises: prior to replicating at least one barcoded sample index oligonucleotide, contacting a capture probe with at least one sample index oligonucleotide to produce a capture probe hybridized to the sample index oligonucleotide; and extending the capture probe hybridized to the sample index oligonucleotide to produce a sample index oligonucleotide associated with the capture probe. Replicating at least one sample index oligonucleotide may comprise replicating the sample index oligonucleotide associated with the capture probe to produce more than one replicated sample index oligonucleotide.
[0286] Also disclosed herein are methods for sample identification that allow, for example, identification of cell overload and multiplexes. The methods may include: contacting a first more than one cell and a second more than one cell, respectively, with two sample indexing compositions, wherein each of the first more than one cell and each of the second more than one cell comprises one or more cellular components, wherein each of the two sample indexing compositions comprises a cellular component binding reagent associated with a sample indexing oligonucleotide, wherein the cellular component binding reagent is capable of specifically binding to at least one of the one or more cellular components, wherein the sample indexing oligonucleotide comprises a sample indexing sequence, and wherein the sample indexing sequences of the two sample indexing compositions comprise different sequences; barcoding the sample indexing oligonucleotides using more than one barcode to produce more than one barcoded sample indexing oligonucleotides, wherein each of the more than one barcodes comprises a cell marker sequence, a barcode sequence (e.g., a molecular marker sequence), and a target binding sequence; A region, wherein the barcode sequences of at least two of the more than one barcodes comprise different sequences, and wherein at least two of the more than one barcodes comprise the same cell marker sequence; obtaining sequencing data of more than one barcoded sample index oligonucleotide; and identifying one or more cell marker sequences each associated with two or more sample index sequences in the obtained sequencing data; and removing sequencing data associated with such one or more cell marker sequences from the obtained sequencing data: the one or more cell marker sequences are each associated with two or more sample index sequences, and / or excluding sequencing data associated with such one or more cell marker sequences from subsequent analysis (e.g., single cell mRNA profiling or whole transcriptome analysis): the one or more cell marker sequences are each associated with two or more sample index sequences. In some embodiments, the sample index oligonucleotide comprises a barcode sequence (e.g., a molecular marker sequence), a binding site for a universal primer, or a combination thereof. Methods for sample identification can be used for this method.
[0287] For example, the method can be used to load 50000 or more cells (compared to 10000-20000 cells) using sample index. Sample index can use oligonucleotide conjugated cellular component binding reagents (such as antibodies) or cellular component binding reagents for cellular components (such as universal protein markers) to mark cells from different samples with unique sample index. When two or more cells from different samples, two or more cells from different cell populations of a sample, or two or more cells of a sample, are captured in the same micropore or droplet, the "cell" (or the content of two or more cells) of the combination can be associated with sample index oligonucleotides (or cell identification oligonucleotides with different cell identification sequences) with different sample index sequences. In different embodiments, the number of different populations of cells can be different. In some embodiments, the number of different populations can be below, about below, at least below, or at most below: 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or range between any two of these values. In various embodiments, the number or average number of cells in each population can be different. In some embodiments, the number or average number of cells in each population can be below, about below, at least below, or at most below: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or a number or range between any two of these values. When the number or average number of cells in each population is sufficiently small (e.g., equal to or less than 50, 25, 10, 5, 4, 3, 2, or 1 cells per population), the sample indexing composition used for cell overload and multiplet identification can be referred to as a cell identification composition.
[0288] Oligonucleotide-conjugated antibodies
[0289] Unique molecular marker sequence
[0290] Oligonucleotides associated with cellular component binding reagents (e.g., antibody oligonucleotides ("AbOligo" or "AbO"), binding reagent oligonucleotides, cellular component binding reagent-specific oligonucleotides, sample index oligonucleotides) can contain unique molecular marker sequences (also referred to as molecular indices (MI), "molecular barcodes," or unique molecular identifiers (UMIs)). Cellular component binding reagents can include intracellular target binding reagents, cell surface target binding reagents, and / or nuclear target binding reagents. Binding reagent oligonucleotides can include intracellular target binding reagent-specific oligonucleotides, cell surface target binding reagent-specific oligonucleotides, and / or nuclear target binding reagent-specific oligonucleotides. In some embodiments, binding reagent oligonucleotide materials comprising molecular barcodes as described herein reduce bias by increasing sensitivity, reducing relative standard error, or increasing sensitivity and / or reducing standard error. Molecular barcodes can contain unique sequences such that when multiple sample nucleic acids (which can be identical and / or different from each other) are associated with a molecular barcode, different sample nucleic acids can be distinguished from each other by the molecular barcodes. In this way, even if a sample contains two nucleic acids with the same sequence, each of the two nucleic acids can be labeled with a different molecular barcode so that the nucleic acids in the population can be quantified, even after amplification. A molecular barcode can comprise a nucleic acid sequence of at least 5 nucleotides, such as at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides, including numbers or ranges of nucleotides between any two of these values. In some embodiments, the nucleic acid sequence of a molecular barcode comprises, for example, a unique sequence, such that each unique oligonucleotide species in the composition comprises a different molecular barcode. In some embodiments, two or more unique oligonucleotide materials can comprise the same molecular barcode, but still different from each other. For example, if the unique oligonucleotide material comprises a sample barcode, each unique oligonucleotide material with a specific sample barcode can comprise different molecular barcodes. In some embodiments, the composition comprising the unique oligonucleotide material comprises the molecular barcode diversity of at least 1000 different molecular barcodes, and therefore comprises at least 1000 unique oligonucleotide materials. In some embodiments, the composition comprising the unique oligonucleotide material comprises the molecular barcode diversity of at least 6500 different molecular barcodes, and therefore comprises at least 6500 unique oligonucleotide materials.In some embodiments, a composition comprising unique oligonucleotide species comprises a molecular barcode diversity of at least 65,000 different molecular barcodes, and thus comprises at least 65,000 unique oligonucleotide species.
[0291] The unique molecular marker sequence can be located 5' of the unique identifier sequence without any intervening sequence between the unique molecular marker sequence and the unique identifier sequence. In some embodiments, the unique molecular marker sequence is located 5' of the spacer sequence, which is located 5' of the unique identifier sequence, such that the spacer sequence is located between the unique molecular marker sequence and the unique identifier sequence. In some embodiments, the unique identifier sequence is located 5' of the unique molecular marker sequence, without any intervening sequence between the unique identifier sequence and the unique molecular marker sequence. In some embodiments, the unique identifier sequence is located 5' of the spacer sequence, which is located 5' of the unique molecular marker sequence, such that the spacer sequence is located between the unique identifier sequence and the unique molecular marker sequence.
[0292] The unique molecular marker sequence can comprise a nucleic acid sequence of at least 2 nucleotides, for example, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 nucleotides, a number or range of nucleotides between any two of these values.
[0293] In some embodiments, the unique molecular marker sequence of the binding agent oligonucleotide comprises a sequence of at least three repetitions of the duplex "VN" and / or "NV" (wherein each "V" is any one of A, C or G, and wherein "N" is any one of A, G, C or T), at least three repetitions such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 repetitions, including ranges between any two of the listed values. Examples of multiple repetitions of the duplex "VN" include VN, VNVN, VNVNVN and VNVNVNVN. It should be noted that, although the formulas "VN" and "NV" describe constraints on the basic content, not every V or every N must be the same or different. For example, if the molecular barcodes of the unique oligonucleotide species in the composition comprise VNVNVN, one molecular barcode may comprise the sequence ACGGCA, while another molecular barcode may comprise the sequence ATACAT, while another molecular barcode may comprise the sequence ATACAC. It is noted that any number of repeats of the duplex "VN" will have a T content of no more than 50%. In some embodiments, at least 95% of the unique oligonucleotide species of a composition comprising at least 1000 unique oligonucleotide species comprise a molecular barcode comprising at least three repeats of the duplex "VN" and / or "NV", at least three repeats such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99% of the unique oligonucleotide species of a composition comprising at least 1000 unique oligonucleotide species comprise a molecular barcode comprising at least three repeats of a duplex "VN" and / or "NV", at least three repeats, such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99.9% of the unique oligonucleotide species of a composition comprising at least 1000 unique oligonucleotide species comprise a molecular barcode comprising at least three repeats of a duplex "VN" and / or "NV", at least three repeats, such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 repeats, including ranges between any two of the listed values.In some embodiments, at least 95% of the unique oligonucleotide species of a composition comprising at least 6500 unique oligonucleotide species comprise a molecular barcode comprising at least three repeats of a duplex "VN" and / or "NV", at least three repeats, such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99% of the unique oligonucleotide species of a composition comprising at least 6500 unique oligonucleotide species comprise a molecular barcode comprising at least three repeats of a duplex "VN" and / or "NV", at least three repeats, such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99.9% of the unique oligonucleotide species of a composition comprising at least 6500 unique oligonucleotide species comprise a molecular barcode comprising at least three repeats of a duplex "VN" and / or "NV", at least three repeats, such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 95% of the unique oligonucleotide species of a composition comprising at least 65,000 unique oligonucleotide species comprise a molecular barcode comprising at least three repeats of a duplex "VN" and / or "NV", at least three repeats, such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 repeats, including ranges between any two of the listed values. In some embodiments, at least 99% of the unique oligonucleotide species of a composition comprising at least 65,000 unique oligonucleotide species comprise a molecular barcode comprising at least three repeats of a duplex "VN" and / or "NV", at least three repeats, such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 repeats, including ranges between any two of the listed values.In some embodiments, at least 99.9% of the unique oligonucleotide species of a composition comprising at least 65,000 unique oligonucleotide species comprise a molecular barcode comprising at least three repeats of a duplex "VN" and / or "NV", at least three repeats such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 repeats, including ranges between any two of the listed values. In some embodiments, the composition consists of or consists essentially of at least 1000, 6500, or 65,000 unique oligonucleotide species, each having a molecular barcode comprising the sequence VNVNVN. In some embodiments, the composition consists of or consists essentially of at least 1000, 6500, or 65,000 unique oligonucleotide species, each having a molecular barcode comprising the sequence VNVNVNVN. In some embodiments, at least 95%, 99% or 99.9% of the barcode regions of the compositions as described herein contain at least three repeats of the duplex "VN" and / or "NV" as described herein. In some embodiments, the unique molecular marker sequence containing repeated duplexes "VN" and / or "NV" can produce low bias, while providing a compromise between reducing bias and maintaining a relatively large amount of available nucleotide sequences, so that relatively high diversity can be obtained in a relatively short sequence, while still minimizing bias. In some embodiments, the unique molecular marker sequence containing repeated duplexes "VN" and / or "NV" can reduce bias by increasing sensitivity, reducing relative standard error, or increasing sensitivity and reducing standard error. In some embodiments, the unique molecular marker sequence containing repeated duplexes "VN" and / or "NV" improves informatics analysis by acting as a geographic marker. In some embodiments, the repeated duplexes "VN" and / or "NV" described herein reduce the incidence of homopolymers within the unique molecular marker sequence. In some embodiments, the repeating duplexes "VN" and / or "NV" described herein interrupt the homopolymer.
[0294] In some embodiments, the sample index oligonucleotide comprises a first molecular marker sequence. In some embodiments, the first molecular marker sequences of at least two sample index oligonucleotides are different, and the sample index sequences of at least two sample index oligonucleotides are the same. In some embodiments, the first molecular marker sequences of at least two sample index oligonucleotides are different, and the sample index sequences of at least two sample index oligonucleotides are different. In some embodiments, the cell component binding reagent specific oligonucleotide comprises a second molecular marker sequence. In some embodiments, the second molecular marker sequences of at least two cell component binding reagent specific oligonucleotides are different, and the unique identifier sequences of at least two cell component binding reagent specific oligonucleotides are the same. In some embodiments, the second molecular marker sequences of at least two cell component binding reagent specific oligonucleotides are different, and the unique identifier sequences of at least two cell component binding reagent specific oligonucleotides are different. In some embodiments, the number of unique second molecular marker sequences associated with the unique identifier sequence of the cell component binding reagent that can be specifically bound to at least one cell component target in the sequencing data indicates the copy number of at least one cell component target in one or more of more than one cell. In some embodiments, a combination of the following (1) and (2) (e.g., minimum, average, and maximum) indicates the copy number of at least one cellular component target in one or more cells among more than one cell: (1) the number of unique first molecular marker sequences in the sequencing data that are associated with a unique identifier sequence for a cellular component binding reagent that is capable of specifically binding to the at least one cellular component target; and (2) the number of unique second molecular marker sequences in the sequencing data that are associated with a unique identifier sequence for a cellular component binding reagent that is capable of specifically binding to the at least one cellular component target.
[0295] Alignment sequences
[0296] In some embodiments, the binding agent oligonucleotide (e.g., intracellular target binding agent specific oligonucleotide, cell surface target binding agent specific oligonucleotide, nuclear target binding agent specific oligonucleotide) comprises an alignment sequence adjacent to the poly (dA) region (e.g., alignment sequence 825bb described with reference to FIG. 9). The length of the alignment sequence can be 1 or more nucleotides. The length of the alignment sequence can be 2 nucleotides. The alignment sequence can contain guanine, cytosine, thymine, uracil, or a combination thereof. The alignment sequence can contain poly (dT) regions, poly (dG) regions, poly (dC) regions, poly (dU) regions, or a combination thereof. In some embodiments, the alignment sequence is 5' in the poly (dA) region. Advantageously, in some embodiments, the presence of the alignment sequence makes the poly (A) tails of each of the binding agent oligonucleotides have the same length, resulting in greater uniformity of performance. In some embodiments, the percentage of binding reagent oligonucleotides having the same poly (dA) region length in more than one binding reagent oligonucleotide (each of which comprises an alignment sequence) may be or may be about 80%, 90%, 91%, 93%, 95%, 97%, 99.9%, 99.9%, 99.99%, or 100%, or a number or range between any two of these values. In some embodiments, the percentage of binding reagent oligonucleotides having the same poly (dA) region length in more than one binding reagent oligonucleotide (each of which comprises an alignment sequence) may be at least or may be at most 80%, 90%, 91%, 93%, 95%, 97%, 99.9%, 99.9%, 99.99%, or 100%.
[0297] In different embodiments, the length of the alignment sequence can be different. In some embodiments, the length of the alignment sequence can be or can be about or at least or at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 93, 94, 95, 96, 97, 98, 99, 100, or a number or range between any two of these values. In different embodiments, the number of one or more guanines, one or more cytosines, one or more thymines, or one or more uracils in the aligned sequences may be different.The number of one or more guanines, one or more cytosines, one or more thymines, or one or more uracils can be or can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 93, 94, 95, 96, 97, 98, 99, 100, or a number or range between any two of these values. The number of one or more guanines, one or more cytosines, one or more thymines, or one or more uracils may be at least the following or may be at most the following: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 , 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100. In some embodiments, the sample index oligonucleotide comprises an alignment sequence. In some embodiments, the cellular component binding agent-specific oligonucleotide comprises an alignment sequence.
[0298] Connectors
[0299] Binding agent oligonucleotide (for example, intracellular target binding agent specific oligonucleotide, cell surface target binding agent specific oligonucleotide, nuclear target binding agent specific oligonucleotide) can be conjugated with cell component binding agent (for example, intracellular target binding agent, cell surface target binding agent, nuclear target binding agent) by various mechanisms. In some embodiments, binding agent oligonucleotide can be covalently conjugated with cell component binding agent. In some embodiments, binding agent oligonucleotide can be non-covalently conjugated with cell component binding agent. In some embodiments, binding agent oligonucleotide is conjugated with cell component binding agent through joint. In some embodiments, binding agent oligonucleotide can include joint. Joint can include chemical group. Chemical group can be reversibly or irreversibly attached to the molecule of cell component binding agent. Chemical group can be UV light cleavable group, disulfide bond, streptavidin, biotin, amine or any combination thereof. Joint can include carbon chain. Carbon chain can include, for example, 5-50 carbon atoms. In different embodiments, carbon chain can have different number of carbon atoms. In some embodiments, the number of carbon atoms in the carbon chain can be below, can be about below, at least below, or can be at most below: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or a number or range between any two of these values. In some embodiments, the carbon chain comprises 2-30 carbons. In some embodiments, the carbon chain comprises 12 carbons. In some embodiments, the amino modifier used for binding agent oligonucleotide can be conjugated with cellular component binding agent. In some embodiments, the joint comprises 5' amino modifier C6 (5AmMC6) or its derivative. In some embodiments, the joint comprises 5' amino modifier C12 (5AmMC12) or its derivative. In some embodiments, longer joints achieve higher conjugation efficiency. In some embodiments, longer joints achieve higher modification efficiency before conjugation. In some embodiments, increasing the distance between functional amine and DNA sequence produces higher conjugation efficiency. In some embodiments, increasing the distance between functional amine and DNA sequence produces higher modification efficiency before conjugation. In some embodiments, using 5AmMC12 as a joint produces higher modification efficiency (before conjugation) than using 5AmMC6 as a joint. In some embodiments, using 5AmMC12 as a joint produces higher conjugation efficiency than using 5AmMC6 as a joint.In some embodiments, the sample indexing oligonucleotide is associated with the cellular component binding reagent via a linker. In some embodiments, the cellular component binding reagent specific oligonucleotide is associated with the cellular component binding reagent via a linker.
[0300] Antibody-specific barcode sequences
[0301] In several embodiments, disclosed herein are improvements in the design of unique identifier sequences (e.g., antibody-specific barcode sequences) for binding reagent oligonucleotides (e.g., intracellular target binding reagent-specific oligonucleotides, cell surface target binding reagent-specific oligonucleotides, nuclear target binding reagent-specific oligonucleotides). The intracellular target binding reagent-specific oligonucleotide may comprise a unique intracellular target identifier for the intracellular target binding reagent-specific oligonucleotide. The cell surface target binding reagent-specific oligonucleotide may comprise a unique cell surface target identifier for the cell surface target binding reagent-specific oligonucleotide. The nuclear target binding reagent-specific oligonucleotide may comprise a unique nuclear target identifier for the nuclear target binding reagent-specific oligonucleotide. In some embodiments, the unique identifier sequence (e.g., sample index sequence, cellular component binding reagent-specific oligonucleotide) is designed to have a Hamming distance greater than 3. In some embodiments, the Hamming distance of the unique identifier sequence may be or be about the following: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or a number or range between any two of these values. In some embodiments, the unique identifier sequence has a GC content in the range of 40% to 60% and does not have a predicted secondary structure (e.g., a hairpin). In some embodiments, the unique identifier sequence does not comprise any sequence predicted by computer simulation to bind to mouse and / or human transcripts. In some embodiments, the unique identifier sequence does not comprise any sequence predicted by computer simulation to bind to Rhapsody and / or SCMK system primers. In some embodiments, the unique identifier sequence does not comprise a homopolymer.
[0302] Primer adapter
[0303] In some embodiments, the binding reagent oligonucleotide (e.g., intracellular target binding reagent specific oligonucleotide, cell surface target binding reagent specific oligonucleotide, nuclear target binding reagent specific oligonucleotide) comprises a primer adapter. In some embodiments, the primer adapter comprises the following sequence: the first universal primer, its complementary sequence, its partial sequence, or a combination thereof. In some embodiments, the first universal primer comprises an amplification primer, its complementary sequence, its partial sequence, or a combination thereof. In some embodiments, the first universal primer comprises a sequencing primer, its complementary sequence, its partial sequence, or a combination thereof. In some embodiments, the sequencing primer comprises an Illumina sequencing primer. In some embodiments, the sequencing primer comprises a portion of an Illumina sequencing primer. In some embodiments, the sequencing primer comprises a P7 sequencing primer. In some embodiments, the sequencing primer comprises a portion of a P7 sequencing primer. In some embodiments, the primer adapter comprises an adapter for Illumina P7. In some embodiments, the primer adapter comprises a partial adapter for Illumina P7. In some embodiments, the amplification primer is an Illumina P7 sequence or a subsequence thereof. In some embodiments, the sequencing primer is an Illumina R2 sequence or a subsequence thereof.In some embodiments, the length of the first universal primer is 5-50 nucleotides. In some embodiments, the primer adapter can comprise a nucleic acid sequence of at least 5 nucleotides, such as at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides, or a number or range of nucleotides between any two of these values.The primer adapter may comprise a nucleic acid sequence that is at least 5 nucleotides of the sequence of the first universal primer, the amplification primer, the sequencing primer, the complementary sequence thereof, the partial sequence thereof, or a combination thereof, such as at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 48, 49, or 50 nucleotides, including numbers or ranges between any two of these values.
[0304] A conventional amplification workflow for sequencing library preparation can employ three rounds of PCR, such as, for example: a first round ("PCR 1") employing target-specific primers and primers for a universal Illumina sequencing primer 1 sequence; a second round ("PCR 2") employing nested target-specific primers flanked by Illumina sequencing primer 2 sequences and primers for a universal Illumina sequencing primer 1 sequence; and a third round ("PCR 3") adding Illumina P5 and P7 and a sample index. Advantageously, in some embodiments, the primer adapters disclosed herein enable a shorter and simpler workflow in library preparation than if the starting template (e.g., a sample index oligonucleotide attached to a bead) does not have a primer adapter. In some embodiments, the primer adapter reduces the pre-sequencing PCR amplification of the template by one round (compared to a template if a primer adapter is not included). In some embodiments, the primer adapter reduces the pre-sequencing PCR amplification of the template to one round (compared to a template if a primer adapter is not included). In some embodiments, templates comprising primer adapters do not require a PCR amplification step for attaching Illumina sequencing adapters, and if the template does not contain primer adapters, pre-sequencing is required. In some embodiments, the primer adapter sequence (or a subsequence thereof) is not part of the sequencing read of the sequencing template comprising the primer adapter sequence, and therefore does not affect the read quality of the template comprising the primer adapter. Templates comprising primer adapters can have reduced sequencing diversity compared to templates if they do not contain primer adapters.
[0305] In some embodiments, the sample index oligonucleotide comprises a primer adapter. In some embodiments, replicating the sample index oligonucleotide, the barcoded sample index oligonucleotide, or a product thereof comprises using a first universal primer, a first primer comprising the sequence of the first universal primer, or a combination thereof to produce more than one replicated sample index oligonucleotide. In some embodiments, replicating a sample index oligonucleotide, a barcoded sample index oligonucleotide, or a product thereof comprises using a first universal primer, a first primer comprising the sequence of the first universal primer, a second universal primer, a second primer comprising the sequence of the second universal primer, or a combination thereof to produce more than one replicated sample index oligonucleotide. In some embodiments, the cellular component binding reagent-specific oligonucleotide comprises a primer adapter. In some embodiments, the cellular component binding reagent-specific oligonucleotide comprises the following sequence: a first universal primer, its complementary sequence, its partial sequence, or a combination thereof.
[0306] Binding reagents for oligonucleotide barcoding
[0307] Figure 8 A schematic diagram of a non-limiting exemplary workflow of barcoding of a binding reagent oligonucleotide 825 (an antibody oligonucleotide illustrated here) associated with a binding reagent 805 (an antibody illustrated here). The binding reagent oligonucleotide 825 can be associated with the binding reagent 805 through a joint 825l. The binding reagent oligonucleotide 825 can be separated from the binding reagent using chemical, optical or other means. The binding reagent oligonucleotide 825 can be an mRNA mimic. The binding reagent oligonucleotide 825 can include a primer adapter 825pa, an antibody molecule tag 825am (e.g., a unique molecule tag sequence), an antibody barcode 825ab (e.g., a unique identifier sequence), an alignment sequence 825bb and a poly (A) tail 825a. In some embodiments, the primer adapter 825pa includes the following sequence: a first universal primer, a complementary sequence thereof, a partial sequence thereof, or a combination thereof. In some embodiments, the primer adapter 825pa can be the same for all or some binding reagent oligonucleotides 825. In some embodiments, the antibody barcode 825ab can be the same for all or some of the binding reagent oligonucleotides 825. In some embodiments, the antibody barcode 825ab is different for different binding reagent oligonucleotides 825. In some embodiments, the antibody molecule label 825am is different for different binding reagent oligonucleotides 825.
[0308] The binding reagent oligonucleotide 825 can be barcoded using more than one barcode 815 (e.g., a barcode 815 associated with a particle such as a bead 810) to produce more than one barcoded binding reagent oligonucleotide 840. In some embodiments, the barcode 815 can include a poly (dT) region 815t for binding to the binding reagent oligonucleotide 825, optionally a molecular label 815m (e.g., for determining the number of occurrences of the binding reagent oligonucleotide), a cell label 815c, and a universal label 815u. In some embodiments, the barcode 815 hybridizes to the poly (dT) region 815t of the binding reagent oligonucleotide 825. In some embodiments, the barcoded binding reagent oligonucleotide 840 is generated by extending the barcode 815 hybridized to the binding reagent oligonucleotide 825 (e.g., by reverse transcription). In some embodiments, the barcoded binding reagent oligonucleotide 840 comprises a primer adapter 825pa, an antibody molecular tag 825am (e.g., a unique molecular tag sequence), an antibody barcode 825ab (e.g., a unique identifier sequence), an alignment sequence 825bb, a poly (dT) region 815t, a molecular tag 815m, a cell tag 815c, and a universal tag 815u.
[0309] In some embodiments, the barcoded binding reagent oligonucleotide disclosed herein comprises two unique molecular marker sequences: a molecular marker sequence derived from a barcode (e.g., molecular marker 815m) and a molecular marker sequence derived from a binding reagent oligonucleotide (e.g., antibody molecular marker 825am, a first molecular marker sequence of a sample index oligonucleotide, a second molecular marker sequence of a cell component binding reagent specific oligonucleotide). As used herein, "double molecular indexing" refers to the methods and compositions disclosed herein that employ a barcoded binding reagent oligonucleotide (or its product) comprising a first unique molecular marker sequence and a second unique molecular marker sequence (or its complementary sequence). In some embodiments, the sample identification method disclosed herein and the quantitative analysis method of a cell component target may include obtaining an information sequence of a barcode molecular marker sequence and / or a binding reagent oligonucleotide molecular marker sequence. In some embodiments, the number of barcode molecular marker sequences associated with a unique identifier sequence for a cell component binding reagent capable of specifically binding to at least one cell component target in sequencing data indicates the number of copies of at least one cell component target in one or more of more than one cell. In some embodiments, the number of binding reagent oligonucleotide molecule tag sequences associated with a unique identifier sequence for a cellular component binding reagent capable of specifically binding to at least one cellular component target in the sequencing data indicates the number of copies of at least one cellular component target in one or more of more than one cell. In some embodiments, the number of both binding reagent oligonucleotide molecule tag sequences and barcode molecule tag sequences associated with a unique identifier sequence for a cellular component binding reagent capable of specifically binding to at least one cellular component target in the sequencing data indicates the number of copies of at least one cellular component target in one or more of more than one cell.
[0310] Using PCR to amplify the amount of material before starting the sequencing protocol increases the likelihood of artifacts, such as artificial recombination during amplification when premature termination products trigger subsequent rounds of synthesis. In some embodiments, the methods of dual molecular indexing provided herein allow for the identification of PCR chimeras given sufficient sequencing depth. Additionally, in some embodiments, the addition of unique molecular marker sequences to binding reagent oligonucleotides increases the complexity of random labeling. Therefore, in some embodiments, the presence of unique molecular marker sequences in binding reagent oligonucleotides can overcome limitations in UMI diversity. In some embodiments, the dual molecular indexing methods provided herein reduce the number of cellular component targets marked as "saturated" during post-sequencing molecular coverage calculations by at least or about 2% (e.g., 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 40%, 50%, 75%, 100%, 150%, 200%, 250%, 500%, 1000% or more, and overlapping ranges therein) compared to if the methods and compositions were not used.
[0311] AbSeq marker-specific flow surrogate assays
[0312] Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq) is a single cell phenotyping method that can detect proteins by sequencing using quantitative readouts using antibody oligonucleotide conjugates (e.g., AbSeq reagents). Despite the increasing awareness and adoption of this advanced technology by researchers, the cost of performing single cell CITE-Seq can be high when researchers want to detect a large number of AbSeq markers. When designing an AbSeq panel for a single cell CITE-Seq experiment for a biological system, it can be difficult to know the marker expression levels using AbSeq reagents before the single cell CITE-Seq workflow. Some markers in the AbSeq panel show little or universally high expression, and money may be wasted on reagents that do not provide much information. Therefore, before single cell CITE-seq, an assay is needed to estimate AbSeq marker expression. Therefore, a cost-effective assay is needed to check surface protein expression using accurate AbSeq reagents in relevant biological samples before sequencing to guide AbSeq panel design and ensure protein expression.
[0313] In a currently available method called a "flow cytometry assay," cells from a sample of interest are stained with AbSeq reagents and then with a dye-dT oligonucleotide conjugate. Due to the binding between the polyA sequence of the AbSeq reagents and the dye-dT oligonucleotide conjugate, the fluorescent signal measured by flow cytometry correlates with protein levels ( Fig.13A ). While this assay can be used to identify optimal amounts of AbSeq reagents and for confirming oligoantibody conjugation of custom conjugated reagents, only one protein marker can be tested at a time. In some embodiments, provided herein are compositions, methods, and kits for detecting multiple cellular component targets (e.g., protein markers) using improved flow cytometric proxy assays prior to single-cell CITE-Seq. These methods, compositions, and kits have various advantages over currently available flow cytometric proxy assays. Currently available flow cytometric proxy assays can only detect one protein marker at a time by using dye-dT conjugates—therefore, if researchers want to detect 10 markers, they must set up 10 reactions, which inevitably increases the workload and is not feasible for precious samples. However, using the workflow provided herein, researchers can detect several cellular component targets (e.g., protein markers) simultaneously (e.g., at least 4 proteins, such as Fig.13A ). Some embodiments of the workflow provided herein rely on the non-covalent binding of complementary oligonucleotide sequences between the AbSeq reagent (e.g., the cell component binding reagent-specific oligonucleotide of the first cell component binding reagent) and the dye-oligonucleotide conjugate (e.g., the first detectable conjugate, the second detectable conjugate). In the embodiment of the third workflow provided herein, the user does not use the first detectable conjugate (e.g., the AbSeq specific dye-oligonucleotide conjugate), but uses the second detectable conjugate (e.g., the universal dye-dT oligonucleotide conjugate), which can enable the detection of any protein marker. Therefore, this method can significantly save the user the cost of purchasing dye-oligonucleotide conjugates. The user can design a sequence complementary to the unique AbSeq barcode or universal sequence (e.g., poly-A tail) of the dye-oligonucleotide conjugate described herein. When combined, the stained sample can be visualized using flow cytometry.
[0314] Provided herein are multiplexed flow proxy assays in which multiple AbSeq markers can be measured simultaneously in one reaction using flow cytometry. Various embodiments of compositions, methods, and kits for multiplexed protein marker detection are provided (e.g., workflow 1, workflow 2, and workflow 3 as described herein). Workflow 1 and workflow 2 can include AbSeq barcode-specific (e.g., unique identifier-specific) dye-oligonucleotide conjugates (e.g., first detectable conjugates) to achieve AbSeq marker-specific detection. Some embodiments of workflow 3 include pre-incubating the dye-oligonucleotide conjugate (e.g., second detectable conjugate) with the AbSeq reagents before the cells are added, so that the user can avoid ordering different dye-oligonucleotide conjugates specific for each AbSeq reagent (but only need to use dye-dT oligonucleotide conjugates for multiplexed AbSeq marker detection). Figures 12A-12D Non-limiting exemplary workflows provided herein are depicted. Fig. 12A A non-limiting exemplary schematic diagram of currently available flow cytometry assays is depicted. Fig. 12B A non-limiting exemplary schematic diagram of a first multiplex protein marker detection workflow disclosed herein is depicted. Fig. 12C A non-limiting exemplary schematic diagram of a second multiplex protein marker detection workflow disclosed herein is depicted. Fig.12D A non-limiting exemplary schematic diagram of a third multiplex protein marker detection workflow disclosed herein is depicted. Hybridization between antibody-oligonucleotide and dye-oligonucleotide conjugates Figures 12A-12D The workflows are depicted on the right side of each workflow. By using AbSeq barcode-specific dye-oligonucleotide conjugates (e.g., Workflow 1-Workflow 2), users can detect multiple AbSeq markers in one sample instead of one AbSeq marker. In addition, by pre-incubating AbSeq reagents and dye-oligonucleotide conjugates before adding cells, users can use dye-dT oligonucleotide conjugates to detect multiple markers simultaneously (e.g., Workflow 3).
[0315] The various compositions and methods provided herein (e.g., Workflow 1, Workflow 2, and Workflow 3) enable the simultaneous detection of multiple markers using flow cytometry. Experimental data showed that the group resolution was comparable in the three assay workflows ( Fig. 13B In addition, the cell composition identified using the multiplex protein marker detection workflow provided herein is similar to that achieved using currently available single-plex flow cytometry assays ( Fig. 13C). Depending on the needs of the user, various compositions and methods provided herein (e.g., Workflow 1, Workflow 2, and Workflow 3) can be employed. In some embodiments, the disclosed methods can directly measure the dynamic range of AbSeq expression, allowing the user to adjust the AbSeq stain concentration before performing high-cost sequencing (e.g., by diluting high expressors with unconjugated oligonucleotides). Users can use this as a QC step before incurring high sequencing costs.
[0316] The dye-oligonucleotide conjugates provided herein can be widely used in fluorescence in situ hybridization (FISH), spatial transcriptomics / proteomics and sequencing. Fig.14 A non-limiting exemplary workflow for preparing the disclosed detectable conjugates (e.g., dye-oligonucleotide conjugates, first detectable conjugates, second detectable conjugates) is depicted. Various chemistries can be used for oligonucleotide-dye conjugation. In some embodiments, a Sirigen dye is reacted with a modified oligonucleotide to produce a dye-oligonucleotide conjugate. The modified oligonucleotide can include an NHS ester derivative. In some embodiments, the 5' end is first enzymatically dephosphorylated. The residual phosphate group can then be converted to a reactive ester using CDI (N,N'-carbonyldiimidazole) or EDC (1-ethyl-3,3'-dimethylaminopropylcarbodiimide) with sulfo-NHS or imidazole. Then, in some embodiments, the activated ester is reacted with Monoamino- reaction, and thus it can be conjugated via an amide linkage.
[0317] In some embodiments, the systems, methods, compositions, and kits provided herein can be used in conjunction with the systems, methods, compositions, and kits for non-sequencing PCR-Based detection of antibody-conjugated oligonucleotides described in international patent application PCT / US2022 / 076056, entitled “Non-Sequencing PCR-Based Method For Detection Of Antibody-Conjugated Oligonucleotides,” filed on September 7, 2022, the contents of which are incorporated herein by reference in their entirety.
[0318] Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq) is a single-cell technology that utilizes antibody oligonucleotide conjugates (e.g., AbSeq reagents from BD) to measure counts of both mRNA and protein molecules at single-cell resolution using sequencing. Despite the increasing awareness and adoption of this advanced technology by researchers, in some embodiments, users may encounter difficulties when designing an AbSeq panel for a biological system of interest. For example, in some embodiments, due to the lack of information about AbSeq protein expression in their biological system, users may encounter situations where some AbSeq markers are commonly expressed or not expressed in their sequencing results. There is a need for methods and compositions that can perform quality control assays, where users can pre-test protein expression using AbSeq reagents in a specific biological system prior to (expensive) sequencing.
[0319] The flow proxy assay provided herein can fill this gap. In some embodiments of the flow proxy assay, the poly A sequence from the AbSeq reagent is combined with a dye-dT oligonucleotide conjugate. The fluorescent signal measured by flow cytometry can be associated with the protein level. In some embodiments, disclosed herein include multiple flow proxy assays for simultaneously detecting multiple markers. By incubating the AbSeq reagent with the dye-dT conjugate before adding cells, users can use multiple flow proxy assays to detect multiple protein markers at one time. Traditional and multiple flow proxy assays together provide a useful tool for evaluating the protein level of the AbSeq group design.
[0320] How many AbSeq markers a user can detect using the multiplexed flow cytometry provided herein is an important consideration. Example 4 demonstrates the feasibility of a four-marker flow cytometry proxy set using dye-oligonucleotide conjugates for quantitative PCR. In some embodiments of the methods and compositions provided herein, a higher gravity flow cytometry proxy set is provided to support the versatility of multiplexed flow cytometry proxy assays (e.g., Table 1). In some embodiments, a limitation of multiplexed flow cytometry assays is the limited available dye-oligonucleotide conjugates. To overcome this challenge, in some embodiments, a new dye-oligonucleotide conjugate is provided, which comprises RY586 and / or RB780 (from the Real Blue and Real Yellow dye families) Fig.15A In addition, in some embodiments, novel binding formats for flow cytometry assays provided herein are provided by introducing, for example, streptavidin-dye and biotin-dT binding ( Fig. 15B In addition, the multiplex flow cytometry assays provided herein may include novel reagents peptide nucleic acid (PNA)-dye conjugates ( Fig. 15CUsing all conventional and novel dye-oligonucleotide conjugates, a 10-color flow panel was successfully resolved with overlapping dyes using spectral flow cytometry (Example 5).
[0321] Table 1: Detectable conjugates
[0322]
[0323]
[0324] Provided herein are multicolor flow cytometry assays using novel dye-oligonucleotide conjugates and AbSeq reagents. Example 5 provides a proof of principle for a 10-color multicolor flow cytometry assay using spectral cytometry and overlapping dyes. Conventional flow cytometry assays only allow detection of one marker at a time. Example 4 provides a proof of principle for detecting four AbSeq markers at a time. In some embodiments, the limited number of dye-oligonucleotide conjugates currently available may limit the multiplicity of flow cytometry assays. However, this problem is solved by the methods and compositions provided herein, such as, for example, by creating new reagents or providing new binding forms to provide expanded dye options for dye-oligonucleotide conjugates. As shown in Example 6, RY586 and RB780 are conjugated to oligonucleotides, which are novel reagents and are significantly brighter than traditional dye oligonucleotide conjugates ( Fig.17A In addition, Example 6 demonstrates the feasibility of using biotin-dT and streptavidin-dye in a flow cytometry assay, which no one has combined in this format into a flow cytometry assay ( Fig. 17B Because there are many dye options for streptavidin-dye conjugates, this significantly increases the possible panel multiplicity for flow cytometric proxy assays. Finally, PNA-dye conjugates were used in the multicolor flow cytometric proxy panel in Example 6, which is a new binding format for AbSeq reagents with higher binding affinity ( Fig. 17C Using three new dye-oligonucleotide conjugates, a 10-color flow cytometry panel was designed and demonstrated large panel resolution using spectral flow cytometry and spectral overlapping dyes (Example 5).
[0325] The number of dye-oligonucleotide conjugates currently available may be limited. Disclosed herein are brighter dye-oligonucleotide conjugates using BD RealYellow and Real Blue proprietary dyes. Also provided herein is a flow agent assay in which a streptavidin-biotin binding form is incorporated into a detectable conjugate. Disclosed herein is the first principle verification of the use of PNA-dye conjugates in combination with AbSeq reagents in a flow agent assay. By adopting those new dye-oligonucleotide conjugates and applying the new binding form to the flow agent assay, the disclosed compositions and methods push the limits of available dye-oligonucleotide conjugates and establish a 10-color flow agent group, which allows users to simultaneously detect at least 10 AbSeq markers by using a universal dT dye conjugate (see Example 5). These dye-oligonucleotide conjugates provided herein make it possible to have a higher weight flow agent assay. Depending on the customer's application and needs, they can choose any combination of the novel dye-oligonucleotide conjugates (e.g., detectable conjugates) provided herein. For example, if a customer requires higher binding affinity between AbSeq reagents and dye-oligonucleotide conjugates, they can utilize multiple PNA-dye conjugates. As described herein, in some embodiments, the binding sequence in the dye-oligonucleotide conjugate can be AbSeq marker specific, rather than multiple thymidines.
[0326] Some embodiments of the flow agent assay provided herein include detectable conjugates containing PNA. As a synthetic DNA analog, PNA has 2-aminoethylglycine bonds instead of conventional DNA phosphodiester backbones. In the absence of any charge in the backbone, PNA-nucleic acid hybrids have higher binding affinity, stability and selectivity compared to DNA or RNA hybrids. In addition, the reagent is water-soluble and less toxic to cells. In terms of manufacturing, PNA synthesis is easier and cost-effective compared to DNA synthesis. PNA can be widely used in different applications, and PNA-dye conjugates can be used as detection probes for a variety of molecular biology and diagnostic assays. In some embodiments provided herein, PNA-dye oligonucleotide conjugates can be used as spatial transcriptomics reagents and in other applications. In some embodiments, the detectable conjugate provided herein includes peptide nucleic acid (PNA) and can provide a novel binding form for flow agent detection. The use of PNAs in the detectable conjugates provided herein can provide one or more of the following advantages: (i) high binding affinity, specificity, and selectivity for forming PNA-RNA or PNA-DNA hybrids; (ii) lower synthesis cost; (iii) water solubility and / or lower toxicity to cells; and (iv) no charge -> no electrostatic repulsion -> higher stability.
[0327] In some embodiments, a method for measuring the expression of a cellular component target in a cell is provided. In some embodiments, the method includes: contacting more than one first cellular component binding reagent with a first more than one cell comprising more than one cellular component target, wherein each of the more than one first cellular component binding reagents includes a cellular component binding reagent-specific oligonucleotide, the cellular component binding reagent-specific oligonucleotide includes a unique identifier sequence for the first cellular component binding reagent, and wherein the first cellular component binding reagent is capable of specifically binding to at least one of the more than one cellular component targets. The method may include: contacting the first more than one cell associated with the first cellular component binding reagent with more than one first detectable conjugate, wherein each of the more than one first detectable conjugates includes a detectable portion or a precursor thereof and a unique identifier-specific oligonucleotide, t...
Claims
1. A method for measuring the expression of a cellular component target in a cell, the method comprising: include: contacting more than one first cellular component binding reagent with a first more than one cell comprising more than one cellular component target, wherein each of the more than one first cellular component binding reagent comprises a cellular component binding reagent-specific oligonucleotide comprising a unique identifier sequence for the first cellular component binding reagent, and wherein the first cellular component binding reagent is capable of specifically binding to at least one of the more than one cellular component targets; contacting the first more than one cell associated with the first cellular component binding reagent with more than one first detectable conjugate, wherein each of the more than one first detectable conjugate comprises a detectable moiety or a precursor thereof and a unique identifier-specific oligonucleotide comprising a sequence configured to bind a unique identifier sequence, wherein first detectable conjugates capable of binding to the same unique identifier sequence comprise the same detectable moiety or a precursor thereof, and wherein first detectable conjugates capable of binding to different unique identifier sequences comprise different detectable moieties or precursors thereof; as well as The emission of the detectable portion of each first detectable conjugate is measured with an instrument as an indication of the amount of each first cellular component binding agent bound to the cellular component target and the first detectable conjugate.
2. A method for measuring the expression of a cellular component target in a cell, the method comprising: include: contacting more than one first cellular component binding reagent with more than one first detectable conjugate, wherein each of the more than one first cellular component binding reagents comprises a cellular component binding reagent-specific oligonucleotide comprising a unique identifier sequence for the first cellular component binding reagent, and wherein the first cellular component binding reagent is capable of specifically binding to at least one of the more than one cellular component targets, and wherein each of the more than one first detectable conjugates comprises a detectable moiety or a precursor thereof and a unique identifier-specific oligonucleotide comprising a sequence configured to bind to a unique identifier sequence, wherein first detectable conjugates capable of binding to the same unique identifier sequence comprise the same detectable moiety or a precursor thereof, and wherein first detectable conjugates capable of binding to different unique identifier sequences comprise different detectable moieties or precursors thereof; contacting the more than one first cellular component binding reagents associated with the more than one first detectable conjugates with a first more than one cell comprising more than one cellular component target; as well as The emission of the detectable portion of each first detectable conjugate is measured with an instrument as an indication of the amount of each first cellular component binding agent bound to the cellular component target and the first detectable conjugate.
3. A method for measuring the expression of a cellular component target in a cell, the method comprising: include: contacting more than one first cellular component binding reagent with more than one second detectable conjugate in more than one partition, wherein each of the more than one first cellular component binding reagents comprises a cellular component binding reagent-specific oligonucleotide comprising a unique identifier sequence for the first cellular component binding reagent, wherein each cellular component binding reagent-specific oligonucleotide comprises a shared sequence, wherein The shared sequence is identical across all cellular component binding agent-specific oligonucleotides of the more than one first cellular component binding agent, wherein the first cellular component binding agent is capable of specifically binding to at least one of the more than one cellular component targets, wherein each of the more than one second detectable conjugates comprises a detectable moiety or a precursor thereof and a shared oligonucleotide comprising a sequence configured to bind to the shared sequence, and wherein each of the more than one partitions comprises: a first cellular component binding reagent of the more than one first cellular component binding reagent, wherein the cellular component binding reagents located in the same partition comprise the same unique identifier sequence and are capable of specifically binding to the same cellular component target, and wherein the cellular component binding reagents located in different partitions comprise different unique identifiers and are capable of specifically binding to different cellular component targets; and a second detectable conjugate among the more than one second detectable conjugates, wherein the second detectable conjugates located in the same partition comprise the same detectable moiety or a precursor thereof, and wherein the second detectable conjugates located in different partitions comprise different detectable moieties or precursors thereof; contacting the more than one first cellular component binding reagents associated with the more than one second detectable conjugates with a first more than one cell comprising more than one cellular component target; and The emission of the detectable portion of each second detectable conjugate is measured by an instrument as an indication of the amount of each first cellular component binding agent bound to the cellular component target and the second detectable conjugate.
4. The method according to any one of claims 1 to 3, comprising, if the emission indicates that the abundance of the first cellular component binding reagent is above or below a predetermined abundance range: The second one or more cells are contacted with the first cellular component binding reagent in a manner configured to achieve an abundance of the first cellular component binding reagent within the predetermined abundance range.
5. The method of any one of claims 1-4, wherein the predetermined abundance range comprises a dynamic range over which acceptable linearity and efficiency of detection of the cellular component binding reagent is observed.
6. The method of any one of claims 1-5, wherein contacting a second one or more cells with a first cellular component binding reagent in a manner configured to achieve an abundance of the first cellular component binding reagent within the predetermined abundance range comprises contacting the second one or more cells with an altered amount of the first cellular component binding reagent relative to the first contacting step.
7. The method according to any one of claims 1-6, comprising contacting the first more than one cell and / or the second more than one cell with more than one second cellular component binding reagent, wherein the second cellular component binding reagent is capable of specifically binding to at least one of the more than one cellular component targets, wherein the second cellular component binding reagent does not comprise a cellular component binding reagent-specific oligonucleotide, wherein one or more of the first cellular component binding reagents and one or more of the second cellular component binding reagents are capable of binding to the same cellular component target.
8. A method according to any one of claims 1-7, wherein contacting a second one or more cells with a first cellular component binding reagent in a manner configured to achieve an abundance of the first cellular component binding reagent within the predetermined abundance range includes contacting the second one or more cells with a mixture of the first cellular component binding reagent and a second cellular component binding reagent capable of binding to the same cellular component target as the first cellular component binding reagent in a titration ratio configured to achieve an abundance of the first cellular component binding reagent within the predetermined abundance range, optionally the titration ratio is configured such that sequencing reads containing the unique identifier sequence of the first cellular component binding reagent account for less than about 5% of the total sequencing reads.
9. The method according to any one of claims 1-8, comprising, after contacting the more than one first cellular component binding reagent with the first more than one cell and / or the second more than one cell, removing one or more first cellular component binding reagents that are not in contact with the first more than one cell and / or the second more than one cell among the more than one first cellular component binding reagents, optionally removing the one or more first cellular component binding reagents that are not in contact with the first more than one cell and / or the second more than one cell comprising removing the one or more first cellular component binding reagents that are not in contact with at least one corresponding one of the more than one cellular component targets.
10. The method according to any one of claims 1-9, comprising, after contacting the first more than one cell associated with the first cellular component binding reagent with the more than one first detectable conjugate, removing one or more first detectable conjugates of the more than one first detectable conjugates that are not in contact with the first more than one cell associated with the first cellular component binding reagent, optionally removing the one or more first detectable conjugates that are not in contact with the first more than one cell associated with the first cellular component binding reagent comprises removing the one or more first detectable conjugates that are not in contact with the corresponding unique identifier sequence of the cellular component binding reagent-specific oligonucleotide.
11. The method according to any one of claims 1-10, comprising, after contacting the more than one first cellular component binding reagent with more than one first detectable conjugate, removing one or more first detectable conjugates among the more than one first cellular component binding reagents that have not been in contact with the more than one first cellular component binding reagents, optionally removing the one or more first detectable conjugates that have not been in contact with the more than one first cellular component binding reagents comprising removing the one or more first detectable conjugates that have not been in contact with the corresponding unique identifier sequence of the cellular component binding reagent-specific oligonucleotide.
12. The method according to any one of claims 1-11, comprising, after contacting the more than one first cellular component binding reagent with the more than one second detectable conjugate, removing one or more second detectable conjugates among the more than one second detectable conjugates that are not in contact with the more than one first cellular component binding reagent, optionally removing the one or more second detectable conjugates that are not in contact with the more than one first cellular component binding reagent comprising removing the one or more second detectable conjugates that are not in contact with the corresponding shared sequence of the cellular component binding reagent-specific oligonucleotide.
13. The method of any one of claims 1-12, comprising pooling the contents of the more than one partitions after contacting the more than one first cellular component binding reagent with the more than one second detectable conjugate in the more than one partitions.
14. The method of any one of claims 1-13, wherein the method does not comprise a protein-based reagent capable of binding to the first cellular component binding reagent.
15. The method of any one of claims 1-14, wherein the unique identifier specific oligonucleotide and / or the shared oligonucleotide do not bind to the first cellular component binding reagent via a mechanism other than nucleic acid hybridization.
16. The method of any one of claims 1-15, wherein the first cellular component binding reagent does not comprise a detectable moiety or a precursor thereof.
17. The method of any one of claims 1-16, wherein the first one or more cells and the second one or more cells (a) are derived from the same sample; and / or (b) comprise T cells, B cells, tumor cells, bone marrow cells, blood cells, normal cells, fetal cells, maternal cells, or a mixture thereof.
18. The method of any one of claims 1-17, wherein the cellular component target comprises (a) a protein target, optionally wherein the first cellular component binding reagent and / or the second cellular component binding reagent comprises an antibody or a fragment thereof; and / or (b) a carbohydrate, a lipid, a protein, an extracellular protein, a cell surface protein, a cell marker, a B cell receptor, a T cell receptor, a major histocompatibility complex, a tumor antigen, a receptor, an intracellular protein or any combination thereof.
19. The method according to any one of claims 1 to 18, wherein the method is multiplexed.
20. The method according to any one of claims 1 to 19, wherein the more than one cellular component target comprises at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10000 different cellular component targets; wherein the more than one first cellular component binding reagent and / or the more than one second cellular component binding reagent comprises at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10000 different cellular component binding reagents; wherein the more than one first detectable conjugate comprises at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10000 different first detectable conjugates, optionally wherein the different first detectable conjugates comprise two or more overlapping dyes that can be resolved by spectroscopic cytometry; wherein the more than one second detectable conjugate comprises at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10000 different second detectable conjugates, optionally wherein the different second detectable conjugates comprise two or more overlapping dyes that can be resolved by spectroscopic cytometry; and / or Wherein the unique identifier specific oligonucleotide and / or the shared oligonucleotide has a length of 5-500 nucleotides.
21. The method of any one of claims 1-20, wherein the sequence configured to bind to a unique identifier sequence comprises a sequence that is complementary to at least a portion of the unique identifier sequence.
22. A method according to any one of claims 1-21, wherein (a) the shared sequence is a sequence complementary to a capture sequence configured to capture the cellular component binding reagent specific oligonucleotide, and wherein the sequence configured to bind to the shared sequence is the capture sequence, optionally the capture sequence comprises a poly (dT) region; and / or (b) the shared sequence is a second universal sequence, and wherein the sequence configured to bind to the shared sequence is a sequence complementary to at least a portion of the second universal sequence.
23. The method according to any one of claims 1-22, wherein the second universal sequence comprises a binding site for a sequencing primer and / or a sequencing adapter, its complementary sequence and / or a portion thereof; and optionally (a) wherein the sequencing adapter comprises a P5 sequence, a P7 sequence, its complementary sequence and / or a portion thereof; and / or (b) wherein the sequencing primer comprises a read 1 sequencing primer, a read 2 sequencing primer, its complementary sequence and / or a portion thereof.
24. The method of any one of claims 1-23, wherein the contacting step comprises (a) hybridization of a cellular component binding reagent specific oligonucleotide and a unique identifier specific oligonucleotide; or (b) hybridization of a cellular component binding reagent specific oligonucleotide and a shared oligonucleotide.
25. The method of any one of claims 1-24, wherein the detectable moiety comprises an optical moiety, a luminescent moiety, an electrochemically active moiety, a nanoparticle, or a combination thereof, optionally wherein the nanoparticles comprise quantum dots, and / or wherein the luminescent moiety comprises a chemiluminescent moiety, an electroluminescent moiety, a photoluminescent moiety or a combination thereof; and optionally wherein the photoluminescent moiety comprises a fluorescent moiety, a phosphorescent moiety or a combination thereof, optionally the fluorescent moiety comprises a fluorescent dye.
26. The method of any one of claims 1-25, comprising performing a reaction to convert a precursor of the detectable moiety into the detectable moiety.
27. The method of any one of claims 1-26, wherein the detectable moiety comprises (a) BD Horizon RealBlue TM 780 (RB780), BD Horizon RealYellow TM 586 (RY586) and / or BrilliantViolet TM 421 (BV421); and / or (b) one or more of DAPI, BUV661, RY586, AF647, Cy5, RB780, ROX, BV421, FAM and Cy3.
28. The method according to any one of claims 1-27, wherein the unique identifier specific oligonucleotide and / or the shared oligonucleotide is or comprises locked nucleic acid (LNA), peptide nucleic acid (PNA), DNA, LNA / PNA chimera, LNA / DNA chimera, PNA / DNA chimera or any combination thereof.
29. The method according to any one of claims 1-28, wherein the unique identifier specific oligonucleotide and / or the shared oligonucleotide comprises a linker, and wherein the unique identifier specific oligonucleotide and / or the shared oligonucleotide is associated with the detectable moiety or a precursor thereof via the linker; and optionally wherein the linker comprises a carbon chain, optionally the carbon chain comprises 2-30 carbons, and further optionally the carbon chain comprises 12 carbons, or The linker comprises 5' amino modification C12 (5AmMC12) or a derivative thereof.
30. The method according to any one of claims 1 to 29, wherein said unique identifier specific oligonucleotide and / or said shared oligonucleotide comprises an affinity moiety; wherein the detectable moiety or a precursor thereof comprises a binding partner for the affinity moiety; and wherein the affinity moiety comprises biotin, streptavidin, heparin, an aptamer, a click chemistry moiety, digoxigenin, one or more primary amines, one or more carboxyl groups, one or more hydroxyl groups, one or more aldehydes, one or more ketones, derivatives thereof, or any combination thereof.
31. The method of any one of claims 1-30, wherein the detectable moiety or a precursor thereof is conjugated to the unique identifier-specific oligonucleotide and / or shared oligonucleotide via a 1,3-dipolar cycloaddition reaction, a hetero-Diels-Alder reaction, a nucleophilic substitution reaction, a non-aldol type carbonyl reaction, a carbon-carbon multiple bond addition, an oxidation reaction, a click reaction, or any combination thereof.
32. The method of any one of claims 1-31, wherein the instrument comprises a flow cytometer, optionally comprising a conventional flow cytometer, a spectral flow cytometer, a hyperspectral flow cytometer, an imaging flow cytometer, or any combination thereof.
33. A method according to any one of claims 1-32, wherein the cell component binding reagent specific oligonucleotide comprises a sequence complementary to a capture sequence of an oligonucleotide barcode, the capture sequence of the oligonucleotide barcode is configured to capture the sequence of the cell component binding reagent specific oligonucleotide, and optionally, the sequence of the cell component binding reagent specific oligonucleotide complementary to the capture sequence comprises a poly (dA) region.
34. The method according to any one of claims 1 to 33, wherein the method include: contacting more than one oligonucleotide barcode with the cellular component binding reagent-specific oligonucleotide for hybridization, wherein each of the oligonucleotide barcodes comprises a first molecular tag and a first universal sequence; as well as The more than one oligonucleotide barcodes hybridized to the cellular component binding reagent specific oligonucleotide are extended to generate more than one barcoded cellular component binding reagent specific oligonucleotide, each of the more than one barcoded cellular component binding reagent specific oligonucleotides comprising a sequence complementary to at least a portion of the unique identifier sequence and the first molecular label.
35. The method according to any one of claims 1-34, comprising obtaining sequence information of the more than one barcoded cellular component binding reagent-specific oligonucleotides or their products to determine the copy number of at least one of the more than one cellular component targets in one or more of the first more than one cells and / or the second more than one cells.
36. The method of any one of claims 1-35, wherein obtaining the sequence information comprises attaching sequencing adaptors to the more than one barcoded cellular component binding reagent-specific oligonucleotides or products thereof.
37. A method according to any one of claims 1-36, wherein the number of unique first molecular marker sequences associated with the unique identifier sequence of the first cellular component binding reagent capable of specifically binding to the at least one cellular component target in the sequencing data indicates the copy number of the at least one cellular component target in one or more of the first more than one cell and / or the second more than one cell.
38. The method of any one of claims 1-37, wherein the more than one cellular component targets comprise more than one protein target, and wherein the first cellular component binding reagent is capable of specifically binding to at least one of the more than one protein targets, optionally, the more than one cellular component targets comprise cell surface proteins, intracellular proteins, cell markers, B cell receptors, T cell receptors, antibodies, major histocompatibility complexes, tumor antigens, receptors or a combination thereof.
39. The method of any one of claims 1-38, wherein the cellular component binding agent-specific oligonucleotide comprises one or more of: (a) a second molecular marker sequence, optionally, the second molecular marker sequence is 2-20 nucleotides in length; (b) an alignment sequence adjacent to the poly(dA) region, optionally, the alignment sequence is one or more nucleotides, or two or more nucleotides in length; and (c) a linker, wherein the cellular component binding agent-specific oligonucleotide is associated with the first cellular component binding agent via the linker.
40. The method according to any one of claims 1 to 39, wherein said second molecular marker sequences of at least two cellular component binding reagent specific oligonucleotides are different, and wherein said unique identifier sequences of said at least two cellular component binding reagent specific oligonucleotides are the same; and / or wherein said second molecular tag sequences of at least two cellular component binding agent specific oligonucleotides are different, and wherein said unique identifier sequences of said at least two cellular component binding agent specific oligonucleotides are different.
41. A method according to any one of claims 1-40, wherein the number of unique second molecular marker sequences in the sequencing data associated with the unique identifier sequence of the first cellular component binding reagent capable of specifically binding to the at least one cellular component target indicates the copy number of the at least one cellular component target in one or more of the first more than one cell and / or the second more than one cell.
42. The method according to any one of claims 1 to 41, in: (a) the aligned sequences contain guanine, cytosine, thymine, uracil or a combination thereof; (b) the alignment sequence comprises a poly(dT) sequence, a poly(dG) sequence, a poly(dC) sequence, a poly(dU) sequence or a combination thereof; and / or (c) The alignment sequence is located 5' of the poly(dA) region.
43. The method of any one of claims 1-42, wherein the linker comprises a carbon chain, a 5' amino modifier C12 (5AmMC12) or a derivative thereof; optionally, the carbon chain comprises 2-30 carbons; and further optionally, the carbon chain comprises 12 carbons.
44. The method of any one of claims 1-43, wherein the cellular component binding reagent specific oligonucleotide is associated with the first cellular component binding reagent, optionally, the cellular component binding reagent specific oligonucleotide is covalently attached to the first cellular component binding reagent and / or is non-covalently attached to the first cellular component binding reagent.
45. A method according to any one of claims 1-44, wherein (a) the cellular component binding reagent specific oligonucleotide is conjugated to the first cellular component binding reagent, and optionally, the cellular component binding reagent specific oligonucleotide is conjugated to the first cellular component binding reagent via a chemical group selected from the group consisting of a UV light cleavable group, streptavidin, biotin, amines and combinations thereof; and / or (b) wherein the cellular component binding reagent specific oligonucleotide is configured to be detachable from the first cellular component binding reagent.
46. A method according to any one of claims 1-45, wherein the method comprises dissociating the cellular component binding reagent specific oligonucleotide from the first cellular component binding reagent, optionally, dissociating the cellular component binding reagent specific oligonucleotide comprises detaching the cellular component binding reagent specific oligonucleotide from the first cellular component binding reagent by UV light cleavage, chemical treatment, heating, enzyme treatment or any combination thereof.
47. The method of any one of claims 1-46, wherein the dissociation occurs after the cellular component binding reagent-specific oligonucleotide is barcoded, and / or wherein the dissociation occurs before the cellular component binding reagent-specific oligonucleotide is barcoded.
48. The method of any one of claims 1-47, wherein the cellular component binding reagent-specific oligonucleotide is configured to be non-detachable from the first cellular component binding reagent.
49. The method of any one of claims 1-48, wherein one or more single cells in the first more than one cell and / or the second more than one cell comprise a copy of a nucleic acid target, the method further comprising: include: contacting more than one oligonucleotide barcode with the copy of the nucleic acid target for hybridization, wherein each of the more than one oligonucleotide barcode comprises a first universal sequence, a target binding region capable of hybridizing to the copy of the nucleic acid target, and a first molecular label; extending the more than one oligonucleotide barcodes hybridized to the copy of the nucleic acid target to generate more than one barcoded nucleic acid molecule, each of the more than one barcoded nucleic acid molecule comprising a sequence complementary to at least a portion of the nucleic acid target; and Sequence information of the more than one barcoded nucleic acid molecules or products thereof is obtained to determine the copy number of the nucleic acid target in each of the one or more single cells.
50. The method of any one of claims 1-49, wherein determining the copy number of the nucleic acid target in each of the one or more single cells comprises determining the copy number of the nucleic acid target in each of the one or more single cells based on the number of first molecular markers with different sequences, their complements, or a combination thereof associated with the more than one barcoded nucleic acid molecules or their products.
51. The method of any one of claims 1-50, wherein obtaining sequencing data comprises attaching sequencing adapters to the more than one barcoded nucleic acid molecules or products thereof.
52. The method of any one of claims 1-51, wherein the more than one barcoded nucleic acid molecule comprises a barcoded deoxyribonucleic acid (DNA) molecule and / or a barcoded ribonucleic acid (RNA) molecule.
53. The method of any one of claims 1-52, wherein the nucleic acid target comprises a nucleic acid molecule, optionally ribonucleic acid (RNA), messenger RNA (mRNA), microRNA, small interfering RNA (siRNA), RNA degradation products, RNA comprising a poly (A) tail, or any combination thereof, and further optionally the mRNA encodes an immune receptor.
54. The method of any one of claims 1-53, wherein at least 10 of the more than one oligonucleotide barcodes comprise different first molecular marker sequences.
55. The method of any one of claims 1-54, wherein each first molecular label of the more than one oligonucleotide barcode comprises at least 6 nucleotides.
56. The method of any one of claims 1-55, wherein the more than one oligonucleotide barcode is associated with a solid support, and optionally, the more than one oligonucleotide barcodes associated with the same solid support each comprise the same sample label, and further optionally, each sample label of the more than one oligonucleotide barcode comprises at least 6 nucleotides.
57. The method of any one of claims 1-56, wherein each of the more than one oligonucleotide barcodes comprises a cell marker, and optionally each cell marker of the more than one oligonucleotide barcodes comprises at least 6 nucleotides.
58. The method of any one of claims 1-57, wherein the oligonucleotide barcodes associated with the same solid support comprise the same cellular marker or different cellular markers.
59. The method of any one of claims 1-58, comprising associating a synthetic particle comprising the more than one oligonucleotide barcode with a single cell of the first more than one single cell and / or the second more than one single cell.
60. The method of any one of claims 1-59, comprising lysing the single cell after associating the synthetic particles with the single cell, and optionally lysing the single cell comprises heating the sample, contacting the sample with a detergent, changing the pH of the sample, or any combination thereof.
61. The method of any one of claims 1-60, wherein the synthetic particle and the single cell are in the same well or in the same droplet.
62. A method according to any one of claims 1-61, wherein at least one of the more than one oligonucleotide barcodes is fixed or partially fixed on the synthetic particle, or at least one of the more than one oligonucleotide barcodes is encapsulated or partially encapsulated in the synthetic particle; and optionally wherein the synthetic particle is destructible.
63. The method of any one of claims 1-62, wherein the synthetic particles comprise beads, and optionally the beads comprise Sepharose beads, streptavidin beads, agarose beads, magnetic beads, conjugated beads, protein A conjugated beads, protein G conjugated beads, protein A / G conjugated beads, protein L conjugated beads, oligo(dT) conjugated beads, silica beads, silica-like beads, anti-biotin microbeads, anti-fluorescent dye microbeads, or any combination thereof; A material selected from the group consisting of polydimethylsiloxane (PDMS), polystyrene, glass, polypropylene, agarose, gelatin, hydrogel, paramagnetic substances, ceramics, plastics, glass, methylstyrene, acrylic polymers, titanium, latex, Sepharose, cellulose, nylon, silicone, and any combination thereof; or Destructible hydrogel particles.
64. The method according to any one of claims 1 to 63, wherein each of the more than one oligonucleotide barcodes comprises a linker functional group, wherein the synthetic particle comprises a third solid support functional group, and wherein the support functional group and the linker functional group are associated with each other, and optionally the linker functional group and the support functional group are individually selected from the group consisting of: C6, biotin, streptavidin, one or more primary amines, one or more aldehydes, one or more ketones, and any combination thereof.
65. A kit comprising: more than one first cellular component binding reagent, wherein each of the more than one first cellular component binding reagent comprises a cellular component binding reagent specific oligonucleotide, the cellular component binding reagent specific oligonucleotide comprising a unique identifier sequence for the first cellular component binding reagent, and wherein the first cellular component binding reagent is capable of specifically binding to at least one of more than one cellular component targets, optionally each cellular component binding reagent specific oligonucleotide comprises a shared sequence, and further optionally the shared sequence is the same across all cellular component binding reagent specific oligonucleotides of the more than one first cellular component binding reagents; more than one second cellular component binding reagent, wherein the second cellular component binding reagent is capable of specifically binding to at least one of the more than one cellular component targets, wherein the second cellular component binding reagent does not comprise a cellular component binding reagent-specific oligonucleotide, wherein one or more of the first cellular component binding reagents and one or more of the second cellular component binding reagents are capable of binding to the same cellular component target; more than one first detectable conjugate, wherein each of the more than one first detectable conjugate comprises a detectable moiety or a precursor thereof and a unique identifier-specific oligonucleotide comprising a sequence configured to bind to the unique identifier sequence, wherein first detectable conjugates capable of binding to the same unique identifier sequence comprise the same detectable moiety or a precursor thereof, and wherein first detectable conjugates capable of binding to different unique identifier sequences comprise different detectable moieties or precursors thereof; and / or More than one second detectable conjugate, wherein each of the more than one second detectable conjugate comprises a detectable moiety or a precursor thereof and a shared oligonucleotide comprising a sequence configured to bind to the shared sequence, wherein at least two of the more than one second detectable conjugates comprise different detectable moieties or precursors thereof.
66. The kit of claim 65, wherein the sequence configured to bind to a unique identifier sequence comprises a sequence that is complementary to at least a portion of the unique identifier sequence.
67. The kit according to any one of claims 65-66, wherein the shared sequence is: (a) a sequence complementary to a capture sequence configured to capture said cellular component binding reagent-specific oligonucleotide, and wherein the sequence configured to bind to said shared sequence is said capture sequence, optionally comprising a poly (dT) region; and / or (b) a second universal sequence, wherein the sequence configured to bind to the shared sequence is a sequence that is complementary to at least a portion of the second universal sequence, and optionally wherein the second universal sequence comprises a binding site for a sequencing primer and / or a sequencing adaptor, a complementary sequence thereof and / or a portion thereof.
68. A kit according to any one of claims 65-67, wherein the sequencing adaptor comprises a P5 sequence, a P7 sequence, a complementary sequence thereof and / or a portion thereof; and / or wherein the sequencing primer comprises a read 1 sequencing primer, a read 2 sequencing primer, a complementary sequence thereof and / or a portion thereof.
69. The kit according to any one of claims 65-68, wherein the unique identifier specific oligonucleotide and / or the shared oligonucleotide is 5-500 nucleotides in length.
70. A kit according to any one of claims 65-69, wherein the detectable portion comprises an optical portion, a luminescent portion, an electrochemically active portion, a nanoparticle or a combination thereof; optionally (a) the nanoparticle comprises quantum dots, (b) the luminescent portion comprises a chemiluminescent portion, an electroluminescent portion, a photoluminescent portion or a combination thereof, and / or (c) the photoluminescent portion comprises a fluorescent portion, a phosphorescent portion or a combination thereof, optionally the fluorescent portion comprises a fluorescent dye.
71. The kit of any one of claims 65-70, wherein a user is able to perform a reaction to convert the detectable moiety precursor to the detectable moiety.
72. The kit of any one of claims 65-71, wherein the detectable moiety comprises (a) BD Horizon RealBlue TM 780 (RB780), BD Horizon RealYellow TM 586 (RY586) and / or BrilliantViolet TM 421 (BV421); and / or (b) one or more of DAPI, BUV661, RY586, AF647, Cy5, RB780, ROX, BV421, FAM and Cy3.
73. A kit according to any one of claims 65-72, wherein (a) the unique identifier specific oligonucleotide and / or the shared oligonucleotide is or comprises a locked nucleic acid (LNA), a peptide nucleic acid (PNA), DNA, an LNA / PNA chimera, an LNA / DNA chimera, a PNA / DNA chimera or any combination thereof; and / or (b) the unique identifier specific oligonucleotide and / or the shared oligonucleotide comprises a linker, and wherein the unique identifier specific oligonucleotide and / or the shared oligonucleotide is associated with the detectable portion or a precursor thereof via the linker.
74. The kit according to claim 73, wherein the linker comprises a carbon chain, optionally the carbon chain comprises 2-30 carbons, and further optionally the carbon chain comprises 12 carbons, or The linker comprises 5' amino modification C12 (5AmMC12) or a derivative thereof.
75. A kit according to any one of claims 65 to 74, wherein said unique identifier specific oligonucleotide and / or said shared oligonucleotide comprises an affinity moiety; wherein the detectable moiety or a precursor thereof comprises a binding partner for the affinity moiety; and wherein the affinity moiety comprises biotin, streptavidin, heparin, an aptamer, a click chemistry moiety, digoxigenin, one or more primary amines, one or more carboxyl groups, one or more hydroxyl groups, one or more aldehydes, one or more ketones, derivatives thereof, or any combination thereof.
76. The kit of any one of claims 65-75, wherein the detectable moiety or a precursor thereof is conjugated to the unique identifier-specific oligonucleotide and / or shared oligonucleotide via a 1,3-dipolar cycloaddition reaction, a hetero-Diels-Alder reaction, a nucleophilic substitution reaction, a non-aldol type carbonyl reaction, a carbon-carbon multiple bond addition, an oxidation reaction, a click reaction, or any combination thereof.
77. A kit according to any one of claims 65-76, wherein (a) the cellular component target comprises a protein target, optionally the first cellular component binding reagent and / or the second cellular component binding reagent comprises an antibody or a fragment thereof; and / or (b) the cellular component target comprises a carbohydrate, a lipid, a protein, an extracellular protein, a cell surface protein, a cell marker, a B cell receptor, a T cell receptor, a major histocompatibility complex, a tumor antigen, a receptor, an intracellular protein or any combination thereof.
78. A kit according to any one of claims 65 to 77, wherein the more than one cellular component target comprises at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10000 different cellular component targets; wherein the more than one first cellular component binding reagent and / or the more than one second cellular component binding reagent comprises at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10000 different cellular component binding reagents; wherein the more than one first detectable conjugate comprises at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10,000 different first detectable conjugates, optionally wherein the different first detectable conjugates comprise two or more overlapping dyes that can be resolved by spectroscopic cytometry; and / or wherein the more than one second detectable conjugate comprises at least about 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1000 or 10,000 different second detectable conjugates, optionally wherein the different second detectable conjugates comprise two or more overlapping dyes that can be resolved by spectroscopic cytometry; and / or wherein the more than one cellular component targets include more than one protein targets, and wherein the first cellular component binding reagent is capable of specifically binding to at least one of the more than one protein targets, optionally, the more than one cellular component targets include cell surface proteins, intracellular proteins, cell markers, B cell receptors, T cell receptors, antibodies, major histocompatibility complexes, tumor antigens, receptors or a combination thereof.
79. The kit of any one of claims 65-78, wherein the cellular component binding agent-specific oligonucleotide comprises one or more of: (a) a second molecular marker sequence, optionally, the second molecular marker sequence is 2-20 nucleotides in length; (b) an alignment sequence adjacent to the poly(dA) region, optionally, the alignment sequence is one or more nucleotides, or two or more nucleotides in length; and (c) a linker, wherein the cellular component binding agent-specific oligonucleotide is associated with the first cellular component binding agent via the linker.
80. The kit according to any one of claims 65 to 79, wherein said second molecular marker sequences of at least two cellular component binding reagent specific oligonucleotides are different, and wherein said unique identifier sequences of said at least two cellular component binding reagent specific oligonucleotides are the same; and / or wherein said second molecular tag sequences of at least two cellular component binding agent specific oligonucleotides are different, and wherein said unique identifier sequences of said at least two cellular component binding agent specific oligonucleotides are different.
